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Abstract 
Background: The relationship between living in rural areas and the 
acquisition of protective environmental factors against the development of asthma 
and atopy gave rise to the hygiene hypothesis. Between the environmental factors 
attributed to asthma, particular airways microbiota patterns have been encountered 
in adult asthmatics using molecular independent techniques (Hilty et al., 2010) and in 
children using conventional culture methods (Bisgaard et al., 2007). Here a 
retrospective time series study has been performed using samples from infants at 
different ages to study the microbiome variations in a population with very low 
antibiotic use history and no corticosteroid usage.  
Methods: Pyrosequencing of amplicons of the bacterial 16S rRNA gene was 
performed from oropharyngeal samples from 134 infants with episodic wheezing 
versus 200 healthy infants (total of 334 infants examined) sampled at different ages 
(7, 12 and 24 months).  Bioinformatic analyses were conducted using QIIME 1.7 
software and Phyloseq package on R. Additionally a new culture-independent 
pyrosequencing approach using the map gene was successfully developed to 
enable discrimination of streptococci at species level. 
 ix 
Results: Significant abundance differences between infants with wheezing 
history and healthy controls were found for the Fusobacteria, Proteobacteria and 
Actinobacteria phyla. At genera level a significant increase in potential pathogenic 
bacteria (Neisseriacea, Haemophilus, Staphylococcus) was found in wheezers whilst 
a higher prevalence of Veillonella spp. was seen in controls. In addition, using map 
gene pyrosequencing, Streptococcus salivarious was found to be statistically 
significantly related with wheezing syndrome whilst Streptococcus mitis was more 
prevalent in controls. When age was considered differences were found in the 
microbiota displayed as species numbers increased (alpha diversity). 
Conclusions: The respiratory microbiota is different at phyla, genera and 
Operational Taxonomic Unit levels when comparing between wheezing and healthy 
children. A progressive more complex respiratory microbial community develops with 
age. 
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Chapter 1: Introduction 
1.1. Asthma and Wheezing  
Asthma is a cluster of airways diseases that is manifested by a wide variety of 
respiratory symptoms. The disease is characterized by non-specific bronchial hyper-
responsiveness that causes wheezing, dyspnoea, coughing, and chest rigidity 
(Busse and Lemanske, 2001, Nelson and Zorc, 2013). It is important to note that 
many asthmatics exhibit raised total Immunoglobulin E (IgE) and specific IgE to 
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inhaled allergens, for that reason asthma is commonly stated as an ‘atopic’ disease 
(Busse and Lemanske, 2001).  
Immunohistopathology studies of the airways in asthmatics reveal a 
characteristic infiltration of inflammatory cells, thickening of the basal membrane, 
epithelial-cell damage, occlusion of the bronchial lumen by mucus as well as 
hyperplasia and hypertrophy of bronchial smooth muscle (Haley and Drazen, 1998, 
Holgate, 2013, Aoshiba and Nagai, 2004).  
The aetiological cause of asthma is complex with both genetic and 
environmental factors contributing and influencing age of onset and the severity of 
symptoms (Cookson, 2002, Martinez and Vercelli). Typically an asthma exacerbation 
occurs when inhaled allergens (antigens), such as house dust mite, trigger a strong 
T helper type 2 lymphocyte (Th2) response with in the airways. Mast cells through 
activation of their IgE receptors release potent inflammatory mediators including 
histamine, leukotrienes, RANTES, and interleukins (IL) including IL-4 and IL-5 
(Busse and Lemanske, 2001). These cytokines result in the activation of eosinophils 
that in turn secrete adhesion molecules such as VCAM-1, ICAM-1 and selectins 
whilst activation of Th2 lymphocytes results in production of Th2 interleukins 
including 4, 5, 6, 7, 9, 11 and 18. With the recruitment of inflammatory cells, 
subsequent complement activation results in epithelial cell damage, a cholinergic 
 19 
stimulus leading to broncho-constriction and B lymphocyte conversion into plasma 
cells capable of producing more IgE thereby perpetuating this altered inflammatory 
cycle (Figure 1.1) (Mamessier and Magnan, 2006, Afshar et al., 2008, Kohl and 
Wills-Karp, 2007, Wenzel, 2012). 
 20 
 
Figure 1.1. The Allergic Th2 Pathway. The allergen penetrates into the 
organism and is taken up by antigen presenting cells (APC) which 
migrate to the nearest lymphoid organ where the allergen is processed 
and presented by the MHC-II molecule to T lymphocytes. A naive T cell 
recognizes the allergen, expands clonally, and migrates to the site of 
inflammation. In situ, activated Th2 cells produce Th2 cytokines: IL-5 
causes eosinophil recruitment and activation leading to tissue damage; 
IL-4 and IL-13 predominantly activate B cells and allow IgE commutation 
and synthesis. IgE binds FcεR1 on non-specific immune cells. When 
contact with allergen occurs again, already bound IgE immediately 
captures the allergen, resulting in receptor cross-linking and rapid mast 
cell and basophils activation. These cells are responsible for the release 
of most of the inflammatory and toxic mediators (such: iNOS, induced 
nitric oxide synthase; PGD2, prostaglandin D2; TSLP, thymic stromal 
lymphoprotein) that cause the immediate allergic symptoms. Taken 
under permission (see appendix) from Wenzel (2012).  
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1.2. Asthma Diagnosis in Infants 
To define a single ‘asthma’ phenotype is not straight forward as different types 
and severities of the disease are increasingly being recognized.  Diagnosis in 
children includes clinical history, physical examination, as well as functional and 
laboratory tests. Clinical diagnosis is crucial in the investigation of apparent asthma 
symptoms such as wheezing, shortness of breath and cough. In infants, asthma 
diagnosis is additionally complicated by the fact that before the age of 6 years, lung 
function tests are not easy to perform and invariably are inaccurate (Szefler et al., 
2014).  Consequently analysis of recurrent wheezing not related with infections is the 
most important diagnostic indicator of asthma in this age group (<6 years) 
(Wechsler, 2009).  
Not all children who experience wheezing events will develop asthma, and 
conversely not all children with asthma wheeze (Just et al., 2010, Wechsler, 2009).  
It has been reported that around 50% of children have at least one episode of 
wheezing in the first three years of life; but only 27% of recurrent wheezing infants 
were found to have wheezing at 6 years of age. Consequently in children that are 
less than 24 months old rather than a diagnosis of asthma being assigned it is 
recommended that the diagnosis of recurrent non-infectious wheezing syndrome be 
given (Just et al., 2010, Wechsler, 2009). The Global Initiative for Asthma (GINA) 
 22 
and the European Respiratory Society (ERS) have classified this type of wheezing 
as multiple-trigger wheeze.  Multiple-trigger wheeze is characterized by “episodes 
that occur as episodic exacerbations, but also with symptoms including cough and 
wheeze occurring between these episodes, during sleep or as a consequence of 
triggers such as activity, laughing or crying” (Kroegel, 2009, Bousquet et al., 2007). 
Asthma is considered an atopic disease with high total and specific IgE levels 
determined by enzyme-linked immunosorbent assay (ELISA). ELISA is a direct 
method of measuring proteins using specific antibodies against those proteins. 
These antibodies have an enzyme linked that produces a specific chemical reaction 
that can be measured (usually by a fluorometer). Skin prick test (SPT) is another 
method of measuring specific IgE against particular allergens. This method involves 
the sub-epidermic inoculation of the allergens and if a positive reaction occurs, a 
wheal is produced that can be measured in diameter. 
1.3. Epidemiology of Asthma and Wheezing Worldwide 
GINA has determined that there are 300 million people with asthma worldwide 
including all ages, ethnicities and socioeconomic status (FitzGerald et al., 2013). 
When not efficiently controlled asthma causes restriction of an individual’s normal life 
style invariably hospitalization and even fatalities. The prevalence of asthma notably 
increases with Western and urbanized lifestyles (Figure 1.2). In 2025, it is anticipated 
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that from 45% to 59% of the worldwide population will live in urban areas, resulting in 
a notable increase in asthma prevalence of an additional 100 million people (Masoli 
et al., 2004). Annually worldwide asthma causes approximately 180,000 deaths. Its 
fatality rate worldwide is about 1 in every 250 deaths although the majority of the 
deaths are due to insufficient health care in certain regions of the world (Masoli et al., 
2004, Kroegel, 2009). 
Asthma is also considered an economic burden with the yearly costs 
worldwide being approximately 19.7 billion USD, of which 14.7 billion are direct 
medical costs, and 5 billion are indirect costs (related to losses in productivity and 
premature death). Drug prescriptions alone have an annual cost of more than 6 
billion USD. In developed countries the financial cost of treating a patient with 
asthma ranges from 300 to 1,300 USD per year. About 15 million disability-adjusted 
life years (DALYs) per year are lost because of asthma, corresponding to 1% of all 
DALYs lost (FitzGerald et al., 2013, Bateman and Jithoo, 2007, Masoli et al., 2004).   
Asthma is therefore not only a disease of importance in terms of human health but 
has significant financial impact globally.  
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1.4. Epidemiology of Asthma and Wheezing in Latin America 
and Ecuador  
Latin America is very varied ethnically, geographically and economically. 
Approximately 25% of the population lives on an income of less than 2 
Figure 1.2. Prevalence of Asthma Worldwide. Dark red areas 
show a higher prevalence (see scale). Note Ecuador has a 
prevalence of asthma of 8.2% whilst in the United Kingdom it is 
between 15.3 % (England) and 18.4 % (Scotland). It is important 
to note that for some country data is not standardized. Taken 
under permission (see appendix) from Masoli et al., 2004. 
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USD/person/day (Lancet Editorial, 2007). As part of the International Study of 
Asthma and Allergies in Childhood (ISAAC), it has been estimated that diagnosed 
asthma prevalence ranges from 1.2% to 33.1%, whilst recurrent wheezing ranges 
from 3.9% to 30.8%. Geographical localization (as determined by latitude, altitude or 
tropical location) has been found to have no statistical correlation with asthma 
prevalence (Mallol et al., 2010). In Latin America only 11% of asthma appears to be 
related with the atopic phenotype (Weinmayr et al., 2007), with stronger correlations 
being seen with poverty (dirt, poor diet, obesity and psychosocial stress) (Cooper et 
al., 2012). 
The Latin American country Ecuador has regional differences revealed by 
studies that have been conducted in rural versus urban areas. According to the 
GINA criteria the prevalence of asthma in Ecuador is 8.2% (Figure 1.3) (Masoli et al., 
2004) although the ISAAC study has found the incidence to be slightly higher at 
10.9%. The incidence of wheezing however is 16.6% in urban areas, ISAAC centres 
in Quito and Guayaquil (Mallol et al., 2010, Masoli et al., 2004), whilst in rural areas, 
the Pichincha province, the rate of current wheezing is only 0.8%, and atopic 
wheezing 0.2% (Weinmayr et al., 2007, Cooper et al., 2009). In Ecuador, the fatality 
rate is 2.3 cases per 100,000 asthmatics. According to the World Health 
Organization (WHO) report 1998 only between the 50% and 80% of asthma patients 
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in Ecuador have access to appropriate medications (Masoli et al., 2004). 
Furthermore, the estimated prevalence of current wheeze in relation to SPT 
reactivity (>3 mm) and allergen-specific IgE (>0.35 kU/L) is 0.1% (Weinmayr et al., 
2007). Non atopic asthma has been associated with recurrent chest infections, otitis 
media, croup, household damp or mould and pet exposures during the first year of 
life Moncayo et al 2010.  In addition parasitic infections as Trichuris trichiura has 
been shown to be strongly inversely associated with atopic wheeze (Moncayo et al., 
2010), and similarly Ascaris lumbricoides or Ancylostoma duodenale with atopy 
(Cooper et al., 2003). People in the tropics of Ecuador usually have high polyclonal 
IgE levels but low specific IgE (Cooper et al., 2012), therefore atopy has to be 
redefined in this population. Consequently it would appear that the atopic component 
of asthma often seen in Western developed countries is not a feature in 
asthma/wheeze in Ecuador.  
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 Figure 1.3. Prevalence of Asthma Symptoms by Country. 
Ecuador has a wheezing prevalence of 16.6 % Taken under 
permission (see appendix) from ISAAC study published by 
Masoli et al., 2004 . 
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1.5. Human Genetics and Asthma 
Asthma is a complex disease involving both environmental and host-
dependant factors (Cookson and Moffatt, 2011), and therefore host genetics plays 
an important role in asthma development. Caused by the asthma a multi-genic 
origin, it has been difficult to address a common gene that explains the wide range of 
symptomatology produced (Cookson et al., 2011), and strikingly possible candidates 
like the IgE expression associated genes were not been found related (Moffatt et al., 
2010, Zhang et al., 2012). For that reason genome-wide association studies 
(GWASs) have been a successful tool identifying loci related with this disease 
(Zhang et al., 2012, Cookson et al., 2011).  
A large scale asthma consortium in Europe (the GABRIEL Consortium) using 
the GWAS approach identified a number of key loci related with asthma that involves 
the genes: IL18R1, IL33, IL1rL1, SMAD3 and ORMDL3 (Moffatt et al., 2010). 
Several markers in chromosome 17q21 (where are located the genes ORMDL3 and 
GSDMB) are more commonly related with childhood-onset asthma (Moffatt et al., 
2010), and particular variants regulating the ORMDL3 gene expression have been 
related with childhood-onset asthma in different ethnic populations (Moffatt et al., 
2007, Zhao et al., 2014). Additionally this gene locus also has been related with 
severe asthma phenotypes (Binia et al., 2011). 
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1.6. The Hygiene Hypothesis and Asthma 
The hygiene hypothesis has attempted to explain why some populations have 
a higher frequency of an over-reactive immune system in relation with the 
environmental factors affecting a particular group of people. This hypothesis was 
originally proposed following a number of epidemiological studies of asthma and 
atopy (Strachan, 1989), and the original study that included British children, 
postulated that allergic diseases could be prevented by the development of infection 
in infancy (there are mentioned in this study the viral infections) that could be 
transmitted by older siblings or by contact with the mother. Consequently, the 
reduction of family size and improvement in hygiene that has happened since the 
modern centuries, has resulted in notable increases in the development of 
developing atopic disease (Strachan, 1989),. It is noteworthy that the Strachan, 1989 
study has subsequently been supported by data from studies involving both 
functional immunology and genetics (Liu, 2007).   
It is interesting to also note that urbanization, migration and modernization are 
some of the most important factors related to asthma risk and these factors reflect 
the resultant changes in nutrition, exercise, exposure to allergens, use of antibiotics 
and vaccines, microbial exposures, effects of pollution, and psychosocial stressors 
(Cooper et al., 2009, Weinberg, 2000). Poverty exhibits a dual association with 
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asthma depending on locality. Strikingly poverty in rural areas has been found to not 
be associated with asthma, whilst in urban areas poverty is an important risk factor 
for the disease (Benicio et al., 2004).  
Several studies suggest that factors including improved hygiene, antibiotics 
use, vaccinations, etc. and removal of certain microbial contacts during childhood 
may promote the development of atopy and asthma. These factors cause an 
imbalance in the immune system that becomes oversensitive to harmless antigens 
such as those of the house dust mite as reviewed by Liu (2007). Atopy has been 
shown to be related with asthma in developed countries. In Latin America however, 
several studies have shown a predominance of non-atopic wheeze in children 
especially in rural areas (Moncayo et al., 2010). 
1.7. Microorganisms and Asthma 
Several microorganisms that produce respiratory infections during infancy and 
childhood have been associated with the development of asthma. Most of the 
microorganisms associated are viruses which have been related not only with 
asthma exacerbations (Nicholson et al., 1993, Sebastian et al., 1995) but as an 
aetiological agent of chronic inflammation on the airways (Tsukagoshi et al., 2013, 
Openshaw et al., 2003, Moser et al., 2014). The viruses that have most frequently 
been implicated in the aetiology of asthma are: respiratory syncytial virus (RSV) 
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(Lotz et al., 2013, Piedimonte, 2013), human rhinovirus (HRV) (Camargo, 2013, 
Engelmann et al., 2013, Kotaniemi-Syrjanen et al., 2003), human metapneumovirus 
(HMPV) (Schuster and Williams, 2013, Edwards et al., 2013), human parainfluenza 
virus (HPIV) (Henrickson, 2003, Henrickson and Savatski, 1997) and human 
enterovirus (Lu et al., 2013). 
The mechanism from which viruses induce asthma is still controversial. Some 
studies consider that children born with a deficient innate immune response also 
tend to develop viral infections (Okayama, 2013). This in turn has been related to 
specific polymorphisms in genes that have been functionally implicated in the innate 
immune response including: VDR, JUN, NOS2A and IFNA5 (Janssen et al., 2007, 
Jackson et al., 2012) as well as SFTPA (surfactant protein A), SFTPD (surfactant 
protein D), TLR 4, TNF, IL4, IL9, IL10, IL8, IL13, IL4RA, and CCL5 (Huckabee and 
Peebles, 2009).  There are however notably more publications and evidence 
suggesting that viral infections tend to skew the immune response (Lemanske et al., 
2005, Sigurs et al., 2000, Schauer et al., 2002, Stern et al., 2008). There are two 
potential mechanisms by which viral infections in early life lead to subsequent 
chronic inflammation: the immune system response and airways remodelling (Gern 
et al., 2005). For instance, an increased frequency of viral infections in infancy has 
been shown to result in increased IFN- responses at 1 year of age (Friedlander et 
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al., 2005, Culley et al., 2002). Other studies have shown that children that suffered 
an RSV infection and developed asthma later on life present a higher production of 
Th2 cytokines (IFNA13, IL15, IL10, and IL17) as well as cytokine receptor signalling 
molecules (IL4R, IL9R, and STAT1) (Castro et al., 2008). 
Fungal infections have also been implicated with the development of asthma 
exacerbations. Fungi are specially related with seasonal asthma phenotypes 
specifically the genders Alternaria, Cladosporium, and Didymella (Pulimood et al., 
2007). Additionally more than 20 fungal species have been implicated due to 
possessing highly immunogenic antigens (Bowyer et al., 2006), that could potentially 
result in atopic diseases.  
Although to a lesser extent than viruses, bacterial pathogens have also been 
implicated in causing asthma exacerbations (Edwards et al., 2012). Bacterial species 
that have been associated with wheezing episodes in childhood include 
Streptococcus pneumoniae, Haemophilus influenza and Chlamydia pneumoniae 
(Jackson et al., 2011).  These in turn have been linked with a higher total immune 
cell counts, neutrophilia, sputum IL-8 and free radicals concentrations (8-
isoprostane) in patients (Wood et al., 2010). Interestingly when patients diagnosed 
with asthma are challenged with S. pneumoniae they show a delayed activation of 
the immune response with low concentrations of TNF-α and a higher production of 
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IL-5 (Otero et al., 2013). Recently the importance of bacteria in the development of 
asthma has been supported by the development of culture independent molecular 
techniques.  This has allowed more accurate characterization of the human 
microbiome including that of the airways (Brar et al., 2012, Cox et al., 2013a).  
1.8. The Human Microbiome 
Ninety percent of the cells in the human body are not human but microbial 
(Savage, 1977). These microorganisms are part of the commensal microbiota (also 
known as the microbiome, normal microflora or indigenous microbiota) present on 
body surfaces that are exposed to the external environment e.g. the gastrointestinal 
tract, respiratory tract and skin (a total of approximately 300m2) (Tlaskalova-
Hogenova et al., 2004). It has therefore been suggested that we should perhaps 
regard ourselves as ‘super-organisms’ together with the indigenous microbes 
(Lederberg, 2000).  
Most of the microorganisms in a natural environment, including the 
microbiome in animals and humans, live in mixed populations (Staley and Konopka, 
1985). Culture based techniques are the most frequent method used for bacterial 
identification but these techniques have many limitations including long culturing 
times, demanding growth requirements and isolation difficulties. It has been 
estimated that only approximately 1% of the total bacteria in a sample can be 
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cultured using standard conditions (Relman, 2002). These limitations in culture 
based methods means that the full extent of bacterial diversity has the potential to be 
underestimated.  Similarly novel organisms may remain undetected despite the fact 
they could play a significant role in disease causation.   
By using more rapid and accurate bacterial identification techniques morbidity 
and mortality rates could be significantly improved and there is the potential of 
streamlining and reducing the use of expensive wide spectrum antibiotics (Relman, 
1999). In the diagnosis of airways infections, it is already recognised that culture 
techniques have limitations. For example it has been estimated that approximately 
30-40% of purulent sputum samples from patients with bronchiectasis fail to give a 
positive result with standard clinical microbial culture (King, 2011). As a result, the 
most powerful approach to study the microbial diversity in a community would be the 
use molecular culture-independent techniques.  
1.9. The Gut Microbiome and Asthma 
The first study of the microbiome that compared asthmatics with healthy 
individuals was in fact not focused on the airways but instead examined the microbial 
communities of the gut (Murray et al., 2005), Moreover several studies have 
encountered that the intestinal microbiome plays a very important role in the 
development of the immune system from early infancy (Torrazza and Neu, 2011, 
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Vael and Desager, 2009). Recent studies have shown that the microbiome in turn 
can modulate the development of the immune response of the host (Kaplan et al., 
2011, Vael and Desager, 2009). The immune response produced depends on the 
balance of particular bacteria in the microbiome and this dictates whether a balanced 
or non-balanced Th1/Th2 immune response occurs and can result in enhancement 
of the systemic innate immunity (Kaplan et al., 2011). It has been suggested that the 
mechanism by which this happens is direct activation of the immune response by 
bacterial metabolites and antigens (Allan and Devereux, 2011).  It has also been 
postulated that some bacterial metabolites could affect epigenetic gene expression 
control in the host (Licciardi et al., 2010). 
From birth the immune systems displays a Th2 immune profile (Prescott et al., 
1998), but as time progresses, depending on exposures and stimuli, one starts to 
develop the Th1 and cellular immune response. Both the Th1 and Th2 arms of 
immunity in turn influence the microbial communities that develop in the intestine 
(the gut microbiome) (Holt et al., 2005). In addition, nutrients, immune cells, 
cytokines and maternal antibodies in the breast milk can also impact and modulate 
the gut microbiome of the neonate.  This specifically occurs via TLR mediated 
immune response (LeBouder et al., 2006).  
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1.10. The Airways Microbiome in Healthy Individuals 
The airways anatomy starts in the air entrances corresponding to the nose 
and the mouth, and continues through the pharynx, larynx, trachea and bronchial 
tubes until reaching the alveoli of the lungs. The respiratory airways system is a 
complex interplay between the ciliated mucosal epithelia, the mucus, connective 
tissue, the immune system and the musculature (Ward et al., 2006). There are 
different types of epithelia forming the mucosa in the airways, different types of 
muscle cells, different ratios of connective tissue on the airways course, and 
moreover different environmental conditions such as temperature, humidity and air 
pressure. As a consequence such environments mean that each different area 
harvested contain different types of microorganisms (Hilty et al., 2010), and the 
bacterial microbiome in the airways varies in abundance and diversity in their 
anatomical trajectory. There are three main unique established bacterial niches in 
the airways: nasopharynx, oropharynx and lower airways-alveoli (Hilty et al., 2010). 
The healthy lower airways in humans historically were considered sterile using 
standard culturing methods (Thorpe et al., 1987). With the advancement in 
sequencing technologies and the capability to conduct more high throughput studies, 
newer and more sensitive culture-independent methods have revealed that bacterial 
communities are permanent residents of the lower airways and that different 
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microbiome configurations are related with the development of disease (Hilty et al., 
2010). 
Studies have revealed that the nasopharynx (nasal) microbiome has a lower 
diversity of bacteria (in terms of species number) when compared with that of the 
oropharynx (Lemon et al., 2010, Huse et al., 2012). The nasal microbiome was found 
to be dominated by Actinobacteria (represented mainly by Corynebacterium spp. and 
Propionibacterium spp,), Firmicutes (represented mainly by Staphylococcus spp.), 
and Proteobacteria (represented by Enterobacter spp.) (Hilty et al., 2010, Lemon et 
al., 2010, Frank et al., 2010). More than 50% of the bacteria present in the 
nasopharynx are Gram-negatives compared with the oropharynx where more than 
80% of its community are Gram-positives (Bogaert et al., 2011). The microbiome in 
the nostril and nasopharynx shows strong similarity to that seen for the skin 
microbiome due to the high presence of Staphylococcus spp. (Lemon et al., 2010, 
Huse et al., 2012, Costello et al., 2009).  
Several species of staphylococci are present in the nasal microbiome 
principally S. aureus and S. epidermidis (Frank et al., 2010). The nasal mucosa is 
known to be a suitable carriage environment for difficult to treat methicillin-resistant 
S. aureus (MRSA)  (Gupta et al., 2013). Although S. aureus can act as a commensal 
in the healthy nasal microbiome, some virulent strains can grow at higher rates and 
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produce an impact on the bacterial community structure, specifically diminishing the 
abundance of the commensals Propionibacterium acnes and Sthaphylococcus 
epidermidis (Frank et al., 2010). Interestingly using a metagenomic approach, a 
seasonal variability has also been observed in the nasopharynx microbiome. During 
fall and winter it was found that there was a higher prevalence of Proteobacteria and 
Fusobacteria, whilst in spring a preponderance of Bacteroidetes and Firmicutes 
(mainly caused by an increase in Bacillus and Lactobacillus spp.) existed (Bogaert et 
al., 2011). 
The oropharynx normal microbiome has been shown to be characterized by a 
high prevalence of Firmicutes, Proteobacteria and Bacteroidetes (Hilty et al., 2010, 
Cardenas et al., 2012, Huse et al., 2012). The bacterial species within these groups 
correspond in many instances with those seen in the microbiome of the saliva and 
are substantially less similar to those of the oral, gingival and esophagic microbiome 
(Lemon et al., 2010). When alpha diversity was compared between gingiva, tongue, 
buccal mucosa and saliva, the oropharynx was found to have lower values (Huse et 
al., 2012). At genera level Prevotella, Streptococcus, Staphylococcus, 
Corynebacterium, Veilonella, Haemophilus and Neisseria were found to be the 
normal commensals in the oropharynx (Hilty et al., 2010, Charlson et al., 2010, 
Cardenas et al., 2012). If age is taken into consideration, the most abundant genus 
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seen adults is Prevotella whilst in children Streptococcus is the most common 
(Charlson et al., 2010, Hilty et al., 2010), 
The lower airways have a lower biomass of bacteria compared with the upper 
airways (Hilty et al., 2010, Charlson et al., 2011) but their community structure is 
similar to that of the oropharynx (Hilty et al., 2010) (Figure 1.4). Bacteroidetes, 
Firmicutes and Proteobacteria were found to be the most abundant phyla in the 
lower airways microbiome. At genera level the most relevant bacteria were 
Prevotella, Haemophilus, Pseudomonas, Streptococcus, Fusobacterium, Veillonella 
and Porphyromonas (Hilty et al., 2010, Erb-Downward et al., 2011). Interestingly 
when compared with the oropharynx, Haemophilus spp. were found to be more 
prevalent in the lower airways (Hilty et al., 2010). Whether the left lung varies from 
the right lung was investigated by Charlson et al. (2010), who found  no 
dissimilarities. 
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Variations in the oral microbiome related with life-style activities have been 
found. In patients suffering alcoholism there was a higher prevalence of Bacteroides, 
Prevotella, Veilonella, Fusobacterium, Peptostreptococcus, Propionibacterium, 
Bifidobacterium, Clostridium species and enterobacteria compared with non-
alcoholic adults (Golin et al., 1998). Smoking has also been found to have an effect 
on the upper airways microbiome, with both the naso and oropharynx bacterial 
ecology being more diverse in smokers than in non-smokers (Charlson et al., 2010, 
Figure 1.4. The Regional Differences in the Airways Microbiome. 
Percentage distribution of common phyla and genera at different airway 
levels (nose, OP and LUL), subdivided into the seven most frequent 
genera Croynebacterium, Prevotella, Staphylococcus, Streptococcus, 
Veilonella, Haemophilus and Neisseria) found in the samples (Hilty et 
al., 2010). Taken under permission (see appendix). 
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Erb-Downward et al., 2011). At genera level smokers showed an increase in the 
anaerobic Gram-negative Megasphaera spp. and other potential pathogenic bacteria 
such as Streptococcus, Veillonella, Actinomyces and Atopobium spp.  In contrast 
there were decreased level of species including Peptostreptococcus, 
Capnocytophaga, Fusobacterium and Neisseria (Charlson et al., 2010).  
Although there is very limited data to draw definitive conclusions about the 
effect of latitude on the airway microbiome, one could anticipate that climate as well 
as ethnicity, culture and access to antibiotics could be additional important influences 
on the airway microbiome (Costello et al., 2009). In a study on cystic fibrosis in which 
the microbiome of the lower airways was compared between patients from the 
United Kingdom and United States, both groups were found to cluster separately as 
well as vary on community diversity and structure (Stressmann et al., 2011). 
1.11. The Airways Microbiome in Asthma 
The microbiome mediates mechanisms of immunological tolerance and is 
essential in regulating mucosal inflammation (Yamanaka et al., 2003, Herbst et al., 
2011).  Consequently it could contribute to the development of atopic disease and 
asthma in children (Noverr and Huffnagle, 2005). Several studies have found that an 
early exposure during infancy to infections and antibiotics could cause a higher 
prevalence of asthma and atopy (McKeever et al., 2002, Droste et al., 2000). A 
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number of studies have found a relationship between distinct airways microbiome 
patterns between asthmatics and healthy controls. In a study comparing the airways 
microbiome of asthmatic adults with that of healthy age matched controls a higher 
frequency of Proteobacteria was seen in cases with Haemophilus spp. more 
abundant in asthmatics (Hilty et al., 2010). Bactereoidetes, Firmicutes and 
Actinobacteria were more common in controls (Hilty et al., 2010, Marri et al., 2013). 
Additionally bacterial DNA quantification has shown that asthmatics have larger 
bacterial burdens than controls (Huang et al., 2011).  
In poorly controlled asthmatics, bacterial genera not commonly found in the 
airways have been observed to be more abundant (Huang et al., 2011).  These 
included Nitrosomonas, Oxalobacter formigenes, Comamonadaceae and 
Sphingomonadaceae.  Interestingly these particular genera have been observed 
previously in cystic fibrosis (CF) patients and may be related with high bronchial 
hyper-responsiveness (Huang et al., 2011).  
In a birth cohort in children using periodical culture based bacterial 
identification showed that Streptococcus pneumoniae, Haemophilus influenzae, 
Moraxella catarrhalis and Staphylococcus aureus are more common in wheezing 
children and are related with future development of asthma (Bisgaard et al., 2007). In 
the first culture-independent study of bronchoalveolar lavage taken from difficult 
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asthmatic children, a higher prevalence of Proteobacteria was related with asthma 
development, particularly Haemophilus and Staphylococcus species whilst 
Prevotella was considered a protective genus (Hilty et al., 2010).  
Particular airways microbiome patterns also have been associated with other 
respiratory diseases including chronic obstructive pulmonary disease (COPD) (Erb-
Downward et al., 2011), cystic fibrosis (CF) (Klepac-Ceraj et al., 2010) and non-CF 
bronchiectasis (Rogers et al., 2014). 
1.12. How to Study the Human Microbiome? 
Culturing has been since more than a century ago the most commonly used 
technique for bacterial identification. This method involves the growing of a specific 
type of bacteria in media (containing specific nutrients for the type of bacteria 
studied), and the observation of a colony growing on a plate. This approach has 
fundamentally not changed since Koch presented it at the International Medical 
Congress in London in 1881 (James, 2009) and has been used for numerous 
environmental and clinical studies (Davis, 2014, Burns and Rolain, 2014, Joint et al., 
2010). 
Since a couple of decades ago with the development of culture-independent 
techniques, it has been determined that between 5 to 50% of bacteria (depending of 
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the sample type being environmental or human) can be cultured whilst the rest 
remained unstudied (Hengstmann et al., 1999, Chin et al., 1999).  The recent 
development of culture-independent techniques and the studies in mucosal immunity 
has resulted in an increased interest in studying the human microbiome. The Human 
Microbiome Project (HMP) was established in 2008 with its main goal being the 
identification and characterization of microbial communities associated with healthy 
and diseased states. The first phase of the HMP has been focused on sequencing 
microbial reference genomes particularly the most commonly found bacteria in the 
gut. So far 356 genomes have been sequenced including members of two kingdoms 
(Bacteria and Archaea), 9 phyla, 18 classes, and 24 orders that are part of the 
microbiome (Nelson et al., 2010). Other large-scale studies already conducted for 
the gut microbiome have resulted in the identification of at least 1800 genera (90% 
ID), 16000 phylotypes at the species level (97% sequence identity) and 36000 
phylotypes at the strain level (99% sequence identity) (Frank et al., 2007a). Only 
20% of these organisms have however been cultured in the laboratory using 
conventional techniques (Eckburg et al., 2005).  
The majority of the molecular tools used for the characterization of the 
bacterial microbiome are based on the genomic evolutionary relationships (Cox et 
al., 2013a) (mainly in the similarities of housekeeping genes) between the bacterial 
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genomes. Comparisons of the 16S rRNA gene (which encodes for a section of the 
RNA that constitutes the small subunit of the ribosome) are the most popular 
techniques to classify bacteria phylogenetically due to the gene possessing both 
highly conserved sequences as well as highly variable segments and the ease with 
which evolutionary relationships can be identified (Wang et al., 2005, Turnbaugh et 
al., 2007, Grice et al., 2008). This gene is relatively short with 1,542 nucleotides of 
longitude, and is part of the 30S subunit of the bacterial ribosome (Woese and Fox, 
1977). It consists of conserved and variable regions (Figure 1.5), the latter allowing 
differentiation between different organisms with the former being utilised for primer 
design to allow comprehensive amplification of all types of bacteria (Woese and Fox, 
1977).   
Several experiments have been developed using the 16S rRNA gene to 
identify the bacteria existent in the microbiome. One of the first approaches that 
allowed identifying several bacterial taxons in a mixed microbial community is 
denaturing gradient gel electrophoresis (DGGE). This technique uses 16S rRNA 
PCR, and is based on the differences in the variable regions on this gene between 
different bacteria (McAuliffe et al., 2005). Such differences produce variation on the 
migration of the amplicons in a denaturant gel, which produce different band patterns 
(see Chapter 2: Section 2.6). As there is the need to use a marker for taxonomical 
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identification, and invariably bands cannot be assigned with 100% confidence to any 
bacterial genus, the technique is often complemented with cloning and sequencing 
of the amplicons.   Although more labour intensive, this provides a better insight of 
the bacterial abundance present in the microbiome, which allows a more accurate 
ecological analysis (Ahmed et al., 2007). Usually using this approach, bacteria can 
be assigned to a specific genus and, in some cases, to specific species by 
comparing the obtained sequence to those of already characterized species in the 
GeneBank and Ribosomal DNA databases (Wang et al., 2005). 
Currently, the new next generation sequencing techniques such as 454 
Roche pyrosequencing and later Illumina HiSeq and MiSeq have allowed hundreds 
thousands of sequences to be generated in a few hours avoiding the creation of 
genomic libraries and subsequent cloning. These new techniques also allow 
multiplexing of numerous samples at the same time using barcode sequences or 
MIDs (a unique sequence for each sample is used in the 3’ extreme of the reverse 
primer) in the PCR step.  This then permits the discrimination between samples in 
the subsequent data analysis step. All these advantages have allowed the 
characterization on a large scale of very complex microbial communities (Cox et al., 
2013a). 
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Bioinformatics tools have also become indispensable in the analysis of the 
microbiome.  Tools have been developed widely to allow a more easy analysis of the 
huge loads of data produced by next generation sequencing.  New algorithm 
calculations have been set to determine operational taxonomic units (OTUs) (Edgar, 
2010a), annealing sequences (Caporaso et al., 2010a), taxonomy assignation 
(McDonald et al., 2012), phylogeny (Price et al., 2010b) as well as diversity 
calculations (Lozupone and Knight, 2005b). 
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Figure 1.5. The Bacterial 16S rRNA gene.  Secondary structure 
model of the small subunit rRNA, eight variable regions have been 
identified in 16S rRNA, which are termed V1 to V3 and V5 to V9 
(region V4 occurs only in eukaryotic 18S rRNA. These Variable 
regions are used for Molecular based bacterial identification. Taken 
under permission (see appendix) from Lawson (2004). 
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1.13. The Microbiome and the Immune System Development 
Many molecular pathways have portrayed the crosstalk between the 
microbiome and the immune cells. The principal relationships are through the direct 
contact of microorganisms with the epithelia sited at the mucosal barriers (Kabat et 
al., 2014). The toll-like receptors (TLR) are involved in the continuous stimuli of the 
microorganisms to the epithelial cells, which in turn secrete epithelial protective 
cytokines like TNF-α, keratinocyte chemokine-1 (KC-1), and heat shock proteins 
(Rakoff-Nahoum et al., 2004). Additionally short chain fatty acids like butyrate 
produced by the intestinal bacteria, induce IL-18 expression through the G protein-
coupled receptor (GPR) 109A and regulates the apoptotic signals on epithelial cells 
(Kalina et al., 2002), and strikingly bacteria that produce these fatty acids are 
reduced in chronic inflammatory states in the gut like inflammatory bowel disease 
(Frank et al., 2007b). Through TLR-2 activation in epithelia and in dendritic cells 
(DC), the microbiota also stimulates the acquired immune response by secretion of B 
cell activating factor of the TNF family (BAFF), a proliferation–inducing ligand 
(APRIL) and transforming growth factor (TGF)-β. These cytokines promote the 
transformation of B-cells into plasma cells (Hapfelmeier et al., 2010). Consequently 
alterations in the microbiota patterns could trigger the immune response to produce 
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a chronic state of inflammation with a Th2-bias (Kabat et al., 2014), which in the 
airways could be expressed as asthma. 
Environmental exposures early in life are critical determinants of host immune 
development and function (Cooper et al., 2009). Early exposures to microorganisms 
may occur through an infected mother (i.e. trans-placental transfer of antigens) 
(Guadalupe et al., 2009), through breast-feeding (transfer through breast milk), and 
exposures to infections in infancy may ‘program’ infant immunity to a Th2-bias that is 
related with atopy and asthma development (Cooper et al., 2006). Interaction 
between the mucosal microbiome and immune cells is important in the development 
of the immune system. The microbiome mediates mechanisms of immunological 
tolerance and is essential in regulating mucosal inflammation. Modifications in 
microbiome patterns during infancy could therefore alter the subsequent host 
immune responses, and might be essential in preventing mucosal inflammation 
(Yamanaka et al., 2003). Consequently they could contribute to the development of 
atopic disease and asthma in children (Noverr and Huffnagle, 2005, Ege et al., 
2011). 
Several studies conducted in adults and children have supported the 
statement that altered gut (Huang, 2013, Russell and Finlay, 2012) or airways 
bacterial microbiome (Hilty et al., 2010) are related with a higher prevalence of atopic 
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disease and asthma. This could be one of the reasons why the ‘hygiene hypothesis’ 
is influential in allergic disease, explicated by the antibiotic use, the westernized diet 
and a lack of early microbial stimulation.  
For these reasons for this thesis a case/control study was established in order 
to determine the airways microbiome patterns in infancy and relate them with the 
development of wheezing. The project hypothesis was done taking into consideration 
the findings of Hilty et al. (2010) for adults: 
Project hypothesis 
Short and long term colonization of the airways with Proteobacteria is 
associated with the development of early onset wheezing illness during the first 2 
years of life whilst long term colonization with Firmicutes is a protective factor against 
the development of wheezing in the rural tropics. 
Projects Aims 
To identify bacteria associated with increased or decreased risk of wheezing 
in early life. 
Determine the upper airways microbiota patterns of infants during an acute 
episode of wheezing, and to monitor the long-term relationships between wheezing 
and the microbiota.  
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Determine what changes occur in the upper airways microbiota over time by 
characterizing the microbiota present at 7 months, 12 months and 24 months of age 
in healthy children. 
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Chapter 2: Materials and Methods 
2.1. List of Solutions and Kits used 
 454 Junior Titanium Sequencing kit (Roche Applied Biosystems, UK) 
 Acrylamide (Sigma, UK) 
 Ampicillin 500mg (Pfizer, UK) 
 AMPure XP beads (Roche, UK) 
 APS (Ammonium Persulfate) (Sigma, UK) 
 Beads Recovery kit (Roche Applied Biosystems, UK) 
 Brain Heart Infusion (BHI) broth 
 Butanol 100% (Sigma, UK) 
 DMSO (Dimethyl sulfoxide) (Sigma, UK) 
 dNTPs (0.2 mM each of A, T, C and G) (Roche Applied Biosystems, 
UK) 
 Emulsion PCR kit(Roche Applied Biosystems, UK) 
 Ethanol molecular biology gradient (Sigma, UK) 
 Ethidium Bromide (Sigma, UK) 
 FastStart Hifi Polymerase (Roche Applied Biosystems, UK) 
 Formamide 100% (Sigma, UK) 
 Gradient marker GM-100 (C.B.S. Scientific, Del Mar, USA) 
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 High-efficiency competent JM109 E. coli cells (Promega, UK) 
 HotStart Polymerase (Roche Applied Biosystems) 
 IPTG (isopropyl thiogalactoside) (Sigma, UK) 
 Isopropanol 100% (Sigma, UK) 
 LB media (Lysogeny broth) (Sigma, UK) 
 MgCl21.5 mM (Roche Applied Biosystems, UK) 
 MPBio Kit for Soil (Life Technologies, UK) 
 Oil and breaking kit (Roche Applied Biosystems, UK) 
 PCR buffer 10x (Roche Applied Biosystems, UK) 
 PCR sterile water (Qiagen, UK) 
 pGEM-T Easy Vectors (Promega, UK) 
 QIAmp DNA Mini Kit (Qiagen, UK) 
 Quant-iT PicoGreen dsDNA Assay Kit (Life Technologies, UK) 
 Ready-Lyse™ Lysozyme Solution (EPICENTRE, UK) 
 Sterilin swabs (Fisher, UK) 
 TAE 50X (Tris Acetate EDTA buffer pH 8.0) (Sigma, UK) 
 TE 10x (Tris EDTA pH 8.0) (Sigma, UK) 
 TEMED (Tetramethylethylenediamine) (Sigma, UK) 
 Urea (Sigma, UK) 
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 Wizard PCR Clean Up Kit (Promega, UK) 
 XGal (5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside) (Sigma, 
UK) 
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2.2. Study Population  
 Oropharynx throat swabs samples were collected as part of the Wellcome 
Trust-funded Birth Cohort study (ECUAVIDA) in Ecuador. The aim of the ECUAVIDA 
cohort study is the investigation of the effects of early infant infections on the 
development of immunity, allergic sensitization and allergic disease. This ongoing 
study is an unselected population-based birth cohort that has recruited 2,403 new-
Figure 2.1 Study Site. A) Map of Ecuador showing location of district of 
Quinindé, Esmeraldas province (red oval). B) Map showing parishes 
within the district of Quinindé including H-Hospital Padre Alberto Buffoni. 
C) Geographic location of households of cohort infants. Modified from 
Cooper et al. (2011) under permission (see appendix). 
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borns in the rural District of Quinindé in the Esmeraldas Province of Ecuador (Figure 
2.1) (Cooper et al., 2011).  
Esmeraldas Province is located in the North-West coast of Ecuador and is 
considered one of the poorest provinces of the country having less than USD2,000 
per capita income. The rural District of Quinindé includes an extension of 3,471 km2 
and therefore contains an estimated 150,000 people within one urban and six rural 
counties. The District is located in a Tropical secondary rainforest, with an average 
annual day temperature of 30°C with 75% humidity, and is located at an altitude of 
100m above sea level (Cooper et al., 2011).  
The District has an ethnically mixed population with the majority of individuals 
being mestizos (90%), with the remaining either of Afro-Ecuadorian ancestry (7%) or 
Amerindians (3%). Seventy-eight percent of the population lives in the rural counties 
of the District and only 22% in the main town (urban county). In the urban county, 
approximately 90% of the population have access to electricity, 60% to portable 
water, 40% to sanitation; and 60% to solid waste disposal services. In contrast for 
the rural zones, only 10% have access to electricity and none have access to the 
other basic services. The main Quinindé District sources of income are derived from 
agriculture, specifically African palm oil and fruit farming, although livestock cattle 
farming also occurs, and timber extraction.  
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The ECUAVIDA study is facilitated through the Hospital "Padre Alberto 
Buffoni" (HPAB) in Quinindé town, which is the only Hospital in the District and 
therefore the provider of maternity facilities for the region (Cooper et al., 2011). 
2.3. Project Design 
As part of the ECUAVIDA cohort, detailed data has been collected from the 
mothers at the time of their first antenatal visit using questionnaires and during 
periodic health check-ups at different children ages. Additionally, environmental and 
clinical samples have been taken during respiratory and gastrointestinal diseases, 
which were stored in -80ºC freezers. Questionnaires data were recorded in the 
general database of ECUAVIDA. For the present study a sub-cohort of the 
ECUAVIDA was sub-selected based on the patients’ age and clinical characteristics. 
The ECUAVIDA project has been given full ethical approval by the Universidad San 
Francisco de Quito and the Ecuadorian Health Ministry ethical committees. The 
Wellcome Trust funds totally this project. The present study is a case control 
retrospective study, divided into two stages (1 and 2) according to age. Stage 1 has 
additionally been subdivided into two parts according to the phase of disease when 
samples were collected: Part 1a during a current wheezing episode and Part 1b 
during a past wheezing episode.  
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Stage 1 is focussed on early onset wheezing (cases) and healthy (controls) 
children between 7 and 12 months of age. The aim of this stage of the project is to 
profile the upper airways microbiota for the early months of life.  
Stage 1a tries to determine the acute changes in upper airways microbiota 
related with a non-infectious wheezing episode.  Consequently, the case samples 
were collected when infants had a current wheeze episode (not caused by any 
evident respiratory infection) according to the Global Initiative for Asthma [GINA] 
2009, and at least one episode of wheezing that had previously been diagnosed by a 
physician. Healthy controls were paired by age to cases and had no wheezing 
history, current respiratory disease, chronic disease or current infections. 
Stage 1b was designed to determine the mid-term changes in upper airways 
microbiota related with non-infectious wheezing episodes. Consequently, the cases 
were collected when infants had at least two non-infectious wheeze episodes history 
according to GINA with at least one having been diagnosed by a physician.  When 
sampling was performed all cases were asymptomatic. 
Stage 2 was intended to identify the long-term effects of previous non-
infectious wheezing episodes. For this reason, subjects and sampling was almost 
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identical to that of Stage 1b (also using the same infants from stage 1b) with the 
exception that sampling was done when children were 24 months of age. 
For Stage 1a samples were collected from a total of 75 children.  One sample 
failed downstream processing (Section 2.4) and consequently in the final analysis 74 
samples were included (24 cases and 50 controls). For Stage 1b, 180 samples were 
collected of which 172 samples were processed successfully allowing their inclusion 
in the final analysis (72 cases and 100 controls). As part of Stage 1b, the samples 
from children collected at 7 months were 30 cases and 50 controls and at 12 months 
were 42 cases and 50 controls. For Stage 2 although 100 samples were collected, 
post-processing only 88 were suitable for inclusion in the final analysis (38 cases 
and 50 controls). Details of selection criteria for Stages 1a, 1b and 2 are summarised 
in Table 2.1.  
All samples were collected when infants (both cases and controls) did not 
have any evidence of a current airway infection (absence of cold symptoms and 
fever). The infants did not receive antibiotics and corticosteroids for any reason at 
least two weeks prior to sampling. All the subjects were of the same mixed ethnical 
background (mestizos), lived in the same town and had access to the same basic 
services (electricity, water, sanitation, etc.). All of them received the vaccines 
recommended by the Ecuadorian Public Health Ministry (BCG, mumps, measles and 
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rubella, tetanus, diphtheria, hepatitis B and Haemophilus influenza B; MSP, 2005). 
None of the subjects received anti-Streptococcal vaccination (not compulsory for the 
MSP). 
 
 
 
 
 
 
 Stage 
Number of 
samples 
included 
Age 
Cases Controls 
Inclusion Criteria Exclusion Criteria Inclusion Criteria Exclusion Criteria 
1 1a 
74 samples (24 
cases and 50 
controls) 
 
7-12 
months 
a) A current non-
infectious wheezing 
episode during the 
sample collection 
diagnosed by a 
physician in the medical 
control 
a) Use of antibiotics 
in the last 2 weeks 
b) Any respiratory 
infection in the last 
2 weeks 
No history of wheezing 
reported 
a) Use of antibiotics in the last 2 
weeks 
b) Any respiratory infection in the 
last 2 weeks 
 1b 
172 samples in total (72 cases and 100 controls) 
7 months: 30 cases and 50 controls 
12 months:  42 cases and 50 controls. 
 
a) At least 1 non-
infectious wheezing 
episode reported during 
the first 12 months of life 
and diagnosed by a 
physician in the medical 
control 
b) No current wheezing 
episode   e 
a) Use of 
antibiotics 
in the last 2 
weeks 
b) Any 
respiratory 
infection in 
the last 2 
weeks 
 
No 
history of 
wheezin
g 
reported 
a) Use of 
antibiotics 
in the last 
2 weeks 
b) Any 
respirator
y infection 
in the last 
2 weeks 
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2 88 (38 cases and 50 controls) 24 months 
a) At least 2 wheezing 
episodes reported during 
the first 24th months of 
life and diagnosed by a 
physician in the medical 
control 
b) No current wheezing 
episode 
a) Use of 
antibiotics 
in the last 2 
weeks 
b) Any 
respiratory 
infection in 
the last 2 
weeks 
 
No 
history of 
wheezin
g 
reported 
a) Use of 
antibiotics 
in the last 
2 weeks 
b) Any 
respirator
y infection 
in the last 
2 weeks 
 
 Table 2.1. Detailed information about inclusion and exclusion criteria during sample selection.  
 
  
Controls in all the stages were matched by age to cases and had no history of 
wheezing episodes or any chronic morbidity, and were therefore defined as ‘healthy’.  
2.4. Throat Swabs: Collection and Storage 
Throat swabs were collected using sterile cotton swabs (Fisher, UK) and were 
placed in collection tubes (Fisher, UK). Sampling was performed carefully without 
touching any surface (i.e. tongue, mouth, and teeth) other than the oropharynx and 
using a tongue depressor.  
Each swab was rubbed approximately five times around the oropharynx, 
applying an even pressure and rotating the swab without interruption. The swab was 
immediately placed back into the collection tube and stored at -20oC and 
subsequently at -80oC.  Samples were shipped on dry ice under careful temperature 
control to the National Heart and Lung Institute, Imperial College London for DNA 
extraction. 
2.5. Bacterial DNA Extraction from Throat Swabs 
Bacterial DNA was extracted from the 400 throat swabs using a modified 
protocol of the commercial QIAmp DNA Mini Kit (Qiagen). Additional steps at the 
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beginning of the protocol were included to improve the lysis of Gram positive (+ve) 
bacteria (Hilty et al., 2010) and are detailed below. 
Lysozyme (4X concentration = 1000U/µl) was prepared from lysozyme stock 
(30,000 U/µl Ready-Lyse™ Lysozyme Solution, EPICENTRE, UK). Each swab head 
was transferred into a 2 ml sterile microcentrifuge tube and 432µl TE (Tris EDTA pH 
8.0) plus 18µl 4X lysozyme solution added. Samples were incubated for 1 hour at 
37°C to allow improved lysis of Gram +ve bacterial walls. During this hour, samples 
were vortexed for 20 seconds at intervals of 15 minutes. Next 30μl of Proteinase K 
and 450μl of Buffer AL were added to the tube and samples were incubated at 56°C 
for 30 minutes. To terminate the Proteinase K digestion step, samples were 
incubated for 5 min at 95°C. 
Next 450μl of Ethanol (96–100%) was added to the sample and vortexed in 
order to obtain a homogeneous solution.  The solution was then applied to the 
QIAamp Spin Column as per the manufacturer’s protocol. 
In the final step 40μl of nuclease free water was added instead of the elution 
buffer supplied by the kit. If, after extraction, the DNA was not being used 
immediately samples were stored at -20°C until required. 
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2.6. Preliminary Microbiome Studies using Denaturing 
Gradient Gel Electrophoresis (DGGE) and Sanger 
Sequencing 
2.6.1. Amplification of 16S rRNA Gene 
Polymerase chain reaction (PCR) was used to amplify the variable region 3 
(V3) of the gene that encodes for 16S rRNA in bacteria. A nested PCR approach 
was implemented for running samples on Denaturing Gradient Gels (Electrophoresis 
- DGGE). PCR products from the first step of the nested PCR were cloned for the 
purpose of sequencing. 
2.6.2. First Round PCR 
For the first round PCR, the V3 region of the 16S rRNA gene was amplified 
using the following conserved primers: 
339F (Forward) 5’-ACTCCTACGGGAGGCAGCAGT-3' 
907R (Reverse) 5'-CCGTCAATTCATTTGAGTTT-3’ 
Reactions with a final volume of 25μl were set up containing: 2μl of template 
DNA, 2.5μl 10X PCR buffer (Roche Applied Biosystems, UK), 1.5 mM MgCl2, 6% 
DMSO, 0.5 μM of each primer, 0.8 mM dNTPs (0.2 mM each of A, T, C and G) and  
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1U HotStart Polymerase (Roche Applied Biosystems). PCR cycling conditions used 
were: 
 Hot start: 95°C for 5 min,  
 Twenty cycles of 95°C for 30s, 55°C for 30s and 72°C for 60s,  
 Final extension of 72°C for 5 min  
PCR reactions and cycling conditions had previously been optimized within 
the Molecular Genetics and Genomics Group at the National Heart and Lung 
Institute (Hilty et al., 2010).  
2.6.3. Second Round PCR  
To improve detection of single base pair changes, a GC rich clamp was 
incorporated in the second round PCR by including it in the design of the forward 
primer sequence (Sheffield et al., 1989). First round PCR products were diluted with 
PCR sterile water (Qiagen) 1:10 and 2μl of the dilution was used as a template for 
the second round PCR amplification. The primers used were:  
 339F (Forward with [in red font] a GC-clamp)  
5'-CGCCCGGGGCGCGCCCCGGGCGGGGCGGGGGCACGGGGGGA 
CTCCTACGGGAGGCAGCAGT-3’  
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 539R (Reverse) 5'-GTATTACCGCGGCTGCTGGCAC-3’.   
As in the first round PCR, reactions of 25μl were set up containing: 2μl of 
template DNA, 2.5μl 10X buffer (Roche Applied Biosystems, UK), 1.5 mM MgCl2, 6% 
DMSO, 0.5 μM of each primer, 0.8 mM total dNTP (0.2 mM each of A, T, C and G) 
and 1U HotStart Polymerase (Roche Applied Biosystems) (Hilty et al., 2010).  PCR 
cycling conditions used were: 
 Hot start: 95°C for 5 min,  
 Twenty cycles of 95°C for 30s, 55°C for 30s and 72°C for 60s,  
 Final extension of 72°C for 5 min  
After the second round PCR, PCR products were stored at -20°C until 
required. 
2.6.4. Denaturing Gradient Gel Electrophoresis (DGGE) 
DGGE is a technique based on differences in the intrinsic denaturing 
behaviour of double stranded DNA fragments which allows separation of fragments 
that are the same size but that differ in sequence.  The electrophoresis is performed 
in a vertical polyacrylamide gel containing a gradient of denaturant chemicals (Fisher 
& Lerman, 1979). A denaturant gradient of 30 to 60% was used for the DGGE 
experiments. The gel was 0.75 mm thick and contained 8% polyacrylamide. 
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2.6.4.1. Preparation of the Gel  
A vertical electrophoresis system PROTEAN II (Bio-Rad, USA) was used for 
preparation and running of the gels. Both sides of the spacers where covered with a 
thin layer of silicon grease (the full length of the spacer but only a quarter of the 
spacer width). The greased side of the spacers was positioned at the outer edges of 
the glass plates. Sandwich clamps were used to secure the glasses together and to 
prevent leakage during gel pouring.  
The denaturing gradient was created using acrylamide with a 30% and 60% 
concentration of denaturant. To prepare the 400 ml of 60% denaturant acrylamide-
solution, 80 ml of 40% acrylamide, 100.8 g of urea, 96 ml of 100% formamide, 4 ml 
of 50X TAE (Tris Acetate EDTA buffer pH 8.0) were combined and MilliQ water was 
added to a final volume of 400 ml. For the 30% denaturant stock solution, 80 ml of 
40% acrylamide, 50.4 g of urea, 48 ml of 100% formamide, 4 ml of 50X TAE were 
combined and MilliQ water was added to a final volume of 400 ml. 
High and low solutions of acrylamide (11.5 ml each) were set up for 
polymerization using 80μl of APS and 5μl of TEMED and the two solutions were 
placed into the separate chambers of the gradient maker GM-100 (C.B.S. Scientific, 
Del Mar, USA). Both solutions were mixed in the gradient marker and simultaneously 
poured into the gel chamber avoiding bubbles. Immediately after pouring, a few ml of 
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water-saturated butanol were put on top to ensure that a straight surface was 
obtained.  The gel was fully polymerized after 60 minutes.  
After polymerization the butanol was flushed from the top of the gel using 
MilliQ water, the comb inserted, and the stacking gel (consisting of 5 ml 8 % 
acrylamide 5μl TEMED and 50μl APS) was poured using a Pasteur pipette. 
Polymerization of the stacking gel took 15 minutes.  
An aquarium tank with 1 cm thick glass (length: 44cm, width: 30cm, height: 29 
cm) was used.  The tank was filled with 23 litres of 0.5X TAE buffer, and set up at 
60°C using the immersion circulator and thermostat pump DL-30 (Haake Karlsruhe, 
Germany).  
Eight µl of PCR product was mixed with 2μl of loading buffer (Bio-Rad, UK) 
and then loaded onto the gel. Additionally two identification markers were loaded in 
the outer lanes of the gel. These markers were designed by Hilty et al. using 16S 
rRNA amplicons (with the same primers and conditions of the second round PCR). 
The first marker labelled the ´Asthma Marker´ consists of 16S rRNA amplicons of 
bacteria that according to previous studies were identified in asthma patients.  The 
marker therefore includes: 
 Haemophilus sp. 
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 Haemophilus influenzae 
 Finegoldia magna  
 Moraxella sp. 
 Prevotella sp.  
 Streptococcus sp.  
 Moraxellaceae 
 Neisseria sp. 
 Neisseria meningitidis 
 Bordetella hinzii 
The ´Normal Marker´ was designed using 16S rRNA amplicons from 
commensal airway bacteria and includes: 
 Bacteroidales  
 Staphylococcus sp. 
 Haemophilus sp. 
 Porphyromonas sp. 
 Prevotella sp. 
 Neisseria sp. 
 Veillonella sp. 
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The gel chamber was placed in the aquarium and run at 100 Volts (about 20 
mA for one gel) for a total of 16 hours. Afterwards, the gel was removed from the 
chamber and stained in 1 x TBE/Ethidium Bromide at a concentration of 0.5 µg/ml 
for 60 min and then visualized using an ultraviolet lamp (Hilty et al., 2010). 
2.6.5. Cloning and Sequencing 
2.6.5.1. Ligation/Transformation and Amplicon Libraries 
Construction 
First round PCR products were cloned and sequenced. PCR products were 
run in a 0.9 % agarose gel. The bands were excised and cleaned using a Wizard 
PCR Clean Up Kit (Promega, UK). The purified amplicons were re-suspended in 
20μl of sterile MilliQ water.  
Two µl of purified PCR products were ligated into pGEM-T Easy Vectors 
(Promega) and the ligated vectors transformed into high-efficiency competent JM109 
E. coli cells (Promega). Both the ligation and transformation reactions were carried 
out following the protocol set out in the Promega manual (pGEM-T and pGEMT-T 
Easy Vector Systems TM042). Clones were grown in LB/Ampicillin/IPTG-XGal 
medium (Promega) for 24 hours at 37°C.  
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2.6.5.2. Picking Clones and Sequencing 
Ninety-six well plates (well capacity 0.8 ml) were prepared by pipetting 0.2ml 
LB medium containing ampicillin at 0.2mg/ml into each well. White colonies (positive 
selection of lac –ve colonies that have amplicons inserted) were picked with sterile 
pipette tips and transferred to an individual well. Plates were shipped to a private 
sequencing company (Cogenics, UK) and sequenced using the Beckman Coulter 
Genomics sequencer (USA-UK). The sequencing was performed using the Sanger 
di-deoxy technology using the SP6 vector primer as the sequencing primer. Post 
sequencing, files with the sequences (.fasta) and chromatographic traces (.ab1) 
were received back from Cogenics via email.  
2.6.6. Computation Analysis of Preliminary Results 
High quality sequences were selected by checking the chromatographic 
traces using Codon Code Aligner software version 3.5.6 
(http://www.codoncode.com/aligner/).  Next primer and vector sequence regions 
were trimmed and full-length sequences ranging from 359 to 906 were analysed. 
Fasta files were exported and uploaded to the Greengenes project online program 
(http://greengenes.lbl.gov). Sequences were aligned using NAST and ClustalW 
(Thompson et al., 2002). Alignments were manually verified and checked for 
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chimeras using part of the Greengenes project; Bellerophon Version 3 (DeSantis et 
al., 2006). Chimeras identified were excluded from subsequent analyses. 
The DNADist tool (Greengenes) was used to calculate triangular distance 
matrices. Operational taxonomic units (OTUs) were determined using DOTUR 
(Distance based OTU and richness determination program) using the furthest-
neighbour algorithm with a cut off of 97% sequence identity. Chao 1 richness index 
and Shannon diversity index was also estimated in DOTUR (Schloss and 
Handelsman, 2005).  Evolutionary distances were calculated with the Jukes-Cantor 
(tree-Markov) model. 
The phylogenetic tree was created using the Neighbour-Joining algorithm 
(Saitou and Nei, 1987) within Mega 6 (Tamura et al., 2013a). The evolutionary 
distances were computed using the Maximum Composite Likelihood method 
(Tamura, Nei, & Kumar, 2004). Bootstrapping was performed using 1000 tree 
replicates and the confidence levels of over 50% were shown at the internal nodes.  
The identity of OTUs was defined by comparing the sequence of interest to 
those within the ribosomal database (20 best match sequences define taxonomic 
rank) and these were further compared to NCBI BLAST to determine the percentage 
of sequence identity.  
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Microbial community comparisons were made using the Bonferroni correction 
test which corrected the P-values for multiple comparisons in UNIFRAC (Lozupone 
and Knight, 2005a). This is achieved by multiplying the raw P-value by the number of 
permutations. In the single phylum comparison tests, P-values were calculated for 
association between the groups using Two-tailed Fisher’s exact tests and by the 
application of a conservative Bonferroni correction for multiple testing (Durrant et al., 
2004).  
2.7. Pyrosequencing Analysis of the Microbiome 
2.7.1. Amplification of the 16S rRNA Gene 
Polymerase chain reaction (PCR) was used to amplify the variable region 3 to 
5 of the gene that encodes for 16S rRNA in bacteria. To minimize the PCR 
nucleotide insertion mistakes, samples were amplified in quadruplicate reactions with 
20 cycles each and then pooled. 
For the PCR, the V3 region of the 16S rRNA gene was amplified using the 
following conserved primers: 
336F (Forward) 5’-CCATCTCATCCCTGCGTGTCTCCGACTCAG 
CCTACGGGAGGCAGCAG-3' 
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926R (Reverse) 5'-CCATCTCATCCCTGCGTGTCTCCGACTCAG 
CCGTCAATTCMTTTRAGT-3’ 
The Adaptor Sequence in both the reverse and forward primers (highlighted in 
red) are used to link the biotinylated 5’ extreme of the amplicon with a single Enzyme 
bead in the Emulsion PCR (Section 2.6.4 below). 
Multiplexing was achieved using molecular identifiers (MIDs) also known as 
nucleotide barcodes, which are specific sequences of 12 nucleotides long.  There 
were used the MIDs with the numbers 1 to 300 recommended by the US Human 
Microbiome Project (http://www.hmpdacc.org).  
PCR reactions with a final volume of 25μl were set up containing: 1μl of 
template DNA, 2.5μl 10X PCR buffer (Roche Applied Biosystems, UK), 1.3% DMSO, 
1 μM of each primer (μM), 0.5μl dNTPs (10 mM each of A, T, C and G) and 1.25 U 
FastStart Hifi Polymerase (Roche Applied Biosystems). PCR cycling conditions used 
were: 
 Hot start: 92°C for 2 min,  
 Thirty cycles of 94°C for 20s, 50°C for 30s and 72°C for 5min,  
 Final hold 4°C for 5 minutes and then products moved to fridge. 
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Quadruplicate PCRs were conducted for each sample in order to minimise 
PCR nucleotide incorporation errors, which would have an unfavourable impact on 
the downstream sequencing. PCR reactions and cycling conditions had previously 
been optimized within the Molecular Genetics and Genomics Group at the National 
Heart and Lung Institute.  
2.7.2. Amplicon Cleaning  
After PCR, amplicons were purified using the AMPure XP beads (Roche, UK) 
to eliminate any primer dimer products and the PCR reagent remnants. Purification 
was performed using a modified and optimized protocol of DNA cleaning using 96 
well plates (Magnetic plate Ambion® #AM10027 in combination with 96 well round 
bottom plates Costar® 3367) instead of tubes.  To purify the desired Amplicon the 
ratio of AMPure beads volume and PCR product was also modified from a 1:1 ratio 
to a 0.7:1 ratio.  
Products from the quadruplicate PCRs were pooled and the resultant 100μl 
volumes pipetted into a well of the round bottom plate. The AMPure bead bottle was 
vortexed to ensure all the AMPure beads were completely re-suspended 
(approximately 20 seconds) and 70μl of beads transferred to each well.  Beads and 
sample were mixed thoroughly by pipetting up and down at least 12 times thereby 
ensuring a homogeneous was obtained. 
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Plates were incubated for 10 min at room temperature and then placed on to 
the 96-well magnetic stand for 5 min at room temperature until the beads were 
located and fixed to the bottom of the wells. The supernatant was removed and 
discarded by manual pipetting. The beads were then washed twice with addition of 
100μl of 70% ethanol to each well. Plates were then incubated at room temperature 
placed in the magnetic stand until all pellets were completely dry (10-20 min). After 
this time, the pellets were re-suspended by addition of 50μl of 1x TE to each well 
after which the supernatant with the DNA was transferred into a new plate.  The 
latter was stored at -20 ºC until the quantification step. 
2.7.3. DNA quantification 
Quantification of DNA was performed twice during the protocol. First after the 
16S rRNA gene PCR and purification, and the second time after sample pooling 
(library creation). On both occasions the Quant-iT PicoGreen dsDNA Assay Kit (Life 
Technologies, UK) was used. 
Using the DNA standard (100 ng/μl) provided in the kit and diluting with 1x TE, 
a full set of standards, including a blank 1x TE control, were created: 100 ng, 50 ng, 
25 ng, 12.5 ng, 6.25 ng, 3.13 ng, 1.56 ng. Standards were plated in duplicate into 96-
well black fluorometer plates. 
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 To the remaining 80 wells of each 96 well plate, 99µl of TE was added plus 
one microliter of each sample to be quantified, and mixed by up and down pipetting. 
To all wells 100µl of a 1:200 dilution of PicoGreen reagent was added resulting in a 
final total volume of 200µl in each well. The samples were excited at 480 nm and the 
fluorescence emission intensity was measured at 520 nm using a 
spectrofluorometer.  
For each plate measured, it was verified that the R2 value of the standard 
curve was at least 0.98 thereby ensuring accuracy of the quantification. To calculate 
each sample’s DNA concentration it was used the curve equation (y = ax + b). From 
each fluorometry value it was calculated the DNA concentration using the ‘a’ and ‘b’ 
values. 
2.7.4. Pyrosequencing: 
The Amplicon libraries that were generated were quantified using the Quant-it 
Picogreen dsDNA Assay Kit according to the manufacturer protocols (See Section 
2.6.3 and www.454.com). The number of molecules per μl was calculated using the 
formula: 
 
 80 
Amplicon libraries were then diluted separately to 1x109 molecules/μl in 1x TE 
Buffer. The libraries were then pooled to create a working solution with every sample 
containing the same number of molecules per μl. To avoid over-enrichment during 
the Emulsion PCR prior to pyrosequencing, a maximum of 0.5 molecules of amplicon 
per bead was calculated to using the formula: 
 
Emulsion PCR was carried out using the DNA libraries previously constructed. 
There were combined the amplicons with the enzyme beads using their linked 
adaptor sequence.  Prior optimisation within the Molecular Genetics Group of the 
emulsion PCR meant that a slightly modified master mix, to that recommended by 
Roche, was used consisting of molecular biology grade water 397.5µl, additive 
515µl, amp mix 282.5µl, amp primer 80µl, enzyme mix 70µl, PPiase 2µl on a total 
volume of 1347µl (part of the 454 Junior Titanium Sequencing kit). 
Post emulsion PCR beads were captured using a vacuum pump and cleaned 
from the emulsion oil (beads recovery kit) using isopropanol, ethanol and finally the 
enhancing buffer provided on the kit. Only the beads successfully ligated to an 
amplicon were recovered using magnetic filtering. The success of this step was 
validated quantifying the number of beads that had DNA ligated. The result was 
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positive if were counted around 500,000 beads (using the beads counter provided by 
Roche). 
The 454 Roche technology uses enzyme beads (containing sulfurylase and 
luciferase) (part of the 454 Junior Titanium Sequencing kit) placed onto a 
PicoTiterPlate device. This device is necessary to ensure that the DNA remains 
positioned in the wells during the sequencing reaction. On the wells plate occurs a 
de novo synthesis of the complementary DNA template ligated to the beads. The 
sequencing reaction occurs when a nucleotide successfully is ligated to the daughter 
chain as each time PPi is liberated, which reacts with PPiase and produces a 
luminescent signal. If there is not for a certain nucleotide a successful reaction 
during amplification, they are washed out and no signal is produced. The 
luminescent signals are then interpreted as nucleotide sequences on each well.  
2.7.5. Data Analysis 
2.7.5.1. Sequences Analysis in QIIME 
From the raw sequences obtained, data analysis was performed using the 
microbiological communities’ program QIIME http://qiime.sourceforge.net/ (Caporaso 
et al., 2010b). In order to use this multiplatform pipeline, it was initially necessary to 
create the mapping file containing the name of each sample, the barcode sequence 
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used for each sample, the linker/primer sequence used to amplify the sample’s 
desired gene.  In addition all the metadata related to the sample was included e.g. 
age, gender, type of sample, Case/Control, wheezing status, treatment, etc. For the 
data analysis the sequences text file (fasta file *.fna), the sequencing quality file 
(*.qual), and the Standard Flowgram Format binary file (*.sff) were used.  
As the mapping file is generated manually, it was important to check if it had 
been formatted correctly and this check was performed using the script: 
check_id_map.py -m Fasting_Map.txt -o mapping_output 
-m = mapping file 
-o = output directory name 
Read errors were removed if there were <200 and >800 nucleotide (nt), 
mismatches in the barcodes or primers, ambiguous nucleotides and if the quality 
score was <25 recommended by Brockman et al. (2008) for the Titanium platform.  
The Ampliconoise algorithm (Reeder and Knight, 2010) was used to avoid 
overestimates in diversity as well as chimera removal  using the following command 
with appropriate modification of the files name pending on the stage of the project 
being analysed: 
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ampliconnoise.py -i stage1b_1to36.sff.txt -m Map_stage1b_1to36.txt -o 
anoised_stage1b_1to36.fna --platform titanium -n 4 
-i = input file 
-m = mapping file 
-o = output file 
--platform = platform used for pyrosequencing 
-n = cores of CPU used on the analysis  
As many sequencing runs were analysed together, it was necessary to merge 
the data produced from different runs. The following command was used to achieve 
this: 
cat seqs1.fna seqs2.fna >> combined_seqs.fna 
After denoising and ensuring, by using the sequence barcode, that each 
sequence was assigned to a sample, OTUs were defined using the UCLUST 
algorithm (Edgar, 2010b) through the pick_otus.py command at 97% sequence 
identity: 
pick_otus.py -i seqs.fna -r refseqs.fasta -m uclust_ref -C 
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-i = input file 
-r = Path to reference sequences 
-m = otus picking method 
-C = suppress creation of new clusters using seqs that don’t match reference 
After OTU picking, a representative sequence was selected for the posterior 
analysis using the following command: 
pick_rep_set.py -i seqs_otus.txt -f seqs.fna -o rep_set1.fna 
Sequences were aligned to the Greengenes Core reference alignment 
(DeSantis et al., 2006) using a Python based tool, by means of the Nearest 
Alignment Space Termination (NAST) algorithm called PyNAST (Caporaso et al., 
2010a), and the following command in QIIME: 
align_seqs.py –i unaligned.fna -t core_set_aligned.fasta.imputed -o 
pynast_aligned_defaults/ 
-i = input file from alignment 
-t = Greengenes core reference alignment 
-o = output file 
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Phylogenetic classification was assigned using the Greengenes reference 
database version 10.2  (McDonald et al., 2012) and the command line: 
assign_taxonomy.py -i repr_set_seqs.fasta -r ref_seq_set.fna -t 
id_to_taxonomy.txt 
The alignment produced in the previous step was filtered prior to phylogenetic 
tree construction. It was used the default lanemask template file on QIIME 
lanemask_in_1s_and_0s.txt: 
filter_alignment.py -i seqs_rep_set_aligned.fasta -m lanemask_in_1s_and_0s 
-o filtered_alignment/ 
-i = input file from alignment 
-m = lanemask template file located in QIIME 
/Users/caporaso/data/greengenes_core_sets/lanemask_in_1s_and_0s.txt 
In order to build a maximum-likelihood phylogenetic tree using Fasttree 
version 2.1.3 (Price et al., 2010b) the command line: 
make_phylogeny.py -i aligned.fasta -o rep_phylo.tre –r midpoint 
-i = input file filtered alignment 
-o = output file name 
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-r = rooted method midpoint was used. 
Using the taxonomy assignation obtained and the abundance of sequences 
per OTU, an OTU summary table could be constructed: 
make_otu_table.py -i otu_map.txt -t tax_assignments.txt -o otu_table.biom 
-i = input file from the ampliconnoise command 
-t = taxonomy assignations 
-o = output file name in format .biom 
To determine the number of reads per sample obtained in the OTU table, the 
command used was: 
biom summarize-table -i otus/otu_table.biom -o otus/otu_table_summary.txt 
-i = the input OTU table file 
-o = output file summary 
An interactive heatmap showing the number of reads per OTU and per 
sample was initially constructed using: 
make_otu_heatmap_html.py -i otu_table.biom -o heatmap/ 
-i = input OTU table 
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-o = output directory path 
The heatmap obtained was subsequently modified using Microsoft Excel 
2013® to change the colours and to group the samples by age and into cases and 
controls. 
Sequences were rarefied (to remove the heterogeneity in the number of 
sequences per sample) prior to calculation of alpha diversity.  The latter was 
calculated using a multiple rarefaction pipeline: 
 multiple_rarefactions.py -i otu_table.biom -m 10 -x 140 -s 10 -n 2 -o 
rarefied_otu_tables/ 
-i = input out table. 
-m = Minimum number of seqs/sample for rarefaction. 
-x = Maximum number of seqs/sample for rarefaction. 
-s = Size of each steps between the min/max of seqs/sample. 
-n = The number of iterations at each step. 
-o = output directory. 
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Alpha diversity calculations provide a comparison intra-group of the number of 
species found and their distribution on each group. The diversity indexes like 
Shannon and Inverse Simpson are an average calculation of evenness and richness. 
Evenness shows how uniform is the distribution of the bacterial OTUs within each 
group, and richness calculate the number of species per group (Figure 2.2).   
 
Figure 2.2. Alpha Diversity Calculations on Mixed Microbial 
Communities showing Evenness and Richness. Each shape 
represents an individual and the colour and nature of the shape 
represents a different type of organism. Increased numbers of different 
types of organism is described as increased species richness. When no 
one organism is dominant, the community is described as even.  Taken 
under permission (see appendix) from Cox et al. (2013b) 
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The multiple rarefaction OTU tables, alpha diversity coefficients, Shannon; 
OTUs observed per sample; evenness and richness statistics (Chao1) were 
computed: 
alpha_diversity.py -i otu_tables/ -t rep_set.tre -m 
shannon,chao1,eveness,observed_species -o adiv_pd.txt 
-i = multiple rarefactions directory path. 
-t = phylogenetic tree. 
- m = alpha diversity metrics. 
-o = output directory. 
Results from each statistic for each rarefied OTU table were collated in a 
single file using the following command: 
collate_alpha.py -i alpha_div/ -o collated_alpha/ 
-i = alpha diversity files. 
-o = output directory. 
Using the collated alpha diversity files, plots from each statistic were 
constructed by: 
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make_rarefaction_plots.py -i alpha_div_collated/ -m Fasting_Map.txt -d 300 -g 
pdf 
-i = input directory. 
-m = mapping file. 
-d = image resolution. 
-g = image format output 
Beta diversity statistics are performed to provide in a numerical matrix the 
diversity differences compared between two or more groups. They were executed 
using UNIFRAC metrics (Lozupone and Knight, 2005a, Chang et al., 2011) on single 
rarefaction OTU tables. The value of reads per sample on the single rarefaction 
tables was selected using the minimum number of sequences obtained in a sample 
with good enough diversity (seen both on the heatmap and the OTU table). 
single_rarefaction.py -i otu_table.biom -o otu_table_even100.biom -d 100 
Two methods were implemented for beta diversity statistics.  The weighted 
UNIFRAC (that takes into account the abundance and the phylogenetic differences 
of each OTU between samples), and the un-weighted UNIFRAC (which takes 
account of the phylogenetic differences of each OTU between samples). 
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beta_diversity.py -i otu_table.biom -m weighted_unifrac,unweighted_unifrac -o 
beta_div/ -t rep_set.tre 
-i = single rarefied OTU table. 
-m = metrics used. 
-o = output directory path. 
-t = phylogenetic tree. 
Using the beta diversity distance matrices obtained, a principal coordinates 
analysis (PCoA) was used to compare groups of samples based on phylogenetic or 
count-based distance metrics: 
principal_coordinates.py -i beta_div.txt -o beta_div_coords.txt 
-i = input beta diversity metrics 
-o = output file 
Results from the PCoA were visualized using EMPeror, for the analysis and 
visualization of results on 3D plots (Vazquez-Baeza et al., 2013). The following 
command was used: 
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make_emperor.py -i unweighted_unifrac_pc.txt -m mapping_file.txt -b 
"Age,Treatment" -o emperor/ 
-i = beta diversity PCoA file. 
-m = mapping file. 
-b = categories used for comparisons. 
-o = output directory path. 
In addition to the 3D beta diversity plots produced previously, bi-plots that 
include taxa summary were constructed using the command lines: 
make_emperor.py -i wf_bdiv_even146/unweighted_unifrac_pc.txt -m 
Fasting_Map.txt -t wf_taxa_summary/otu_table_L3.txt --n_taxa_to_keep 5 -o 
3d_biplot 
-i = beta diversity PCoA file. 
-m = mapping file. 
-t = taxa summary produced from the OTU tables. 
--n_taxa_to_keep = number of most abundant phylum-level taxa to be 
included. 
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-b = categories used for comparisons. 
-o = output directory path. 
In addition to the UNIFRAC metrics used for the beta diversity analysis, 
Jackknifed Beta Diversity and Hierarchical Clustering were performed. This method 
uses the phylogenetic distances obtained in a tree by dividing the sum of "unshared" 
branch lengths over the sum of all tree branch lengths. As consequence 
phylogenetic distances between two communities are represented in a distance 
matrix (Lozupone et al., 2006).  From the rarefied distance matrices an Un-weighted 
Pair Group Method with Arithmetic mean (UPGMA or average linkage) tree was 
performed:  
upgma_cluster.py -i beta_div.txt -o beta_div_cluster.tre 
-i = beta diversity calculations input file. 
-o = output tree file. 
2.7.5.2. Sequences Analysis in R 
The statistical analysis to compare between groups was performed in R 
version 3.02 (Team, 2014) using Rstudio version 0.98.497 and the following 
packages: phyloseq (McMurdie and Holmes, 2013), picante (R tools for integrating 
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phylogenies and ecologie), ggplot2 (graphical tool), plyr (tools for splitting, applying 
and combining data), Biostrings (string objects representing biological sequences 
and matching algorithms) (Pages et al.), vegan (community ecology package) 
(Dixon, 2003), ape (analyses of phylogenetics and evolution) (Paradis et al., 2004), 
ade4 (analysis of Euclidean data) (Dray et al., 2007). 
OTU tables were imported together with the rooted phylogenetic tree 
produced on QIIME using the following command: 
ecu.biom = import_biom("otus/otu_table.biom", treefilename = "rooted.tre") 
The metadata from samples was uploaded into R using: 
ecu.env = import_qiime(mapfilename = "../mapping_file.txt") 
The reference sequences from each OTU were imported using: 
refseqs = readDNAStringSet("otus/rep_set/anoise_out _rep_set.fasta") 
The OTU table, phylogeny, metadata and reference sequences were merged 
in a single metafile: 
ecu.biom = merge_phyloseq (ecu.biom, ecu.env, refseqs) 
A function called “multiplot” was created to allow plotting multiple graphics 
side by side: 
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multiplot <- function(..., plotlist=NULL, file, cols=1, layout=NULL) { 
require(grid) 
# Make a list from the ... arguments and plotlist 
plots <- c(list(...), plotlist) 
numPlots = length(plots) 
# If layout is NULL, then use 'cols' to determine layout 
if (is.null(layout)) { 
# Make the panel 
# ncol: Number of columns of plots 
# nrow: Number of rows needed, calculated from # of cols 
layout <- matrix(seq(1, cols * ceiling(numPlots/cols)), 
ncol = cols, nrow = ceiling(numPlots/cols)) 
} 
if (numPlots==1) { 
print(plots[[1]]) 
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} else { 
# Set up the page 
grid.newpage() 
pushViewport(viewport(layout = grid.layout(nrow(layout), ncol(layout)))) 
# Make each plot, in the correct location 
for (i in 1:numPlots) { 
# Get the i,j matrix positions of the regions that contain this subplot 
matchidx <- as.data.frame(which(layout == i, arr.ind = TRUE)) 
print(plots[[i]], vp = viewport(layout.pos.row = matchidx$row, 
layout.pos.col = matchidx$col)) 
} 
} 
As the number of sequences obtained varied between samples (575 to 4395) 
and to remove this sample heterogeneity, sequences were rarefied to 575 
sequences per sample. To do this:  
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plot(sort(sample_sums(ecu.biom)), pch = 16, cex = .5, ylab = "Number of 
reads", xlab = "Ranked abundance", main = "Ranked abundance of reads per 
sample", sub = "Selection of random re-sampling (rarefaction) level to optimise both 
reads and samples") 
abline(h = 575, col = "red") 
ecu.biom = rarefy_even_depth(bx.biom, sample.size = 575, rngseed = TRUE, 
replace = FALSE, trimOTUs = TRUE) 
As the default taxa levels on the OTU table are not very informative for studies 
of this nature, the text was replaced with the phylogeny ranks: 
colnames(tax_table(ecu.biom)) = c("Phylum", "Class", "Order", "Family",  
"Genus", "Species") 
Per each sample alpha diversity was additionally calculated using the 
command: 
sample_data(ecu.biom)$Shannon = diversity(t(otu_table(ecu.biom))) 
sample_data(ecu.biom)$InvSimp = diversity(t(otu_table(ecu.biom)), "inv") 
sample_data(ecu.biom)$Rich = specnumber(t(otu_table(ecu.biom))) 
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sample_data(ecu.biom)$Even = specnumber(t(otu_table(ecu.biom))) 
sample_data(ecu.biom)$Shannon/log(sample_data(ecu.biom)$Rich) 
Alpha diversity obtained per sample was plotted using the software 
GraphPrism version 5.0 (http://www.graphpad.com). The alpha diversity values 
influenced by phylogeny were calculated using the net relatedness index (NRI) and 
nearest taxon index (NTI) (Swenson et al., 2006): 
 MPD = ses.mpd(t(otu_table(ecu.biom), cophenetic(phy_tree(ecu.biom)), 
null.model="taxa.labels") 
MNTD = ses.mntd(t(otu_table(ecu.biom), cophenetic(phy_tree(ecu.biom)), 
null.model="taxa.labels") 
To determine normality in the alpha diversity values from samples grouped on 
quantiles, the Shapiro-Wilkinson normality test (SHAPIRO and WILK, 1965) was 
used: 
shapiro.test(sample_data(ecu.biom)$Rich) 
shapiro.test(sample_data(ecu.biom)$Even) 
shapiro.test(sample_data(ecu.biom)$InvSimp) 
shapiro.test(sample_data(ecu.biom)$Shannon) 
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Results from this were then plotted using: 
```(r fig.width=7, fig.height=6) 
par(mfrow = c(2,2)) 
qqnorm(sample_data(bx.biom)$Rich, main = "Richness") 
qqnorm(sample_data(bx.biom)$Even, main = "Evenness") 
qqnorm(sample_data(bx.biom)$InvSimp, main = "InvSimp") 
qqnorm(sample_data(bx.biom)$Shannon, main = "Shannon") 
Results that showed a normal distribution were analysed with t test statistics 
for comparisons between two groups and ANOVA (analysis of variance) when 
considering > than two groups.  
t.test(sample_data(ecu.biom)$Rich ~ sample_data(ecu.biom)$Gender) 
fit = aov(sample_data(ecu.biom)$Rich ~ sample_data(ecu.biom)$Diagnosis) 
summary(fit) 
Whilst non-parametric results were analysed using the Wilcoxon test for two 
group comparison and the Kruskal test for > than two groups: 
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wilcox.test(sample_data(ecu.biom)$Shannon ~ 
sample_data(ecu.biom)$Gender) 
kruskal.test(sample_data(ecu.biom)$Even ~ 
sample_data(ecu.biom)$Diagnosis) 
Correlation for ordinal and continuous variables was also tested for by: 
cor.test(sample_data(ecu.biom)$Shannon, sample_data(ecu.biom)$Age, 
method = "kendall") 
Beta diversity was calculated between groups at OTU level using Adonis R 
package on vegan (Dixon, 2003), and subsequent statistical analysis performed 
using: Canberra, Bray-Curtis, UNIFRAC and Weighted UNIFRAC. 
ecu.dist.cross.canberra = distance(ecu.biom, method = "canberra") 
ecu.dist.cross.bray = distance(ecu.biom, method = "bray") 
ecu.dist.cross.unifrac = distance(ecu.biom, method = "unifrac") 
ecu.dist.cross.wunifrac = UniFrac(ecu.biom, weighted = TRUE) 
ecu.dist.canberra = distance(ecu.biom, method = "canberra") 
ecu.dist.bray = distance(ecu.biom, method = "bray") 
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ecu.dist.unifrac = distance(ecu.biom, method = "unifrac") 
ecu.dist.wunifrac = UniFrac(ecu.biom, weighted = TRUE) 
To determine how the cases/controls status explains a different proportion of 
the variance each time there were used Nonmetric multidimensional scaling (NMDS) 
stress calculations: 
ecu.biom.ord.canberra = ordinate(ecu.biom, "NMDS", "canberra") 
ecu.biom.ord.bray = ordinate(ecu.biom, "NMDS", "bray") 
ecu.biom.ord.unifrac = ordinate(ecu.biom, "NMDS", "unifrac") 
ecu.biom.ord.wunifrac = ordinate(ecu.biom, "NMDS", "unifrac", weighted = 
TRUE) 
And results were plotted: 
r1 = plot_ordination(ecu.biom, ecu.biom.ord.bray, type = "taxa", color = 
"Rank2", title = ecu.biom.ord.bray$Diagnosis) + theme(legend.position = "none") 
r2 = plot_ordination(ecu.biom, ecu.biom.ord.canberra, type = "taxa", color = 
"Rank2",  title = ecu.biom.ord.canberra$Diagnosis) + theme(legend.position = 
"none") 
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r3 = plot_ordination(ecu.biom, ecu.ord.canberra, type = "taxa", color = 
"Rank2", title = ecu.ord.canberra$Diagnosis) + facet_wrap(~Rank2) + 
theme(legend.position = "none") 
r4 = plot_ordination(ecu.biom, ecu.ord.bray, type = "taxa", color = "Rank2", 
title = ecu.ord.bray$Diagnosis) + facet_wrap(~Rank2) + theme(legend.position = 
"none") 
multiplot(r1, r2, r3, r4, layout = matrix(c(1, 2, 3, 4), nrow = 2, byrow = TRUE)) 
To show a clustering per group the following script was implemented: 
plot_ordination(bx.biom, bx.ord.unifrac, type = "samples", color = "Diagnosis") 
Adonis was used to partition variance between variables and to indicate 
whether variance was significant: 
ecu.even.group = subset_samples(ecu.biom, Diagnosis != "<NA>") 
ecu.dist.bray.group = distance(ecu.even.group, method = "bray") 
adonis(ecu.dist.bray.group ~ Diagnosis, as(sample_data(ecu.even.group),  
"data.frame")) 
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ecu.dist.unifrac.group = distance(ecu.even.group, method = "unifrac") 
adonis(ecu.dist.unifrac.group ~ Diagnosis, as(sample_data(ecu.even.group), 
"data.frame")) 
ecu.dist.canberra.group = distance(ecu.even.group, method = "canberra") 
adonis(ecu.dist.canberra.group ~ Diagnosis, as(sample_data(ecu.even.group), 
"data.frame")) 
ecu.dist.wunifrac.group = distance(ecu.even.group, method = "unifrac", 
weighted = TRUE) adonis(ecu.dist.wunifrac.group ~ Diagnosis, 
as(sample_data(ecu.even.group), "data.frame")) 
2.7.5.3. Microbial Community Comparisons 
Microbial community comparisons were performed using parametric statistics 
in METASTATS, with P values corrected for multiple hypothesis testing by using the 
false discovery rate (FDR) (White et al., 2009). As previously for the Sanger 
Sequencing Analysis (Section 2.6.7), multiple groups comparisons were made using 
the Bonferroni correction test which corrected the P-values for multiple comparisons 
in UNIFRAC (Lozupone and Knight, 2005a).  
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2.7.5.4. Phylogenetic Analysis of Bacterial Species 
Neighbour joining with nearest neighbour interchange phylogenetic trees were 
created using the representative sequences of each OTU and FastTree version 2.1.3 
(Price et al., 2010a). The heatmap to represent the abundance of sequences was 
constructed in iTOL (Letunic and Bork, 2011). 
Representative sequences from significantly different OTUs of further interest 
were investigated using more intensive phylogenetic approaches in order to 
maximize the quality of the identification. These test sequences were aligned using 
the online SINA aligner (http://www.arb-silva.de/aligner/version 1.29 (Pruesse et al., 
2012)) and then imported into the ARB phylogenetic software (version 5.1, 
http://www.arb-home.de/ (Ludwig et al., 2004b)) running on Biolinux 6.0 
(http://nebc.nerc.ac.uk/tools/bio-linux/bio-linux-6.0, (Field et al., 2006b)). The aligned 
SILVA reference database SSU_REF108 of 618,442 high quality 16S rRNA gene 
sequences was downloaded and merged with the aligned test sequences. All 
Haemophilus spp. (or Streptococcus spp.) sequences within the database were 
selected and the SINA alignment individually checked for each test sequence in the 
ARB alignment editor. The length of the alignments used depended on the length of 
the available reference reads for each OTU. Thus, for the Haemophilus spp. 
alignment, the 522 bp region corresponding to the region between positions 384 and 
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908 of the Escherichia coli reference were selected, and for Streptococcus spp. 470 
bp between positions 470 and 908. Columns of the alignment containing 
uninformative positions (gaps) were masked from the phylogenetic analysis. Three 
trees were constructed for each of the genera, an ARB neighbour joining (NJ) tree 
with 1000 bootstraps, a Maximum Parsimony (MP) tree with 500 bootstraps and a 
RAxML Maximum Likelihood (ML) tree (version 7.0.3, (Stamatakis et al., 2005a)) 
with GTR substitution model in rapid hill-climbing mode. Trees were rooted with 
sequences from near neighbours outside the genus of interest. Tree topology was 
compared between the three methods and bootstrap values for the NJ and MP trees 
were used to determine stability of the phylogeny.  
2.8. DNA extraction from Bacterial DNA after culture 
Before starting and 24 hours prior extraction, a single bacterial strain was 
inoculated in 500 µl of BHI broth and incubated at 37 degrees Celsius. After this time 
bacterial growth was verified using spectrophotometry at light wave length of 590nm 
verifying the absorbance between 0.2 and 0.4 (to determine turbidity and bacterial 
growth presence) (Pommerville, 2011).    
Two hundred µl from the single bacterial strain culture (BHI broth) were taken 
and added to the lysing matrix E tube (LME). Then 778µl of sodium phosphate buffer 
were poured into the LME tube and 122µl of MT buffer (lysis solution). The LME 
 106 
tubes were homogenized twice in the FastPrep Instrument for 40 seconds at 6.0, 
and centrifuged at 14,000 xg for 10 minutes to pellet debris. 
Two hundred and 50µl volumes of Sodium Phosphate buffer (PPS) were 
aliquotted into a number of clean 2.0ml tubes. From the LME tubes previously 
homogenized and centrifuged, the supernatant was transferred to the 2.0ml tubes 
and mixed by shaking tube by hand 10 times, and again centrifuged at 14,000 xg for 
5 minutes to precipitate the pellet.  
The binding matrix suspension was re-suspended and 1.0ml was added to 
clean 15ml tubes together with the supernatant from the previous stage. These tubes 
were placed on a rotator for 2 minutes to allow binding of DNA, and later transferred 
to a tube rack for 3 minutes to allow settling of silica matrix. 
One ml of supernatant was discarded carefully to avoid touching the settled 
binding matrix, and the rest of volume was transferred into a 2ml tube. The tubes 
were centrifuged for 2 minutes at 14,000 xg, and was removed the supernatant. The 
binding matrix was re-suspended in 500µl SEWS-M & transferred to the column. The 
columns were centrifuged at 14,000 xg for 1 minute, and the catch tube replaced. 
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Without any addition of liquid, the columns were centrifuged a second time at 
14,000 xg for 2 minutes to ‘dry’ the matrix of residual wash solution, and again the 
catch tube was discarded and replaced with a new, clean catch tube. 
The columns were air dried for 5 minutes at room temperature, and gently re-
suspended in 100µl of Tris-low EDTA (10mM Tris-Cl + 0.1mM EDTA). Then the 
tubes were incubated for 5 minutes at 55oC in a heating block, and after that 
centrifuged at 14,000 xg for 1 minute to bring eluted DNA into the clean catch tube. 
Lastly the DNA suspended in the Tris-low EDTA was transferred into a screw-cap 
tube and stored at -80oC. 
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Chapter 3: Current Wheezing Microbiota Study -  
ECUAVIDA Stage 1a 
3.1. Introduction 
Stage 1a of the ECUAVIDA microbiota study, a case control retrospective 
study (Chapter 2: Section 2.3), was established in order to investigate the changes in 
the upper airways microbiota that occur during a current non-infectious wheezing 
episode. Consequently throat swab samples were collected from infants (cases), 
ages ranging from 7 to 12 months that at the time of sampling had a current 
wheezing episode and had had a history of multiple-triggered non-infectious 
wheezing episodes. Additionally, healthy children; age, sex and place of living 
matched to the cases; were also recruited and sampled  (Chapter 2: Section 2.3).     
The microbiota analysis at this stage started as an initial pilot study using 25 
samples (12 cases and 13 controls) to determine if differences did or did not exist 
between cases and controls.  At the time of the pilot the molecular techniques 
available for the investigations were Denaturing Gradient Gel Electrophoresis 
(DGGE) and Sanger sequencing.  Subsequent to the pilot and when next generation 
sequencing of amplicons of the desired length became a reality, a further more 
extensive study was carried out with 48 infants using both the new technology as 
well as a more comprehensive bioinformatics analysis (Chapter 3: Section 3.2). 
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3.2. Pilot Study 
3.2.1. Denaturing Gradient Gel Electrophoresis (DGGE) 
PCR-DGGE is a useful technique to evaluate bacterial diversity and since the 
end of the last century was widely used to characterize bacterial species on mixed 
microbial communities (Muyzer and Smalla, 1998). Nowadays, sequencing 
technology has replaced PCR-DGGE as the gold-standard identification method of 
bacterial species; nonetheless DGGE analysis remains an important initial first step 
technique to determine diversity of microbial communities (Tzeneva et al., 2008, 
Muhling et al., 2008). 
3.2.1.1. Materials and Methods 
DGGE is a technique based on differences in the intrinsic denaturing 
behaviour of double stranded DNA fragments that allows separation of fragments 
that are the same size but that differ in sequence.  It allows using samples of mixed 
microbial communities (and therefore different sequences), and generates distinct 
16S band patterns (Tzeneva et al., 2008). This technique also provides a relatively 
accurate taxonomic identification awareness of the principal bacterial groups. DGGE 
can be a good first step to analyse the microbiota and can provide insight into how 
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diverse samples are (Green et al., 2004). Consequently it can also inform the depth 
of sequencing that may be subsequently required. 
The DGGE that was conducted (Chapter 2: Section 2.6) included the use of 
two different markers; the Asthma Marker and the Normal Marker.  The constituents 
of these markers (their makeup determined by previous studies carried out in the 
Molecular Genetics and Genomics group (Hilty et al., 2010)) allowed an 
approximation of the taxonomy of every sample run on the DGGE to be to 
determined. Additionally it was feasible, by counting the number of bands visible on 
the DGGE to estimate the diversity of each sample. However a band can contain 
multiple amplicons of similar sequences that run at the same level on the DGGE thus 
the real potential to underestimate diversity by band counting exists. Due to the 
somewhat subjective nature of these measures, it was necessary to err on caution in 
making substantive conclusions but they nonetheless served as an initial tool for the 
Stage 1a pilot. 
A total of 25 samples were used for the pilot study (12 cases and 13 controls). 
The samples were obtained from infants that are part of the ECUAVIDA cohort in the 
tropics of Ecuador (Cooper et al., 2011) (Chapter 2: Section 2.2). DNA was extracted 
from the throat swabs (Chapter 2: Section 2.4) and used as template in 25μl PCR 
reactions amplifying the V3-V5 region of the 16s rRNA gene (Chapter 2: Sections 
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2.6.1-2.6.3) after which 8μl aliquots of the PCR products were run on DGGE 
(Chapter 2: Sections 2.6.4). 
3.2.1.2. DGGE Results 
The DGGE for the 25 samples (12 cases and 13 controls) is shown in Figure 
3.1).  Looking at diversity (by counting the number of bands present for each 
sample) there was encountered a broad variability across the samples.  Within the 
cases, individual 17 was the most diverse (with 15 identifiable bands), whilst the 
least variable was individual 23 (having just a single band).  In the controls, individual 
15 was the most diverse (with 13 bands), and individual 24 has the lowest diversity 
(with only 2 bands). From the PCR-DGGE neither group (cases or controls) were 
more diverse than the other (average 7 bands in cases and 8.33 in controls) (Figure 
3.1). 
According to the ´Asthma Marker´ (AM), band 7 (Prevotella sp. and 
Streptococcus sp.) was present in all the samples, and was the most intense band 
seen in 24 out of 25 samples the single exception being individual 15.  
Analysis of band patterns showed that samples shared bands in several 
positions for example:  
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 Band number 1 of the ´Normal Marker´ (NM) (corresponding to 
Bacteroides or Haemophylus sp.) was present in individuals 16, 17, 18, 
20 and 21.   
 Band number 9 in the AM (corresponding to Streptococcus sp. or 
Neisseria sp.) was observed in individuals 9, 13, 6 and 20.  
 Bands 5 and 6 in the AM (corresponding to Haemophilus sp. or 
Moraxella sp.) were present in individuals 4, 17, 3, 15, 7, 10 and 21.  
 Band number 12 in the AM (corresponding to Bordetella hinzii) was 
only present in individual 7.  
 Band number 3 of the NM (corresponding to Porphyromonas sp.) was 
observed in individuals 6, 8, 9 and 17.   
The exact position for the remaining bands observed in individuals was 
difficult to establish in the equivalent asthma and normal markers. In conclusion the 
band patterns are very mixed across the cases and controls with no clear 
segregation by this method. As most of bands cannot be attributed to a bacterial 
taxon because they do not correspond to any band in the markers and that some 
bands have in the same position two types of bacteria, therefore the true content of 
the bands really needs to be determined by a more specific method. For that reason, 
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the next step was to clone the PCR products generated for each individual and 
perform Sanger sequencing.   
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Figure 3.1 Denaturant Gradient Gel 
Electrophoresis (DGGE) of Cases and Controls in 
the Pilot Study. On the left extreme is located the 
“asthma marker” (AM) using bands of bacteria 
previously observed to be present in asthma 
patients, and on the right extreme is located the 
“normal marker” (N) using bands from bacteria 
previously observed to be present in the healthy lung 
(controls)(Hilty et al., 2010). 
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3.2.2. Cloning and Sequencing 
The cloning and sequencing approach is a more robust technique to 
determine the diversity and abundance of microbial communities in a quantitative 
and qualitative form. The technique’s efficiency is directly correlated with the quality 
of the PCR product and the transformation/cloning efficiency. Excessive PCR cycles 
can produce modifications in the sequence introducing mutations caused by errors 
made by the polymerase (Thornhill et al., 2007). For this reason, a limited number of 
cycles were implemented in this present study. In theory it is believed that variable 
size in the PCR product obtained could influence and create bias in cloning step. In 
order to control this, the V3-V5 region of the 16S rRNA gene was selected for 
amplicon design (Ahmed et al., 2007).  This ensured that the size range of PCR 
products would only vary at most by 200bp (450-650 bp).  
3.2.2.1. Materials and Methods 
First round PCR products for each sample (Chapter 2: Section 2.6.2) were 
cloned into pGEM-T vectors.  Following successful cloning 50 clones per sample 
were picked at random for subsequent Sanger sequencing (Chapter 2: Section 
2.6.5.2). 
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Sequences obtained underwent alignment and statistical analysis using 
software specially designed for microbial metagenomic assessment (Greengenes, 
RDP (Cole et al., 2009) and UNIFRAC (Lozupone et al., 2006)). After every step, the 
sequence files and alignments were revised and curated manually to avoid 
mismatches (Chapter 2: Section 2.6.6). 
3.2.2.2. Sanger Sequencing Results 
After removal of chimeras, 2362 high quality sequences were obtained from 
the 25 samples analysed (12 cases and 13 controls). Cladistic classification of the 
ungrouped sequences showed a high prevalence of the phylum Firmicutes (90.90%) 
followed by Proteobacteria (3.26%), Bacteroidetes (4.02%), Fusobacteria (1.48%) 
and Actinobacteria (0.30%).  
Members of the Firmicutes phylum occurred significantly more often in 
controls (P=0.0007) compared to cases. In contrast, members of the phylum 
Proteobacteria (P<0.0001) were more common in wheezing infants compared with 
controls.  No difference was seen between cases and controls for either of the phyla 
Bacteriodetes and Fusobacteria  (both P values >0.05) (Figure 3.2). 
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After alignment, chimera removal and distance matrix batch, using DOTUR 
(Schloss and Handelsman, 2005) high quality sequences were found to cluster into 
52 operational taxonomic units (OTUs). Diversity analysis of sequences showed that 
the phylum Firmicutes was the most diverse with 32 OTUs (62.3% of the found 
OTUs), followed by Proteobacteria with 10 OTUs (17%), then Fusobacteria and 
Figure 3.2. Phyla distribution of the Sequences for Cases 
and Controls.  Fisher exact test was used for statistical 
analysis between both groups. * indicates significant P values. 
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Bacteroidetes with 4 OTUs each (7.5%) and finally Actinobacteria, Synergistetes and 
unclassified bacteria with 1 OTU each (1.9%) (Figure 3.3). 
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Figure 3.3. Neighbour-Joining Circular Phylogenetic Tree. It shows 
the diversity of sequences grouped by OTUs (each colour corresponds 
to a different phylum). The table shows the relative percentages of 
OTUs found.  
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Additionally a heatmap was created using a phylogenetic tree produced in  
MEGA6 (Hall, 2013). There were used the  sequences from the 52 OTUs found after 
eliminating all sequences containing gaps and missing data, and an ‘out group’ 
sequence was added for rooting. The  tree is drawn to scale, with branch lengths in 
the same units as those of the evolutionary distances used to infer the phylogenetic 
tree. The evolutionary distances were computed using the Maximum Composite 
Likelihood method (Yong et al., 2012) and are in the units of the number of base 
substitutions per site (figure 3.4). Firmicutes was the most diverse and frequent 
phyla observed with Streptococcus the most frequent genus. According to 
Kawamura et al. sub-classification of Streptococcus sp. according to the 
phylogenetic relationships in their 16S rRNA gene sequence (Kawamura et al., 
1999), there were found thirteen OTUs identified as belonging to the Streptococcus 
mitis group with Streptococcus mitis Group 11 being the most prevalent OTU 
followed by Streptococcus Group 6 (Figure 3.4).  Two Streptococcus sp. OTUs failed 
to be asigned to a unique group and were classified as being either Streptococcus 
mitis or mutans. Six OTUs could not to be asigned to a group or a species and were 
asigned as Lactobacillales 1 and 2, Carnobacteriacea, Enterococcacea, 
Streptococcus sp. and Veilonella sp. respectively. Taking account the number of 
sequences across all controls versus all the cases, the most marked differences 
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were encountered in the Firmicutes phyla. Controls had a higher prevalence of 
Streptococcus salivarious (66 sequences in controls versus 10 in cases. P<0.005), 
Streptococcus mitis group 7 (controls 100 versus cases 20. P<0.005), Veillonella sp. 
(controls 96 versus cases 48. P<0.005) and Veillonella dispar (controls 51 versus 
cases 2. P<0.005). 
Actinobacteria were found only in controls, in contrast with Synergistetes that 
were only present in cases although in both instances, these diferences were not 
statistically different (Figure 3.4).  
Fusobacteria, represented by Leptotrichia sp., Fusobacterium sp. and 
Streptobacillus sp., were more common in cases but again this was not statistically 
significant (Figure 3.4). No significant differences between cases and controls for 
any of the OTUs observed, Flavovactereacea, Leptotrichia sp., Porphyromonas sp. 
and Prevotella sp. for the Bacteroides phylum. 
The most important differences between cases and controls were found for 
the phylum Proteobacteria. Neisseria was the most prevalent genus although 
discrimination at the species level (N. perflava or subflaba, N. meningitidis or 
subflava, N. cinerea or meningitidis) or genera level (Pasturellacea, Costridiales and 
Burkholderiales) was not feasible in all cases. It was however possible to categorize 
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at species level several OTUs and species included Haemophilus parainfluenzae. 
For every OTU of the Proteobacteria phylum, statistical analysis showed significant 
differences between cases and controls (P<0.001) (Figure 3.4). 
  
Figure 3.4.  Evolutionary Relationships of Bacterial Taxa. The evolutionary history was inferred using the Neighbour-
Joining method. The optimal tree with the sum of branch length = 4.78 is shown. (Coxielacea sp. was used as the ‘out 
group’ control). Phylogenetic analyses were conducted in MEGA6. The Heat map scale shows the abundance of 
sequences from each OTU found per sample (yellow = 1<5%, orange = 5–15%, red = 15–30% and black >30%). On the 
right there are shown with * the significant P values when compare cases versus controls. 
 
 Using the UniFrac metric (Lozupone et al., 2006), which weights the branches 
based on abundance (number of sequences per branch) (Chapter 2: Section 2.6.6), 
a whole community comparison (beta diversity analysis) revealed the bacterial 
microbiome communities from wheezing children and healthy controls to be 
significantly different (P<0.001).   
In order to determine diversity differences within each individual, alpha 
diversity measures were performed (Chapter 1: Section 2.6.6). There were 43 OTUs 
in the cases group and 35 in the healthy control group, and both groups shared 27 
OTUs (51.9%) (Figure 3.5). Alpha diversity analyses in cases and controls were 
estimated by the Shannon index (Marcon et al., 2014, Shannon, 1948):    
Shanon Cases=0.42(CI 95% 0.33-0.51)  
Shanon Controls=0.19 (CI 95% 0.13-0.25).  
These results show that cases are more diverse than controls and contrasting 
the number of OTUs per group this was statistically significant (P<0.001).
  
Figure 3.5. Comparative Diversity and OTUs distribution per Group. Diversity patterns per group (cases 
and controls) are shown. Each OTU has a different colour. A greater number of OTUs were present in the cases 
compared to controls (43 versus 35). 
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Comparison by per sample diversity showed a wide variability across all 
samples.  A standard OTUs pattern for cases or controls was not evident 
(Figure 3.6).  
 
 
Figure 3.6. Distribution of OTUs per Sample. Diversity 
patterns per sample are shown. Each bar represents a single 
individual. Each OTU has a colour assigned. An evident OTU 
pattern of diversity was not evident for cases or control groups. 
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Alpha diversity richness statistics was performed using Chao1 index at 
97% (Chapter 2: Section 2.6) (Chao et al., 2012), which suggested the 
presence of 147.66 expected OTUs. The current analysis was able to identify 
only the 35.21% (52 OTUs) of the estimated. Since diversity between cases and 
controls was found to be significantly different Chao1 Richness estimates were 
performed for each group (Chapter 2: Section 2.6.6).  
For cases Chao1 estimated 312 OTUs of which 18% were identified 
experimentally whilst for controls the estimate was ~34 with 66.9% identified 
experimentally. 
3.3. Stage 1a using Next Generation Sequencing 
Following the initial Stage 1a pilot study using Sanger sequencing (at this 
point pyrosequencing technology was only able to sequence amplicons with a 
maximum length of 200 bp) Roche Diagnostics released the 454 technologies, 
which had the capability of sequencing longer amplicons (600-700 bp). The 
454-pyrosequencing approach then became the gold standard technique to 
characterize in depth the diversity and abundance of mixed microbial 
communities (Lewis et al., 2013, Zemanick et al., 2011, Petrosino et al., 2009, 
Parahitiyawa et al., 2010). In comparison to conventional sequencing it delivers 
a much higher number of sequences per run, which allows one to obtain many  
more sequences per sample. As a consequence, the portrayal of the 
microbiome is more accurate, and the bacteria targeted range from the most 
commonly present to the minor ones within a community. It is important to 
remark however, that the technique’s efficiency is directly correlated with the 
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quality of the samples, the DNA extraction protocols and the PCR products (Kim 
and Yu, 2014).  
As this technology has the capability of sequence amplicons of a 
maximum of 700bp, in this part of the study new primers of region V3 to V5 
were constructed for an accurate taxonomic determination.  And additionally to 
the 25 samples used on the Stage 1a pilot study, there further 23 samples were 
included (cases and controls) giving a total of 48 samples. 
3.3.1. Materials and Methods 
After DNA extraction, the 16S rRNA amplification using barcoded primers 
of the V3-V5 regions was successfully performed for 48 samples part of stage 
1a including all the samples previously analysed using DGGE and Sanger 
sequencing. Twenty-four infants with non-infectious wheezing and 24 controls 
were used (both groups had an average age of 10.2 months of life), and the 
amplicons obtained were pooled through use of the MIDs into a single 454 
Junior sequencing run.  
Data analysis was performed using the third party platform QIIME 1.7 
(Caporaso et al., 2010b), and statistical analysis was performed using 
Metastats V 2.0 (metagenomeSeq) (White et al., 2009, Paulson et al., 2013) 
and the R package phyloseq (McMurdie and Holmes, 2013) (Chapter 2: Section 
2.7.5). 
Representative sequences from significantly different OTUs of further 
interest were investigated using more intensive phylogenetic approaches in 
order to maximize the level of the identification. The representative sequences 
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were aligned using the online SINA aligner (http://www.arb-
silva.de/aligner/version 1.29 (Pruesse et al., 2012)) and then imported into the 
ARB phylogenetic software (version 5.1, http://www.arb-home.de/ (Ludwig et 
al., 2004a)) running on Biolinux 6.0 (http://nebc.nerc.ac.uk/tools/bio-linux/b io-
linux-6.0 (Field et al., 2006a)). The aligned SILVA reference database 
SSU_REF108 of 618,442 high quality 16S rRNA gene sequences was 
downloaded and merged with the aligned test sequences. All Haemophilus spp. 
and Streptococcus spp. sequences within the database were selected and the 
SINA alignment individually checked for each test sequence in the ARB 
alignment editor. The length of the alignments used depended on the length of 
the available reference reads for each OTU. Thus, for the Haemophilus spp. 
alignment, the 522 bp region corresponding to the region between positions 384 
and 908 of the Escherichia coli reference was selected, and for the 
Streptococcus spp. alignment 470 bp between positions 470 and 908 were 
selected. Columns of the alignment containing uninformative positions (gaps) 
were masked from the phylogenetic analysis. Three trees were constructed for 
each of the genera, an ARB neighbour joining (NJ) tree with 1000 bootstraps, a 
Maximum Parsimony (MP) tree with 500 bootstraps and a RAxML Maximum 
Likelihood (ML) tree (version 7.0.3 (Stamatakis et al., 2005b)) with GTR 
substitution model in rapid hill-climbing mode. Trees were rooted with 
sequences from near neighbours outside the genus of interest. Tree topology 
was compared between the three methods and bootstrap values for the NJ and 
MP trees were used to determine stability of the phylogeny. Accession numbers 
for the reference sequences used are recorded in the tree labels (Figure 3.12) 
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and whilst those for the ‘out group’ are DQ358146, AJ301681, AF008582, 
AJ301682, AF008581, AM040491, and AM040495. 
3.3.2. Pyrosequencing Results 
An initial 108,042 raw sequences were obtained from the 
pyrosequencing run. After denoising, singleton exclusion, chimera checking and 
removal of OTUs present in only one sample a total of 76,627 sequences 
remained (37,235 in cases and 39,392 in controls). Between 969 and 6,269 
sequences were obtained per sample, and consequently sequences were 
rarefied to remove the sample heterogeneity using the minimum number of 
sequences (969) obtained in a sample. After exclusion of singletons, chimeras 
and OTUs present in only one-sample 182 operational taxonomic units (OTUs) 
at 97% sequence identity level were identified. 
Cladistic classification of all 76,627 sequences (not split by case and 
control status) showed a high prevalence (72%) of the phylum Firmicutes 
followed by Proteobacteria (12%), Actinobacteria (8%) Bacteroidetes (7%) and 
Fusobacteria (1%). The Firmicutes was the most diverse phylum containing 93 
distinct OTUs (51% of the total OTUs), followed by Actinobacteria with 30 OTUs 
(16%), Proteobacteria with 20 OTUs (11%), then Fusobacteria and 
Bacteroidetes with 18 and 19 OTUs respectively (10%) and finally 
Cyanobacteria with 2 OTUs (1%). There were no statistical differences when 
phyla present in cases versus controls were compared). 
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For the 182 OTUs identified at 97% sequence identity level, a 
representing sequence of each of the OTUs was used to assemble a 
phylogenetic tree using FASTREE (Price et al., 2010b) and heatmaps 
representing the number of sequences per OTU were constructed using ITOL 
(Letunic and Bork, 2011).  Figure 3.8 shows a heatmap with every sample 
included whilst Figure 3.9 shows the total of sequences pooled in cases and 
controls.  
The OTUs assigned to Streptococcus were the most prevalent (32 
OTUs), only 6 of the 32 however showed statistical differences (calculated by 
metastats with 1000 iterations) between cases and controls decreasing to three 
if only those with a sequence frequency of 100 were considered. Of these three 
OTUs, one assigned to Streptococcus was more prevalent in cases (P=0.0003, 
Figure 3.7 Phyla Distribution Cases versus Controls. Y axis shows 
the number of sequences rarefied.  There were no statistical 
differences. 
 
132 
OR 1.20), whilst the other 2 OTUs (also assigned to Streptococcus) were more 
prevalent in controls (P=0.0001, OR 0.70 and P=0.0220, OR 0.23 respectively).  
 
Figure 3.8. Neighbour Joining Phylogenetic Tree of Bacterial 16S 
rRNA using the OTUs found using Pyrosequencing. Boxes in the 
right show the Heatmap of sequences frequencies per OTU in Controls 
and Cases, and the taxonomy assignments at Phyla level (inner column 
– colour coding for the Phyla left panel).  The Legend in the right bottom 
describes the number of sequences assigned to each colour. 
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In Firmicutes the OTUs assigned to Gemella (P=0.0039, OR 0.39), 
Lachnospiracea (P=0.013, OR 0.44) and two OTUs assigned to Veilonella 
(P=0.0209, OR 0.52; P=0.0397, OR 0.54 and P=4.75x10-72, OR 0.58) were 
more common in controls compared to cases. The OTUs assigned to 
Staphylococcus were different when compared between numbers of sequences 
between cases and controls (on pooled samples) although further statistical 
analysis using MetagenomeSeq (which takes account the overall distribution on 
groups) it was apparent that the differences were due to the presence of a 
higher number of sequences in just a few individuals (Figures 3.8 and 3.9). 
In Actinobacteria the most abundant OTUs were significantly more 
prevalent in cases than in controls e.g. Actinomyces (P=0.0017, OR 2.85), 
Atopobium (P=0.0014, OR 2.17) and Corynebacterium (P=0.0004, OR 7.95).  
Within the Phylum Bacteroidetes, an OTU assigned to Porphyromonas 
(P=0.0039, OR 0.11) was more prevalent in controls whilst the OTU assigned to 
Flavobacteriacea (P=0.0270, OR 12.16) was more prevalent in cases.  
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For the phylum Proteobacteria, one of the OTUs assigned to 
Haemophilus (P=0.0040, OR 5.06) and one assigned to Neisseriaceae 
Figure 3.9. Neighbour Joining Phylogenetic Tree of Bacterial 
16S rRNA grouped by OTUs and pooled by Cases and Controls. 
Boxes in the border rings depict the frequency of sequences for 
each operational taxonomic unit (OTU) in Controls (middle ring) and 
Cases (outside ring). The taxonomy assignments at the Phyla level 
are shown in the inner ring. The legend in the right describes the 
abundance of OTUs (number of sequences/per group) whilst top left 
the colour coding for the different Phyla is given.  
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(P=0.0031, OR 1.20) were more prevalent in cases.  In contrast an OTU 
assigned to Neisseria (P=0.001, OR 0.40) and another OTU assigned to 
Haemophilus (P=0.012, OR 0.45) were more abundant in controls.  
The most important differences overall at the OTU level are summarised 
in Table 3.1. 
OTUs 
No. Sequences P* value 
Odds 
Ratio 
Confidence 
Interval 95% 
Controls Cases 
   
Actinobacteria/Actinomyces 50 142 0.0017 2.85 
2.06 to 
3.94 
Actinobacteria/Atopobium 169 364 0.0014 2.17 
1.80 to 
2.61 
Actinobacteria/Corynebacterium 26 205 0.0004 7.95 
5.28 to 
11.96 
Bacteroidetes/Flavobacteriaceae 13 157 0.0270 12.16 
6.90 to 
21.42 
Bacteroidetes/Porphyromonas 226 26 0.0039 0.11 
0.07 to 
0.17 
Firmicutes/Gemella 336 133 0.0039 0.39 
0.32 to 
0.48 
Firmicutes/Lachnospiraceae 129 57 0.0013 0.44 
0.32 to 
0.60 
Firmicutes/Streptococcus 1 3221 3756 0.0003 1.20 
1.13 to 
1.26 
Firmicutes/Streptococcus 2 948 671 0.0001 0.70 
0.63 to 
0.77 
Firmicutes/Streptococcus 3 87 20 0.0220 0.23 
0.14 to 
0.37 
Firmicutes/Veillonella 1 494 257 0.0209 0.52 
0.44 to 
0.59 
Firmicutes/Veillonella 2 3154 1948 0.0397 0.58 
0.54 to 
0.61 
Proteobacteria/Haemophilus 
(OTU 162) 
97 482 0.0040 5.06 4.06 to 6.2 
Proteobacteria/Haemophilus 
(OTU 190) 
86 43 0.0112 0.45 
0.38 to 
0.52 
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Proteobacteria/Neisseria 525 213 0.0001 0.40 
0.34 to 
0.47 
Proteobacteria/Neisseriaceae 1025 1217 0.0031 1.20 
1.10 to 
1.30 
 
Alpha diversity analysis (Chapter 2: Section 2.7.5) using the Chao1 was 
estimated in 289.84 OTUs (95% CI 218.39-361.30). Statistical analysis revealed 
no differences in richness (the maximum of expected OTUs that could be found 
if the sequencing continues until the infinite) when comparing cases versus 
controls (P=0.852) and in overall it (Figure 3.10 A). Using the Shannon Index 
and observed OTUs to measure the diversity in taxa, no significant difference 
between groups was found (P=0.921) (Figure 3.10 B). Evenness was measured 
using the Equitability index and again no differences were seen (P=0.702) 
(Figure 3.10 C).  
 
Table 3.1. Differences at OTU level in Bacterial 16S rRNA sequences from 
Throat Swabs of Infants with Wheeze versus Healthy Controls. *Only groups 
with more than 100 sequences and statistically significant differences are shown. 
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When compared the results obtained in the same samples using 
conventional sequencing (Stage 1a Pilot Study Section 3.2.1.2) and 
pyrosequencing, a higher alpha diversity was encountered. Due to the greater 
depth of sequencing that is cost and time effective by the pyrosequencing 
approach one consequently will detect less common OTUs hence the higher 
alpha diversity. When comparisons at the whole microbial community level or at 
the major OTUs level were performed, there were no statistically significant 
differences observed.  
 Figure 3.10. Alpha Diversity Statistics. A) Scatter dot plot comparing 
cases versus controls values of Chao1 richness index. B) Scatter dot plot 
comparing values of Shannon diversity index. C) Scatter dot plot 
comparing equitability evenness index. 
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Multiple rarefaction curves using the Shannon index (Figure 3.11) 
showed that a plateau of diversity was achieved at around 360 sequences per 
sample. This value would be considered as the minimum sampling depth to 
capture diversity.  In the Stage 1a pilot 120 sequences per sample were 
generated (by Sanger sequencing of randomly picked clones) considerably 
below the plateau of diversity. Using pyrosequencing, the rarefaction of the 
complete Stage 1a sample set was performed at a minimum of 969 sequences 
per sample, which will therefore have captured a realistic panorama of each 
sample’s diversity.  
Beta diversity statistics (Chapter 1: Section 1.12) using the Principal 
Coordinate Analysis (PCoA) of the UniFrac distance matrix (weighted and 
unweight UniFrac, distance-based ANOVA with permutations) revealed no 
significant differences in the microbial communities cluster patterns between 
cases and controls (Figure 3.11). 
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Figure 3.11. Shannon Diversity Collector Curves. Multiple 
rarefaction curves were collated from each sample’s Shannon  
diversity index. The graphic shows the estimated diversity plotted 
against the number of sequences per sample. Each line represents 
one sample. The plateau in each estimated diversity curve indicates 
the minimum number of sequences to capture diversity. For all 
samples the plateau was achieved at approximately 320 sequences 
(red vertical line), well below the chosen rarefaction threshold of 
969 sequences (blue line). 
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Figure 3.12. Beta Diversity Statistics using the 
Principal Coordinate Analysis (PCoA).  A) Unweighted 
UNIFRAC Principal Coordinate Analysis (PCoA) plot 
comparing presence/absence metrics. B) Weighted 
UNIFRAC Principal Coordinate Analysis (PCoA) plot 
comparing presence/absence metrics and abundance 
using the UniFrac distance matrix (weighted unweight 
UniFrac). The results show no cluster patterns different 
between cases (red dots) and controls (blue dots).  
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3.3.3. Phylogenetic Identification using Sequence 
Alignments 
Using three independent phylogenetic treeing methods it was not 
possible to increase the specificity of the identification of the Streptococcus spp. 
OTUs beyond that of the basic Ribosomal Database Project (RDP) classifier 
(Cole et al., 2009). Tree topology between the three methods of treeing was not 
conserved and significance of assignment to major nodes was low. 
By contrast, the tree topology for Haemophilus spp. was conserved in all 
three methods of phylogenetic inference (Figure 3.12), with robust significance 
for assignment for each Haemophilus spp. OTU. This enabled confident 
assignment of OTU 162 to Haemophilus influenzae, OTU 32 and 38 to 
Haemophilus haemolyticus (both with less than 100 sequences and therefore 
not detailed in Table 3.1), and OTU 190 to Haemophilus parainfluenzae. OTU 
162 which was assigned to the known pathogen Haemophilus influenzae was 
significantly more common in cases (P = 0.004, OR 5.06) compared with 
controls, whilst OTU 190 (assigned to Haemophilus parainfluenzae) was 
significantly more prevalent in controls (P = 0.0112, OR 0.45). 
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Figure 3.12. Phylogenetic Identification of Haemophilus OTUs. 
Phylogenetic analysis of the 16S rRNA sequences of the OTUs assigned 
taxonomically to Haemophilus genus (OTUs 32, 108, 162 and 190, shown in 
Red) together with reference Haemophilus sequences from the SILVA 
database, using the ARB alignment editor. The scale bar indicates 10% 
sequence divergence, and NCBI accession numbers are included. The tree 
was rooted with a near neighbour outgroup constructed with sequences from 
Morganella morganii, Proteus mirabilis and Providencia stuartii  (Accession 
numbers Section 3.2.2.1). 
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3.4 Discussion 
In this study the characterization of the upper airways bacterial 
microbiome was conducted to enable comparisons between early onset 
wheezing children suffering a current wheezing episode (cases) and healthy 
controls from the tropics of Ecuador. The results of the study reveal that 
significant differences in diversity and abundance of bacteria exist between 
cases and controls when a wheezing episode is occurring. As has been 
reported in previous studies (Hilty et al., 2010, Bisgaard et al., 2007), and 
independently of the technique used (DGGE, Sanger sequencing and 
pyrosequencing) it was possible to identify in cases a higher prevalence of 
potentially pathogenic bacteria (Neisseria sp. and Haemophilus sp.). This 
finding is consistent with studies that have used standard culture techniques for 
bacterial identification and classification (Bisgaard et al., 2007). Additionally in 
concordance with previous studies of the airways microbiome (Hilty et al., 
2010), Firmicutes was the most prevalent phylum found in the infants´ airways 
microbiome with the majority of the Firmicutes belonging to the Streptococcus 
sp. genus.  
At the beginning, a pilot study using throat swab samples from 25 infants 
of Stage 1a and PCR-DGGE was conducted to estimate the diversity present 
on each sample as well as to provide an indication of how many clones should 
be Sanger sequenced. PCR-DGGE however encountered several issues when 
determining the microbiome taxonomy and diversity, for example the number of 
bands observed do not always reflect the diversity present, a single band can 
represent more than one organism, it is necessary to use a ‘marker’ on the gel 
to extrapolate each band bacteria taxonomy, and usually there are bands that 
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do not correspond to any assignation by the marker therefore their identification 
remains unknown.  
PCR-DGGE failed in the quantification of bacterial diversity (by the 
identification of a real number of species), for instance several samples with a 
single band on the PCR-DGGE had a several number of different bacterial 
species when analysed by sequencing. In regard of taxonomical identification, 
PCR-DGGE was able to detect the high prevalence of Streptococcus spp. later 
determined using DNA sequencing but the technique was not accurate enough 
to differentiate them from Prevotella spp. The second problem of bacterial 
identification using PCR-DGGE is the difficulty that was encountered in 
assigning the gel bands of the samples to bands of the markers used as this 
was completely subjective and done by eye. As a result for the majority of the 
gel bands it was impossible to assign a bacterial genus. In conclusion, this 
technique did not allow comparison quantitatively of the bacterial microbiome in 
cases versus controls. 
The PCR-DGGE experiment however did provide an indication of the 
number of clones that should be sequenced per sample in order to capture the 
real diversity present in each sample. Based on this tool and with the previous 
work within the Molecular Genetics Group (Hilty et al., 2010) one hundred and 
twenty clones were sequenced per sample in the pilot study. Using Sanger 
sequencing, the cases group showed a more complex diversity in the 
microbiome compared with the control group, and most of the diversity was due 
to the presence of a higher frequency of Proteobacteria and a lower frequency 
of Streptococcus spp. Infants with early onset wheezing and suffering a current 
wheezing episode therefore had more bacterial species compared with controls.  
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As anticipated from the initial PCR-DGGE screening, Firmicutes was the 
most common (90.9%) and most diverse phylum seen (32 of 52 OTUs) using 
Sanger sequencing. Most of the OTUs found in this group belong to the 
Streptococcus spp. group, which was expected based on prior observations in 
children (Hilty et al., 2010). In the pilot study all the OTUs in Proteobacteria 
were significantly different between cases and controls, as their prevalence in 
healthy individuals was almost zero. Strikingly the diversity in the cases was 
greater than that seen for the controls, and most of this increased diversity was 
attributable to a higher amount of Proteobacteria spp. being present. Cases 
therefore had more bacterial species than controls with the majority of the 
species being potentially pathogenic bacteria (Neisseria sp. and Haemophylus 
sp.).  This finding is consistent with the prior study of Bisgaard et al. (2007) that 
used culture-based approaches to look at microbial diversity.  
Although there was a reduction in Bacteroidetes present in cases in the 
pilot study, this was not statistically significant. A decrease in the presence of 
Bacteroidetes has however been seen previously in adults and children with 
disease (Hilty et al., 2010) and species of this phylum may therefore be 
considered possible ‘protective’ bacteria. Several studies have shown that 
Prevotella sp. (member of the Bacteriodetes phylum) inhibits the grown of other 
bacteria in the oropharynx (Murray and Rosenblatt, 1976).  
When the whole microbial community of the cases versus the controls 
was compared using UNIFRAC, statistical differences between both 
communities were found in the pilot study. This means that in the upper 
airways, diseased infants with current wheezing and healthy children do appear 
to have distinct microbiomes. 
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Using conventional cloning and sequencing methods, it was possible to 
identify 52 OTUs. Chao 1 richness statistics using rarefaction curves have 
however calculated a maximum of 147 OTUs would exist in the airways 
microbiome. That means that with the current sequencing data generated only 
35% of the possible oropharynx bacterial microbiome in these samples has 
been identified. If cases and controls are considered separately as they have 
shown different diversities in the pilot study, the Chao1 index indicated that for 
cases 18% of the expected OTUs have been identified in contrast to 66.9% for 
controls.  
On the pyrosequencing analysis the profundity of sequencing was 
increased to 969 sequences per sample. This allowed a more complex analysis 
of the upper airways bacterial microbiome with an increased range of 
exploration of the less common bacterial species, and as consequence a better 
panorama of the real diversity. Likewise using Sanger sequencing, 
pyrosequencing analysis found similar relations Firmicutes/Proteobacteria in 
cases and controls, but the diversity measured by alpha and beta diversity 
indexes did not show dissimilarities. These results also could be explained by 
the improved sensitivity of the next generation sequencing techniques in 
detecting less common bacterial species, specifically by not falling in bias 
caused by the randomization at the time of clones picking (Petrosino et al., 
2009). Using pyrosequencing, Firmicutes likewise turned out to be the most 
prevalent phyla found (72% of the total sequences on the 48 samples), and the 
most diverse with 93 OTUs found (51% of the total).  
Likewise as by conventional sequencing, pyrosequencing encountered 
that the most common genus consistently identified was Streptococcus spp., 
147 
and overall, when sequences are sumarized by genera level, this genus is more 
abundant in controls than in cases. Studies have hypothesised that in the upper 
airways, S. viridans could act as protective bacteria replacing possible 
pathogenic bacteria (Tano et al., 2000). The results from Stage 1a harmonize 
with these findings, as not only do they demonstrate that there is a higher 
prevalence of Streptococcus spp. in healthy children but also that there is a 
lower frequency of posible pathogenic bacteria especially those belonging to the 
Proteobacteria phylum. However when the analysis is performed at OTU level, 
some OTUs assigned to this genus were more common in cases whilst others 
in controls, and the ambiguity of 16S rRNA did not allow differentiation between 
them at species level. 
Other common Firmicutes that were found in the study are: Veillonella 
sp. (Gram negative strict anaerobic cocci) and Gemella sp. (Gram positive 
facultatic aerobic cocci), which are commensal bacteria that similar to S. 
viridans can potentially cause of disease (bacteraemia and endocarditis) after 
invasive orthodontic procedures or in immunocompromised patients (Shenep, 
2000, Bochud et al., 1994), and could also be considered protective against 
asthma in the airways microbiome.  
Proteobacteria was the second most diverse phylum in both the pilot 
study and the pyrosequencing study. In the pyrosequencing study the majority 
of OTUs belonging to this phylum were more common in cases, however if only 
the OTUs with more than 100 sequences are taken account then the OTUs 
found are equally distributed between the two groups. Strikingly, most of the 
OTUs found in this phylum were important etiological agents of disease in 
children such as: Neisseria sp. and Haemophilus sp.  These bacteria are the 
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most prevalent etiological agents of diseases in the airway related structures for 
example including lungs, meninges, paranasal sinus, etc (Rouphael and 
Stephens, 2012, Sabra and Benger, 2011, Watt et al., 2009, Gkentzi et al., 
2012).   
In Bacteroidetes using pyrosequencing, Porphyromonas was 
encountered more commonly in controls whilst Flavovacteriacea in cases. 
Moreover, Prevotella was more common in controls (in concordance with the 
pilot study) but these results were driven by a few samples and therefore were 
not found to be significant when using microbiome specialized statistics 
(UNIFRAC and metastats). 
Actinobacteria was consistently more commonly found in cases (also 
using pyrosequencing), and within this phylum are potentially pathogenic 
genera such as Actinomyces, Atopobium and Corynebacterium (Kutluhan et al., 
2011, Francavilla et al., 2014). These genera are important agents of diseases 
in infants, and their range of diseases go from mild cold symptoms to important 
opportunistic infections and life threatening illnesses as diphtheria (Byard, 
2013). It is interesting however than Atopobium spp. have been related with 
other chronic inflammatory diseases as celiac disease (Francavilla et al., 2014, 
Collado et al., 2007). 
Due to the limitation of cloning and sequencing (sequencing a wide 
number of clones selected randomly), it is usually not possible to identify more 
than 70% of the microbiome present in a sample (Hilty et al., 2010). 
Consequently, it is estimated that more than 90% of the microbiome in a sample 
could be captured by pyrosequencing (Turnbaugh et al., 2007). Using alpha 
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diversity collector curves, it was possible to determine that the sampling depth 
performed on Stage 1a reached the plateau of diversity identification and 
therefore the perspective obtained of the microbiome was very accurate.  
The biological interpretation of the differences in the frequencies of 
individual OTUs is limited by the imprecision of OTU assignments in identifying 
individual species. In particular, this problem was obvious in our data with OTUs 
assigned to Streptococcus and Haemophilus spp., which were likely to contain 
a mixture of pathogenic and non-pathogenic strains. An attempt to improve the 
classification of these OTUs was made by including them in phylogenetic tress 
constructed from reference sequences. The incorporation of reference strain 
sequences into our phylogenetic trees allowed the discrimination between 
Haemophilus spp. OTUs at species level, and to show that the pathogen H. 
influenzae was more prevalent in wheezing infants, in concordance with 
previous studies (Hilty et al., 2010, Bisgaard et al., 2007). H. parainfluenzae 
was more abundant in healthy children which might be associated with 
wheezing protection. The 16S rRNA gene has previously been suggested for 
use as a marker in MLST of H. influenzae (Sacchi et al., 2005) and the results 
presented in this chapter confirm that its phylogeny is well matched to species 
and strain identification in airway samples. 
In conclusion, the upper airways microbiome of early onset wheezing 
infants from the tropics at the time of a wheezing episode have important 
differences in the number and types of bacteria when compared to healthy 
infants from the same environment. It is noticeable that in controls there is an 
elevated presence of possible ‘protective’ bacteria, whilst in cases there is a 
lack of them in addition to a higher level of potentially pathogenic bacteria.   
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Although the 16S rRNA sequences through more sophisticated phylogenetic 
tree analysis allowed identification of Haemophilus spp., this was not feasible 
for Streptococcus spp. due to the genetic uniformity of the 16S rRNA gene in 
this genus.  This is clearly an important group and discrimination would 
increment our understanding further of the respiratory microbiome (it is not 
possible to discriminate other important groups of bacteria as S. pneumoniae 
from their non-pathogenic pairs the S. viridans).  Consequently an approach 
involving alternative genes in combination with pyrosequencing to allow further 
differentiation of the Streptococcus spp. was developed (Chapter 5).  
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Chapter 4: Mid and Long Term Changes in the 
Upper Airways Microbiota and their Relationship 
with Wheezing - ECUAVIDA Stages 1b and 2 
As described earlier in Chapter 2, Section 2.3, the ECUAVIDA microbiota 
study was separated into two Stages (1 and 2) according to age.  Stage 1 was 
focused on infants less than 12 months of age with Stage 2 being focused on 
infants’ 2 years ± 2 months old. Additionally Stage 1 was further subdivided into 
two parts.  Part 1a: samples taken during a current wheezing episode and Part 
1b: samples taken during a past wheezing episode.  For Stage 2, sampling was 
as per part 1b  (wheezing history and no current wheezing at the time of 
sampling) but when children were 24 months old ± 2 month.   
This chapter deals with the data generation and subsequent analysis and 
results for Stages 1b and 2. As the two stages only differed by age (all children 
had a history of past wheezing episodes), it affords the opportunity to 
investigate the mid and long term changes of the upper airways microbiota that 
occur as a consequence of multiple “non-infectious” wheezing episodes. 
Additionally the current chapter also tries to determine the differences produced 
in the upper airways bacterial microbiota between a current wheezing episode 
and the variations that occur after the episode by comparing the results from 
Chapter 3 (children Stage 1a) and this chapter (children Stage 1b and 2). A 
summary of the different stages compared in this chapter is shown in Figure 
4.1.  
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4.1 Materials and Methods 
As part of the general inclusion criteria of the study, cases and controls 
have no history of frequent antibiotic use and no recurrent respiratory infections 
(Chapter 2: Section 2.3). Additionally it was ensured that, at least during the last 
two weeks prior to sampling, the subjects were not using antibiotics for any 
reason and did not have any evidence of a current airway infection (absence of 
cold symptoms and fever). All the subjects belonged to the same mixed ethnical 
background, live in the same town and had access to the same basic services 
(electricity, water, sanitation, etc.). All of them received the vaccines 
recommended by the Ecuadorian Public Health Ministry (BCG, mumps, 
measles and rubella, tetanus, diphtheria, hepatitis B and Haemophilus influenza 
B; MSP, 2005) but none of the subjects received anti Streptococcal vaccination 
(not compulsory for the MSP) (Chapter 2: Section 2.3).  
ECUAVIDA COHORT 
(2400 infants)
Current Wheezing 
(stage 1a)
7 to 12 
months
Cases
Controls
Past Wheezing
(Stage 1b and 2)
7 months
Cases
Controls
12 
months
Cases
Controls
24 
months
Cases
Controls
Figure 4.1. Summary of the Project Stages.  
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After collecting the samples between October 2010 and April 2011 in the 
rural District of Quininde in the tropics of Ecuador, they were shipped on dry ice 
to the United Kingdom. DNA extraction was performed using a modified kit 
protocol standardized by the Molecular Genetics and Genomics Group (Chapter 
2: Sections 2.4 and 2.5) PCR of the 16S rRNA gene V3-V5 segments was 
performed also as previously described (Chapter 2: Section 2.7). 
For the comparison between current and past wheezing section, 3 
pyrosequencing runs were merged. For this part of the study the DNA 
sequences obtained from the Stage 1a of the project were compared with the 
results from the Stage 1b. Both stages contain samples from infants that range 
on age between 7 and 12 months and belong to the same community of the 
Quininde District on the rural tropics of Ecuador. For the mid and long-term 
changes after wheezing section, six pyrosequencing runs were performed on 
the Roche 454 Junior sequencer using the samples from Stages 1b and 2 of the 
study.  
The resulting data were merged together after sequencing error 
correction had been performed using Ampliconnoise (Chapter 2: Section 2.7.5). 
Results were analysed with QIIME 1.7 and the phyloseq script on R. Statistical 
analysis was performed using Metastats adnon the stat4 script on R. Graphics 
were developed on QIIME, GraphPad 6.0 and R (Chapter 2: Sections 2.7.5). 
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4.2 Results 
4.2.1 Current versus Past Wheezing (Stages 1a versus 1b) 
4.2.1.1 OTUs Comparisons  
For Stages 1a versus 1b a total of 370,000 sequences were analysed 
from 246 samples.  
At phyla level the patterns on the upper airways microbiota were similar 
between acute wheezing sufferers and past wheezing sufferers. In both groups 
Firmicutes remained the most common phylum, whilst overall the rest of phyla 
maintained their abundance and diversity (between Stages 1a and 1b).  
At OTUs level there were encountered several differences when 
comparing the upper airways microbiota in infants with a current wheezing 
episode and infants with a past wheezing episode. However the most abundant 
OTUs in the current wheezing group were the same as for the past wheezing 
group, Streptococcus being the most common bacteria followed by Veillonella 
and Prevotella (Figure 4.2). 
When statistically comparing only cases in both groups (current and past 
wheezing infants), it was possible to determine differences in several OTUs. In 
the phylum Actinobacteria there were encountered differences in three OTUs 
taxonomically assigned to Actinomyces spp. that were more commonly found in 
the current wheezing group (P values = 0.0051, 0.00095 and 0.000091 
respectively). Also in this phylum one OTU assigned to Corynebacterium was 
more common in the current wheezing group (P=0.010). 
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In Bacteroidetes, an OTU appointed as Prevotella sp. was more 
abundant in the past wheezing group (P=0.017) but another OTU assigned to 
Prevotella melaninogenica was more commonly found in the current wheezing 
group (P=0.00009). Two OTUs assigned to Porphyromonas spp. were more 
commonly found in the current wheezing group (P values = 0.001 and 0.006). 
In Firmicutes, Lactobacillus was more abundant in the past wheezing 
group than in the current wheezing one (P=0.001). In contrast the genus 
Sthaphylococcus was more common in the current wheezing group (P=0.012). 
Between the OTUs assigned to Streptococcus spp., several of them (OTUs 
1041 and 1120) were more common in current wheezers (P=0.017 and 0.016), 
but most of them (OTUs 427, 179, 524 and 1142) were more common in past 
wheezers (P values = 0.0001, 0.0002, 0.03 and 0.024). In this phylum 
Veillonella spp., Gemellacea and Leptotrichia spp. were more common also in 
past wheezers (P=0.002, 0.0009 and 0.0044).  
In Proteobacteria, the OTUs assigned to Neisseria, Haemophilus and 
Moraxella were all more abundant in the current wheezing infants (P values = 
0.0009, 0.0009 and 0.022) compared with the past wheezing infants. 
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Taxonomy A45 A46 A47 A48 A49 A50 A51 A52 A53 A54 A55 A56 A57 A58 A59 A60 A61 A62 A63 A65 A66 A67 A68 A69 B51 B52 B53 B54 B55 B56 B57 B58 B59 B60 B61 B62 B63 B64 B65 B66 B67 B68 B69 B70 B71 B72 B73 B74 B75 B76 B77 B78 B79 B80 B81 B82 B83 B84 B85 B86 B88 B89 B90 B91 B92 B93 C1 C11 C12 C13 C14 C15 C16 C18 C19 C2 C3 C4 C5 C6 C7 C8 C9
p__Actinobacteria;?c__Actinobacteria;?o__Actinomycetales;?f__Actinomycetaceae;?g__Actinomyces;?s__?_1092? 0 0 0 1 0 0 0 0 0 3 4 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Actinobacteria;?c__Actinobacteria;?o__Actinomycetales;?f__Actinomycetaceae;?g__Actinomyces;?s__?_1099? 0 0 0 18 0 0 2 1 0 0 0 0 0 31 0 0 0 0 7 0 0 11 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Actinobacteria;?c__Actinobacteria;?o__Actinomycetales;?f__Actinomycetaceae;?g__Actinomyces;?s__?_110? 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
p__Actinobacteria;?c__Actinobacteria;?o__Actinomycetales;?f__Actinomycetaceae;?g__Actinomyces;?s__?_1149? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0
p__Actinobacteria;??g__Actinomyces;?s__?_129? 0 29 0 42 10 43 9 58 46 52 95 5 63 73 11 0 0 8 11 0 59 40 22 38 9 1 31 0 7 31 0 30 15 12 34 2 0 44 15 8 1 0 0 6 1 3 14 24 38 18 9 1 18 2 40 0 15 28 30 52 8 0 59 6 1 4 1 3 47 8 32 19 57 34 5 3 15 0 37 21 46 2 0
p__Actinobacteria;?c__Actinobacteria;?o__Actinomycetales;?f__Actinomycetaceae;?g__Actinomyces;?s__?_196? 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 1 0 0 0 0 0 0 0 0 4 0 0 0 0 0 0 0 2 22 9 8 1 0 0 0 0 3 0 1 0 0 0 0 0 2 1 0 0 0 0 0 0 7 0 0 0 0 0 0 0 0 0 0 0 0
p__Actinobacteria;?c__Actinobacteria;?o__Actinomycetales;?f__Actinomycetaceae;?g__Actinomyces;?s__?_216? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 3 0 0 1 0 0 1 1 0 0 0 0 1 0 0 0 1 0 1 0 0 1 1 3 0 1 4 2 2 0 0 2 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 2 1 0 0
p__Actinobacteria;?c__Actinobacteria;?o__Actinomycetales;?f__Actinomycetaceae;?g__Actinomyces;?s__?_233? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Actinobacteria;?c__Actinobacteria;?o__Actinomycetales;?f__Actinomycetaceae;?g__Actinomyces;?s__?_255? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Actinobacteria;?c__Actinobacteria;?o__Actinomycetales;?f__Actinomycetaceae;?g__Actinomyces;?s__?_554? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
p__Actinobacteria;?c__Actinobacteria;?o__Actinomycetales;?f__Actinomycetaceae;?g__Actinomyces;?s__?_563? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Actinobacteria;?c__Actinobacteria;?o__Actinomycetales;?f__Actinomycetaceae;?g__Actinomyces;?s__?_614? 0 0 0 0 0 0 0 0 0 0 1 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Actinobacteria;?c__Actinobacteria;?o__Actinomycetales;?f__Actinomycetaceae;?g__Actinomyces;?s__?_808? 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Actinobacteria;?c__Actinobacteria;?o__Actinomycetales;?f__Actinomycetaceae;?g__Actinomyces;?s__?_937? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 5 2 0 1 0 0 0 0 1 24 0 0 0 3 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Actinobacteria;?c__Actinobacteria;?o__Actinomycetales;?f__Corynebacteriaceae;?g__Corynebacterium;?s__?_1355? 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Actinobacteria;?c__Actinobacteria;?o__Actinomycetales;?f__Corynebacteriaceae;?g__Corynebacterium;?s__?_302? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 12 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0
p__Actinobacteria;?c__Actinobacteria;?o__Actinomycetales;?f__Corynebacteriaceae;?g__Corynebacterium;?s__?_433? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Actinobacteria;?c__Actinobacteria;?o__Actinomycetales;?f__Corynebacteriaceae;?g__Corynebacterium;?s__?_452? 0 0 116 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Actinobacteria;?c__Actinobacteria;?o__Actinomycetales;?f__Corynebacteriaceae;?g__Corynebacterium;?s__?_453? 0 0 202 0 0 0 0 0 0 0 0 0 0 0 0 51 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Actinobacteria;?c__Actinobacteria;?o__Actinomycetales;?f__Corynebacteriaceae;?g__Corynebacterium;?s__?_944? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 71 0 0 0 0 1 0 0 1 0 2 1 1 0 513 168 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 501 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Actinobacteria;?c__Actinobacteria;?o__Actinomycetales;?f__Corynebacteriaceae;?g__Corynebacterium;?s__durum?_165? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 4 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Actinobacteria;?c__Actinobacteria;?o__Actinomycetales;?f__Dermabacteraceae;?g__Brachybacterium;?s__conglomeratum?_1184? 3 0 2 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Actinobacteria;?c__Actinobacteria;?o__Actinomycetales;?f__Intrasporangiaceae;?g__Janibacter;?s__?_330? 0 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Actinobacteria;?c__Actinobacteria;?o__Actinomycetales;?f__Micrococcaceae;?g__Rothia;?s__mucilaginosa?_1057? 0 0 0 0 0 0 0 0 5 0 1 0 0 1 1 0 6 2 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Actinobacteria;?c__Actinobacteria;?o__Actinomycetales;?f__Micrococcaceae;?g__Rothia;?s__mucilaginosa?_1189? 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 4 1 0 0 3 0 0 0 0 0 0 0 0 3 2 1 0 0 0 0 0 1 1 0 0 0 2 1 3 1 0 2 4 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 9 0 0
p__Actinobacteria;?c__Actinobacteria;?o__Bifidobacteriales;?f__Bifidobacteriaceae;?g__Bifidobacterium;?s__?_1? 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Actinobacteria;?c__Coriobacteriia;?o__Coriobacteriales;?f__Coriobacteriaceae;?g__Atopobium;?s__?_206? 0 0 0 0 0 0 0 6 0 0 7 0 3 0 0 0 1 0 0 0 0 0 4 0 0 0 25 0 1 3 2 0 0 0 0 1 3 5 1 3 1 0 0 6 0 0 16 10 0 1 1 0 0 0 3 0 0 1 2 1 3 0 0 0 0 2 0 0 0 5 3 3 1 0 0 0 0 1 1 1 4 0 0
p__Actinobacteria;?c__Coriobacteriia;?o__Coriobacteriales;?f__Coriobacteriaceae;?g__Atopobium;?s__?_285? 0 6 0 17 2 3 3 0 5 20 1 18 0 43 15 0 25 6 3 1 0 14 0 17 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Bacteroidetes;?c__Bacteroidia;?o__Bacteroidales;?f__[Paraprevotellaceae];?g__[Prevotella];?s__?_1358? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 2 0 0 0 0 1 0 0 0 0 0 3 0 1 0 0 0 0 0 0 1 2 0 2 0 1 0 0 0 0 2 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0
p__Bacteroidetes;?c__Bacteroidia;?o__Bacteroidales;?f__[Paraprevotellaceae];?g__[Prevotella];?s__?_1373? 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Bacteroidetes;?c__Bacteroidia;?o__Bacteroidales;?f__[Paraprevotellaceae];?g__[Prevotella];?s__?_1458? 0 0 0 2 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 4 3 0 0 7 12 4 0 2 7 5 41 1 0 0 5 0 0 0 0 17 3 0 0 1 0 0 0 1 0 0 0 0 2 0 2 5 0 0 5 0 2 0 0 0 8 9 0 3 0 1 2 12 0 2 0 0 0 0
p__Bacteroidetes;?c__Bacteroidia;?o__Bacteroidales;?f__[Paraprevotellaceae];?g__[Prevotella];?s__?_935? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Bacteroidetes;?c__Bacteroidia;?o__Bacteroidales;?f__[Paraprevotellaceae];?g__[Prevotella];?s__?_991? 0 1 1 0 0 0 2 0 12 0 2 0 0 3 0 1 1 1 0 0 1 0 3 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Bacteroidetes;?c__Bacteroidia;?o__Bacteroidales;?f__Porphyromonadaceae;?g__Porphyromonas;?s__?_1485? 0 0 0 1 2 1 4 0 0 0 0 0 0 0 0 0 0 1 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Bacteroidetes;?c__Bacteroidia;?o__Bacteroidales;?f__Porphyromonadaceae;?g__Porphyromonas;?s__?_224? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5 16 1 7 6 0 0 9 0 0 0 5 0 1 0 0 13 27 0 1 1 1 1 52 0 0 1 0 32 0 1 3 8 0 0 24 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Bacteroidetes;?c__Bacteroidia;?o__Bacteroidales;?f__Porphyromonadaceae;?g__Porphyromonas;?s__?_36? 0 1 0 0 0 1 0 0 1 0 0 0 0 4 0 0 1 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Bacteroidetes;?c__Bacteroidia;?o__Bacteroidales;?f__Porphyromonadaceae;?g__Porphyromonas;?s__?_378? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 2 0 1 0 0 1 0 17 1 0 0 3 0 0 2 0 1 1 0 0 0 1 1 0 1 0 0 0 0 0 0 0 2 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 7 0 0 0 0 0 0
p__Bacteroidetes;?c__Bacteroidia;?o__Bacteroidales;?f__Prevotellaceae;?g__Prevotella;?s__?_1306? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Bacteroidetes;?c__Bacteroidia;?o__Bacteroidales;?f__Prevotellaceae;?g__Prevotella;?s__?_178? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5 0 0 1 0 0 0 0 0 0 9 0 0 0 2 0 0 2 0 0 5 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Bacteroidetes;?c__Bacteroidia;?o__Bacteroidales;?f__Prevotellaceae;?g__Prevotella;?s__?_274? 0 0 0 0 1 2 4 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Bacteroidetes;?c__Bacteroidia;?o__Bacteroidales;?f__Prevotellaceae;?g__Prevotella;?s__?_313? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Bacteroidetes;?c__Bacteroidia;?o__Bacteroidales;?f__Prevotellaceae;?g__Prevotella;?s__?_655? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 7 0 0 0 0 0 0 0 0 0 11 0 1 2 4 0 1 3 0 0 8 0 6 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
p__Bacteroidetes;?c__Bacteroidia;?o__Bacteroidales;?f__Prevotellaceae;?g__Prevotella;?s__?_913? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Bacteroidetes;??g__Prevotella;?s__melaninogenica?_373? 0 24 0 3 0 55 23 14 13 0 33 6 19 65 0 0 0 4 34 1 0 31 48 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Bacteroidetes;?c__Bacteroidia;?o__Bacteroidales;?f__Prevotellaceae;?g__Prevotella;?s__melaninogenica?_374? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 2 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Bacteroidetes;?g__Prevotella;?s_870? 0 0 0 0 52 20 0 0 0 28 0 0 0 0 0 0 0 0 0 0 77 0 0 95 11 1 41 0 16 16 5 11 5 8 1 2 1 54 1 4 0 0 0 19 4 21 6 89 21 67 10 30 2 1 64 0 13 56 14 108 4 2 28 4 1 6 0 3 4 7 14 0 13 11 1 1 0 6 24 3 0 1 2
p__Bacteroidetes;?c__Bacteroidia;?o__Bacteroidales;?f__Prevotellaceae;?g__Prevotella;?s__nanceiensis?_400? 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Bacteroidetes;?c__Bacteroidia;?o__Bacteroidales;?f__Prevotellaceae;?g__Prevotella;?s__nanceiensis?_533? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 3 0 0 0 0 0 5 0 0 0 0 5 1 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Bacteroidetes;?c__Bacteroidia;?o__Bacteroidales;?f__Prevotellaceae;?g__Prevotella;?s__nanceiensis?_562? 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Bacteroidetes;?c__Bacteroidia;?o__Bacteroidales;?f__Prevotellaceae;?g__Prevotella;?s__nanceiensis?_632? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 0 1 0 1 0 1 0 0 7 0 0 0 0 0 0 0 0 0 1 0 0 0 2 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 2 0 0 0 0 0 0
p__Bacteroidetes;?c__Flavobacteriia;?o__Flavobacteriales;?f__[Weeksellaceae];?g__;?s__?_785? 0 77 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Bacteroidetes;?c__Flavobacteriia;?o__Flavobacteriales;?f__[Weeksellaceae];?g__;?s__?_926? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 28 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0
p__Bacteroidetes;?c__Flavobacteriia;?o__Flavobacteriales;?f__Flavobacteriaceae;?g__Capnocytophaga;?s__?_1136? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Bacteroidetes;?c__Flavobacteriia;?o__Flavobacteriales;?f__Flavobacteriaceae;?g__Capnocytophaga;?s__?_375? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Bacteroidetes;?c__Flavobacteriia;?o__Flavobacteriales;?f__Flavobacteriaceae;?g__Capnocytophaga;?s__?_710? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 4 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Cyanobacteria;?c__Chloroplast;?o__Streptophyta;?f__;?g__;?s__?_1278? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 24 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Cyanobacteria;?c__Chloroplast;?o__Streptophyta;?f__;?g__;?s__?_1282? 0 0 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli?_675? 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Bacillales?_1133? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Bacillales?_722? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Bacillales?_822? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 147 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 0 0 1 542 2 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 488 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Bacillales;?f__Staphylococcaceae;?g__Macrococcus;?s__caseolyticus?_1062? 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Bacillales;?f__Staphylococcaceae;?g__Staphylococcus;?s__?_299? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Bacillales;?f__Staphylococcaceae;?g__Staphylococcus;?s__?_477? 21 0 28 0 0 0 0 0 0 0 0 6 0 0 0 287 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Gemellales;?f__Gemellaceae?_506? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Gemellales;?f__Gemellaceae;?g__;?s__?_1379? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 2 0 2 1 0 1 1 0 1 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 1 0 1 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Gemellales;?f__Gemellaceae;?g__;?s__?_305? 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;??f__Gemellaceae;?g__;?s__?_35? 0 4 4 0 0 0 0 0 4 0 0 0 2 0 0 0 0 0 0 0 2 4 0 0 8 1 2 0 24 57 7 50 19 0 16 59 1 16 3 23 0 0 1 3 38 51 1 0 12 3 20 11 7 7 3 0 15 4 14 27 19 2 1 7 0 3 0 1 0 14 9 1 5 7 3 3 6 2 13 0 0 0 1
p__Firmicutes;?c__Bacilli;?o__Gemellales;?f__Gemellaceae;?g__;?s__?_377? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Gemellales;?f__Gemellaceae;?g__;?s__?_842? 1 0 0 6 20 4 3 2 1 0 0 0 0 1 0 0 2 0 6 1 0 0 6 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?o__Lactobacillales?_117? 0 10 1 23 25 0 17 48 34 6 11 2 9 24 3 0 1 11 15 0 14 16 12 24 29 9 18 0 7 39 15 78 46 25 16 45 7 17 51 22 0 3 0 14 16 50 28 16 53 18 10 40 17 12 12 0 57 11 18 16 19 6 12 35 0 12 1 14 5 21 14 1 29 12 17 2 37 11 4 11 9 0 1
p__Firmicutes;?c__Bacilli;?o__Lactobacillales?_1347? 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 1 0 2 0 0 0 0 2 0 0 0 0 0 0 1 0 0 0 1 0 1 0 0 0 0 2 1 1 0 0 1 0 1 0 0 0 0 0 0 1 0 1 1 2 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales?_282? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales?_321? 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales?_939? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__;?g__;?s__?_68? 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Aerococcaceae?_1276? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Aerococcaceae;?g__Alloiococcus;?s__?_1361? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 7 39 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Carnobacteriaceae;?g__Granulicatella;?s__?_1040? 0 0 0 0 0 0 3 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Carnobacteriaceae;?g__Granulicatella;?s__?_1263? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Carnobacteriaceae;?g__Granulicatella;?s__?_868? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 2 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 2 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Lactobacillaceae;?g__Lactobacillus;?s__?_1032? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Lactobacillaceae;?g__Lactobacillus;?s__?_345? 0 6 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 9 0 0 0 0 6 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Lactobacillaceae;?g__Lactobacillus;?s__?_427? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 14 0 0 0 23 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Lactobacillaceae;?g__Lactobacillus;?s__?_930? 0 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__;?s__?_423? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__;?s__?_959? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus?_1030? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus?_28? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus;?s__?_1041? 0 0 0 0 0 0 0 1 8 0 1 0 1 0 0 0 0 0 1 0 1 0 0 1 0 0 0 0 0 0 0 2 1 0 0 0 0 0 3 1 0 0 0 0 0 0 0 0 0 0 0 1 0 2 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus;?s__?_1074? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 1 1 0 3 4 0 1 1 0 2 3 3 0 0 0 0 0 1 1 1 6 4 1 6 2 0 1 0 8 0 2 2 0 1 1 0 0 2 1 0 0 0 0 0 0 0 1 0 1 0 0 0 2 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus;?s__?_1120? 0 0 0 0 0 0 0 0 2 2 0 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus;?s__?_1124? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 72 0 0 0 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus;?s__?_1142? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 2 1 0 0 0 0 0 0 0 1 1 3 2 0 0 0 0 1 0 1 2 1 0 0 0 1 0 0 0 0 0 3 0 1 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus;?s__?_1227? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus;?s__?_1244? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus;?s__?_1246? 0 0 0 0 0 1 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 3 0 0 3 1 0 0 0 3 0 2 0 0 0 0 0 0 4 0 1 1 1 7 3 1 11 1 1 0 0 4 0 5 0 0 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus;?s__?_1297? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 1 0 2 0 2 2 0 2 1 1 0 0 0 0 0 0 0 1 0 1 0 1 1 0 1 0 2 0 0 2 0 0 0 2 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus;?s__?_1443? 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;??g__Streptococcus;?s__?_179? 121 162 20 178 85 203 118 187 233 195 120 186 275 120 155 14 236 347 251 499 281 132 222 113 170 303 256 4 180 114 176 73 146 239 153 13 341 275 288 115 4 8 0 231 7 124 258 222 239 281 227 146 345 148 195 498 154 247 173 104 59 456 248 97 4 289 432 361 281 211 199 225 218 261 211 15 130 328 188 249 258 93 396
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus;?s__?_214? 0 2 0 0 0 0 0 0 1 1 0 0 1 0 0 0 0 0 1 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus;?s__?_227? 0 0 0 0 0 0 0 0 0 0 1 0 3 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus;?s__?_269? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus;?s__?_31? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 2 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus;?s__?_38? 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 1 0 2 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 2 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus;?s__?_450? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus;?s__?_491? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 1 0 1 0 0 0 0 0 0 2 0 1 0 0 0 0 0 0 1 0 2 0 0 0 0 0 0 0 0 0 0 2 0 1 0 0 1 0 0 0 2 0 0 1 0 0 1 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus;?s__?_513? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 2 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus;?s__?_521? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 3 0 2 0 0 0 0 0 0 3 0 0 0 2 0 0 0 0 1 0 0 1 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;??g__Streptococcus;?s__?_524? 1 45 4 109 141 30 287 161 106 125 121 97 61 30 240 1 179 79 22 33 24 196 115 25 243 119 106 6 141 121 244 101 168 227 195 152 95 14 144 250 6 11 62 174 318 131 151 20 56 95 41 87 101 221 45 11 84 34 244 151 200 56 161 128 44 212 59 128 214 163 150 279 202 206 292 30 295 137 197 237 209 186 147
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus;?s__?_546? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 1 0 0 0 0 1 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus;?s__?_550? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus;?s__?_564? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus;?s__?_571? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus;?s__?_581? 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus;?s__?_647? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 2 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus;?s__?_747? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus;?s__?_771? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Bacilli;?o__Lactobacillales;?f__Streptococcaceae;?g__Streptococcus;?s__?_911? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 6 0
p__Firmicutes;?c__Clostridia;?o__Clostridiales;?f__;?g__;?s__?_1075? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Clostridia;?o__Clostridiales;?f__;?g__;?s__?_144? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 2 0 3 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Clostridia;?o__Clostridiales;?f__;?g__;?s__?_307? 0 2 0 0 0 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 3 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Clostridia;?o__Clostridiales;?f__;?g__;?s__?_565? 0 0 0 0 0 0 0 3 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Clostridia;?o__Clostridiales;?f__[Mogibacteriaceae];?g__Mogibacterium;?s__?_697? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Clostridia;?o__Clostridiales;?f__Lachnospiraceae;?g__;?s__?_1352? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Clostridia;?o__Clostridiales;?f__Lachnospiraceae;?g__;?s__?_25? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 2 0 0 0 0 5 0 1 0 0 0 5 0 0 0 16 0 0 0 0 0 0 6 0 0 11 0 1 0 0 0 0 0 0 0 0 0 0 4 0 0 0 0 0 0 0 0 0 0 0 1
p__Firmicutes;?c__Clostridia;?o__Clostridiales;?f__Lachnospiraceae;?g__;?s__?_323? 0 0 0 2 0 1 0 0 1 0 0 0 5 9 0 0 0 0 0 0 1 2 3 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Clostridia;?o__Clostridiales;?f__Lachnospiraceae;?g__;?s__?_644? 0 0 0 0 0 0 0 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 8 0 3 4 0 0 2 0 6 0 2 0 0 0 1 0 2 0 10 1 1 0 0 0 1 5 0 1 7 0 2 0 0 2 1 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Clostridia;?o__Clostridiales;?f__Lachnospiraceae;?g__Catonella;?s__?_243? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Clostridia;?o__Clostridiales;?f__Lachnospiraceae;?g__Moryella;?s__?_1380? 0 0 0 0 0 0 0 2 0 0 0 0 2 0 0 0 0 0 3 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Clostridia;?o__Clostridiales;?f__Lachnospiraceae;?g__Moryella;?s__?_99? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 3 0 0 0 0 0 1 0 1 0 7 0 0 7 0 0 0 1 0 0 1 0 2 0 0 0 0 0 2 0 0 0 0 1 0 2 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Clostridia;?o__Clostridiales;?f__Lachnospiraceae;?g__Oribacterium;?s__?_437? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 0 1 0 0 0 0 2 0 0 0 0 0 0 0 1 0 1 0 0 0 4 0 0 3 0 2 2 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Clostridia;?o__Clostridiales;?f__Lachnospiraceae;?g__Oribacterium;?s__?_646? 0 0 0 0 0 0 0 0 0 0 0 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Clostridia;?o__Clostridiales;?f__Peptostreptococcaceae;?g__Peptostreptococcus;?s__?_152? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Clostridia;?o__Clostridiales;?f__Veillonellaceae;?g__Megasphaera;?s__?_858? 0 0 0 0 1 0 0 0 0 3 1 0 0 5 0 0 0 0 1 0 4 0 3 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Clostridia;?o__Clostridiales;?f__Veillonellaceae;?g__Selenomonas;?s__?_1150? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Clostridia;?o__Clostridiales;?f__Veillonellaceae;?g__Veillonella?_1491? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 5 0 0 0 0 0 0 1 0 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?g__Veillonella;?s__?_1403? 0 18 1 12 1 13 1 18 7 0 3 0 7 9 14 0 33 5 4 0 0 6 1 28 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?g__Veillonella;?s__?_762? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 4 1 0 2 4 2 3 7 3 29 9 2 0 1 14 0 0 0 0 23 0 1 2 1 0 0 0 3 9 2 0 0 1 0 2 8 0 0 7 0 0 0 4 1 20 16 1 4 1 2 4 6 1 1 0 0 0 3
p__Firmicutes;?c__Clostridia;?o__Clostridiales;?f__Veillonellaceae;?g__Veillonella;?s__?_965? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Clostridia;?o__Clostridiales;?f__Veillonellaceae;?g__Veillonella;?s__dispar?_1083? 0 0 0 0 0 0 0 0 0 0 1 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Clostridia;?o__Clostridiales;?f__Veillonellaceae;?g__Veillonella;?s__dispar?_1393? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 3 0 2 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 1 2 0 0 0 1 0 0 0 2 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0
p__Firmicutes;??g__Veillonella;?s__dispar?_157? 1 79 2 117 65 116 74 49 66 123 152 234 76 126 75 0 69 90 58 0 92 91 90 86 58 33 68 1 13 9 66 107 21 33 30 6 53 39 39 28 1 3 1 74 22 37 38 59 96 36 13 45 53 43 114 1 39 52 34 38 30 13 26 32 0 18 42 46 4 64 49 31 27 26 22 6 20 68 48 38 20 4 8
p__Firmicutes;?c__Clostridia;?o__Clostridiales;?f__Veillonellaceae;?g__Veillonella;?s__dispar?_376? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Clostridia;?o__Clostridiales;?f__Veillonellaceae;?g__Veillonella;?s__dispar?_536? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Clostridia;?o__Clostridiales;?f__Veillonellaceae;?g__Veillonella;?s__dispar?_540? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 2 0 0 0 1 2 0 0 0 0 0 0 1 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0
p__Firmicutes;?c__Clostridia;?o__Clostridiales;?f__Veillonellaceae;?g__Veillonella;?s__dispar?_73? 0 1 0 0 0 0 1 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Clostridia;?o__Clostridiales;?f__Veillonellaceae;?g__Veillonella;?s__dispar?_805? 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Clostridia;?o__Clostridiales;?f__Veillonellaceae;?g__Veillonella;?s__dispar?_897? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 2 0 0 1 0 0 0 0 0 0 0 0 0
p__Firmicutes;?c__Clostridia;?o__Clostridiales;?f__Veillonellaceae;?g__Veillonella;?s__dispar?_902? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Fusobacteria;?c__Fusobacteriia;?o__Fusobacteriales;?f__Fusobacteriaceae;?g__Fusobacterium;?s__?_1250? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 2 0 0 1 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0
p__Fusobacteria;?c__Fusobacteriia;?o__Fusobacteriales;?f__Fusobacteriaceae;?g__Fusobacterium;?s__?_1260? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 2 1 0 0 0 0 0 0 0 0 6 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Fusobacteria;?c__Fusobacteriia;?o__Fusobacteriales;?f__Leptotrichiaceae;?g__;?s__?_1119? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0
p__Fusobacteria;?c__Fusobacteriia;?o__Fusobacteriales;?f__Leptotrichiaceae;?g__;?s__?_429? 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Fusobacteria;?c__Fusobacteriia;?o__Fusobacteriales;?f__Leptotrichiaceae;?g__;?s__?_821? 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 8 0 0 1 3 1 0 1 0 0 9 0 0 0 1 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 3 0 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
p__Fusobacteria;?c__Fusobacteriia;?o__Fusobacteriales;?f__Leptotrichiaceae;?g__Leptotrichia;?s__?_213? 0 0 2 8 4 4 1 2 9 0 0 0 0 2 0 0 0 4 1 0 0 0 2 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Fusobacteria;?c__Fusobacteriia;?o__Fusobacteriales;?f__Leptotrichiaceae;?g__Leptotrichia;?s__?_215? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 2 0 1 0 0 0 0 0 0 0 0 4 1 1 0 0 0 0 0 11 0 0 0 3 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0
p__Fusobacteria;?c__Fusobacteriia;?o__Fusobacteriales;?f__Leptotrichiaceae;?g__Leptotrichia;?s__?_275? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 0 1 9 0 2 29 6 8 18 0 0 0 0 0 1 0 4 23 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 8 0 0 5 0 0 1 0 0 0 12 0 0 0 0 0 10 0 0 0 0 0 1
p__Fusobacteria;?c__Fusobacteriia;?o__Fusobacteriales;?f__Leptotrichiaceae;?g__Leptotrichia;?s__?_424? 0 1 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Fusobacteria;?c__Fusobacteriia;?o__Fusobacteriales;?f__Leptotrichiaceae;?g__Leptotrichia;?s__?_51? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 5 0 0 0 0 0 0 0 0 0 0 0 0 0 8 1 0 0 0 0 0 0 0 0 0 0 0 6 0 0 0 0 0 0 0 0 0 0 0 1
p__Fusobacteria;?c__Fusobacteriia;?o__Fusobacteriales;?f__Leptotrichiaceae;?g__Leptotrichia;?s__?_552? 0 0 0 0 0 0 0 1 0 0 0 0 11 0 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Fusobacteria;?c__Fusobacteriia;?o__Fusobacteriales;?f__Leptotrichiaceae;?g__Leptotrichia;?s__?_638? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 2 0 2 0 0 1 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Fusobacteria;?c__Fusobacteriia;?o__Fusobacteriales;?f__Leptotrichiaceae;?g__Leptotrichia;?s__?_776? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 3 0 0 1 1 0 0 0 0 8 0 0 1 1 0 0 0 1 1 0 0 0 1 0 1 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Fusobacteria;?c__Fusobacteriia;?o__Fusobacteriales;?f__Leptotrichiaceae;?g__Leptotrichia;?s__?_933? 0 0 0 0 0 4 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 2 0 0 2 0 0 1 0 6 1 1 0 0 0 2 0 0 11 8 3 0 1 0 0 0 14 0 2 1 0 0 0 0 1 2 0 2 0 0 0 0 7 0 0 0 0 1 0 0 0 0 0 0 3
p__Fusobacteria;?c__Fusobacteriia;?o__Fusobacteriales;?f__Leptotrichiaceae;?g__Leptotrichia;?s__?_98? 0 0 0 11 0 6 0 0 3 0 0 0 14 0 0 0 0 0 5 0 0 0 0 70 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Proteobacteria;?c__Alphaproteobacteria;?o__Rhizobiales?_1180? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Proteobacteria;?c__Alphaproteobacteria;?o__Rhodospirillales;?f__Acetobacteraceae;?g__Acetobacter;?s__?_586? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 264 0
p__Proteobacteria;?c__Alphaproteobacteria;?o__Rhodospirillales;?f__Acetobacteraceae;?g__Acetobacter;?s__?_795? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 0
p__Proteobacteria;?c__Betaproteobacteria;?o__Burkholderiales;?f__Burkholderiaceae;?g__Burkholderia;?s__?_1097? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 1
p__Proteobacteria;?c__Betaproteobacteria;?o__Burkholderiales;?f__Burkholderiaceae;?g__Lautropia;?s__?_680? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 4 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Proteobacteria;?c__Betaproteobacteria;?o__Burkholderiales;?f__Oxalobacteraceae;?g__Ralstonia;?s__?_1378? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0
p__Proteobacteria;?c__Betaproteobacteria;?o__Neisseriales;?f__Neisseriaceae;?g__;?s__?_155? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Proteobacteria;?c__Betaproteobacteria;?o__Neisseriales;?f__Neisseriaceae;?g__;?s__?_359? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Proteobacteria;?c__Betaproteobacteria;?o__Neisseriales;?f__Neisseriaceae;?g__;?s__?_547? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 26 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Proteobacteria;?c__Betaproteobacteria;?o__Neisseriales;?f__Neisseriaceae;?g__Kingella;?s__?_445? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Proteobacteria;?c__Betaproteobacteria;?o__Neisseriales;?f__Neisseriaceae;?g__Neisseria?_1140? 0 0 0 0 71 0 1 0 0 0 0 0 0 0 21 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Proteobacteria;?c__Betaproteobacteria;?o__Neisseriales;?f__Neisseriaceae;?g__Neisseria?_270? 0 72 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 23 0 1 0 0 0 0 1 0 0 1 0 0 0 0 0 0 2 0 1 0 0 0 0 0 0 1 0 1 2 0 0 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0
p__Proteobacteria;?c__Betaproteobacteria;?o__Neisseriales;?f__Neisseriaceae;?g__Neisseria;?s__?_1068? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 3 0 3 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Proteobacteria;g__Neisseria;?s__?_148? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 6 0 1 0 39 26 0 15 52 1 46 73 43 2 0 8 0 0 1 0 32 32 1 0 0 4 2 64 1 1 1 1 39 13 2 7 2 2 1 165 0 1 0 0 0 35 12 0 0 0 0 2 16 1 3 0 0 0 0
p__Proteobacteria;??g__Neisseria;?s__?_175? 1 1 0 1 0 0 0 0 1 0 0 4 0 0 0 2 0 4 89 10 0 0 11 17 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Proteobacteria;?c__Gammaproteobacteria;?o__Enterobacteriales;?f__Enterobacteriaceae;?g__;?s__?_181? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Proteobacteria;?c__Gammaproteobacteria;?o__Pasteurellales;?f__Pasteurellaceae;?g__Actinobacillus?_352? 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 10 0 0 0 0 0 1 0 0 0 69 1 1 58 3 0 3 0 0 3 0 3 0 0 0 0 0 23 1 0 1 2 38 12 0 0 0 0 0 6 5 0 48 2 0 12 0 0 0 0 0 0 2 0 0 0 0 0 0 0 40 0 0 0 0
p__Proteobacteria;?c__Gammaproteobacteria;?o__Pasteurellales;?f__Pasteurellaceae;?g__Actinobacillus;?s__parahaemolyticus?_569? 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Proteobacteria;?c__Gammaproteobacteria;?o__Pasteurellales;?f__Pasteurellaceae;?g__Aggregatibacter;?s__?_147? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Proteobacteria;?c__Gammaproteobacteria;?o__Pasteurellales;?f__Pasteurellaceae;?g__Haemophilus;?s__?_1138? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Proteobacteria;g__Haemophilus;?s__?_131? 201 9 1 1 59 0 0 0 0 0 0 2 0 2 25 0 0 0 8 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Proteobacteria;?c__Gammaproteobacteria;?o__Pasteurellales;?f__Pasteurellaceae;?g__Haemophilus;?s__influenzae?_23? 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 1 0 0 1 19 0 1 1 0 4 19 1 6 0 3 0 7 191 0 0 3 2 0 0 2 67 12 0 1 0 45 54 2 1 1 8 3 0 10 0 0 0 0 0 1 0 0 0 0 0 0 0 2 3 0 0 0 0
p__Proteobacteria;?c__Gammaproteobacteria;?o__Pasteurellales;?f__Pasteurellaceae;?g__Haemophilus;?s__parainfluenzae?_602? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Proteobacteria;?c__Gammaproteobacteria;?o__Pasteurellales;?f__Pasteurellaceae;?g__Haemophilus;?s__parainfluenzae?_694? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 2 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 3 2 1 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Proteobacteria;?c__Gammaproteobacteria;?o__Pseudomonadales;?f__Moraxellaceae;?g__Acinetobacter;?s__?_627? 4 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Proteobacteria;?c__Gammaproteobacteria;?o__Pseudomonadales;?f__Moraxellaceae;?g__Moraxella;?s__?_1005? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Proteobacteria;?c__Gammaproteobacteria;?o__Pseudomonadales;?f__Moraxellaceae;?g__Moraxella;?s__?_1333? 193 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 468 0 14 0 0 0 0 0 0 0 0 0 40 0 0 75 0 0 0 0 0 0 0 93 0 0 0 0 0 0 0 0 0 108 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Proteobacteria;?c__Gammaproteobacteria;?o__Pseudomonadales;?f__Moraxellaceae;?g__Moraxella;?s__?_316? 0 0 141 0 23 0 0 0 0 0 0 0 0 0 0 3 0 0 15 16 0 0 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
p__Proteobacteria;?c__Gammaproteobacteria;?o__Pseudomonadales;?f__Moraxellaceae;?g__Moraxella;?s__?_416? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Current?Wheezing Past?wheezing
Figure 4.2. Current versus Past Wheezing Heatmap. that 
compares the sequences abundance per OTU in cases between 
current wheezing and past wheezing infants. The taxonomy 
assignation is shown in the left and the boxes in right show the 
number of sequences. Dark red represents a high number of reads 
per OTU, yellow low number and white represents absence.  
157 
4.2.1.2 Beta Diversity 
For the beta diversity analysis of Stages 1a and b, analysis was almost 
identically done to the pilot study analysis with the exception of the addition of 
the UNIFRAC statistics there have been added to the analysis and the Bray-
Curtis and Canberra statistics in order to determine differences without the use 
of phylogenetic information. Inclusion of these approaches has the potential to 
detect more sensitively dissimilarities in larger data sets. When comparing 
between groups at OTUs level, there were found statistical differences using 
Adonis Canberra (P<0.001), Bray-Curtis (P<0.001), UNIFRAC (P<0.001), and 
Weighted UNIFRAC (P<0.001). However current and past wheezing status 
explains a different proportion of the variance each time: Canberra = 58%, 
Bray-Curtis 14%, UNIFRAC = 15%, weighted UNIFRAC = 7%.  One can 
conclude that the abundance of the different OTUs is not important (UNIFRAC 
and Canberra are presence/absence and show higher values), and that 
phylogenetic information is not relevant to show differences (UNIFRAC versus 
Canberra).  
On the NMDS plots, the stress (disagreement between 2-D configuration 
and predicted values from regression) is 0.10 in Bray-Curtis, 0.10 in Canberra, 
0.19 in UNIFRAC and 0.11 Weighted-UNIFRAC showing a very good 
representation in a bi-dimensional plot. The NMDS plots in Canberra show a 
clear clustering between current and past wheezers (Figure 4.3). The NMDS 
and PCoA plots using UNIFRAC and weighted UNIFRAC did not show a clear 
clustering between groups. 
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4.2.1.3 Alpha Diversity 
For this analysis the inverse Simpson diversity was also included as it 
increases the sensitivity of detecting differences in non-normal distributed data. 
This index is complementary to Shannon but instead of measuring entropy 
associated with the prediction of similar abundances between groups (Shannon, 
1948), the inverse Simpson measures the grade of concentration when 
individuals are grouped (Simpson, 1949). Alpha diversity grouped on quantiles 
on multiple rarefaction curves using Shapiro-Wilkinson normality tests, showed 
Figure 4.3. NMDS Plot using Canberra Statistics 
(presence/absence of OTUs). Each dot represents a sample 
and current wheezers are coloured on red whilst past wheezers 
are in green. 
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a non-normal distribution on Richness (P<0.0001), Evenness (P<0.0001), 
Shannon diversity (P=0.025) and Inverse Simpson (P<0.001) (Figure 4.4). For 
this reason, non-parametric tests were used to analyse between the current and 
past wheezing groups. 
Alpha diversity analysis using the Shannon index per group was 
performed using a rarefied OTU table at 565 sequences per sample to see if 
any group shows a more diverse microbiota. There were no statistical 
differences found (P>0.05). Kruskal-Wallis non-parametric analysis showed no 
statistical differences in richness, Shannon and inverse Simpson indexes when 
compared between current and past wheezing groups. Evenness however, was 
found to be statistically different between the two groups (P=0.019). 
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4.2.2 Mid and Long-term Changes after Recurrent 
Wheezing Episodes (Stages 1b and 2) 
For Stages 1b and 2, 260 throat swabs were obtained and underwent 
DNA extraction. The 16S rRNA amplification was successful for 244 samples. 
Using Multiplex Identifier (MID) adaptors and six sequencing runs an initial 
792,000 raw sequences were obtained for the 244 samples. After denoising, 
singleton exclusion, chimera checking and removal of OTUs present in only one 
sample a total of 478,988 sequences remained assigned to 455 OTUs (at 97% 
sequence identity level). The number of sequences obtained varied between 
Figure 4.4. Alpha Diversity normality plots using Shapiro-
Wilkinson test. Richness, Evenness, and Diversity with 
Inverse Simpson and Shannon indexes were calculated. Plots 
show the comparison of the theoretical versus sample quantiles 
to determine normality. None of the indexes showed normal 
distribution. 
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samples from 575 to 4,395. Consequently to remove the sample heterogeneity 
sequences were rarefied to 575 sequences per sample.  
4.2.2.1 OTUs Comparisons  
Cladistic classification of all the sequences (cases and controls 
combined) showed a high prevalence of the phylum Firmicutes (76% of the total 
number of sequences obtained) followed by Bacteroidetes (9%), Proteobacteria 
(7%), Actinobacteria (6%) and Fusobacteria (2%) respectively. Firmicutes was 
the most diverse phylum containing 113 distinct OTUs (51% of the total OTUs) 
followed by Proteobacteria with 37 OTUs (17%), Bacteroidetes with 36 OTUs 
(16%), Actinobacteria with 23 OTUs (10%), and Fusobacteria with 14 OTUs 
(6%). 
At the OTU level, Streptococcus spp. were found to be the most common 
with more than half of the sequences identified assigned to this genus (55.3% of 
the total). Veillonella spp. were the second most common with 8.3% of 
sequences followed by Prevotella spp. with 5.5%, Granulicatella spp. with 3.8%, 
Actinomyces spp. with 3.6%, Neisseria spp. with 3.3%, and Gemella spp. with 
2.5% of sequences.  
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At Phyla level when comparing all cases versus all controls, 
Actinobacteria and Proteobacteria were slightly more prevalent in cases but 
these differences were not significant. In contrast Firmicutes, Fusobacteria and 
Bacteroidetes were more prevalent in controls although only for Bacteroidetes 
was this statistically significant (P=0.017, OR 0.73) (Figure 4.5).  
 
Taking age and case control status into consideration, analysis at the 
phyla level revealed statistically significant differences using two-way ANOVA 
(P<0.0001) and when multiple comparisons were performed (Tucke´s multiple 
comparison test). Statistical differences were seen between cases versus 
controls at 7 months of age for Firmicutes (P<0.0001), as well as for cases at 7 
months compared with controls at 12 and 24 months (P<0.001), with more 
Firmicutes present in wheezing infants at 7 months compared with the other 
Figure 4.5. Comparisons at Phyla level between Cases 
versus Controls. Each bar represents the OTUs 
taxonomy assignation summarized per phylum. Error bars 
are also shown. 
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groups. In addition at 7 months, an increase in Bacteroidetes in controls was 
observed when compared to cases (P<0.001) (Figure 4.6). 
 
 
 
At the OTU level, there were several differences found when comparing 
between the pooled samples i.e. all cases versus all controls irrespective of 
age, and additionally when comparisons per status as well as age were 
examined (Table 4.1 – note only the OTUs with more than 100 sequences in 
total are shown).  
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Figure 4.6. Comparisons at Phyla level per Group. Each 
bar represents the OTUs taxonomy assignation summarized 
per phylum percentage.  
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For Actinobacteria, one single OTU (Corynebacterium) was more 
common in cases whilst two OTUs (Actinomyces and Propionibacterium) were 
more common in controls. The OTU assigned to Actinomyces sp. was most 
common in controls for the overall comparison (P=0.033, OR 0.902 95% CI: 
0.86 - 0.95) and these differences were also observed at 12 months (P=0.0028) 
and at 24 months (P=0.0009). In the same phylum Propionibacterium was more 
prevalent in controls (P=0.0216, OR 0.890, CI=0.819 to 0.974), with the 
differences when age was considered only being significant at 24 months 
(P=0.0205). Both Actinomyces and Propionibacterium are commensal bacteria 
of the upper airways and rarely cause opportunistic infections. In contrast, 
Corynebacterium sp. (which has been associated with disease more commonly 
7 months 12 months 24 months
P value P value P value P value OR CI (95%)
Actinobacteria_Actinomyces NS 0.0029 0.0010 0.0330 0.9021 0.8556 to 0.9511
Actinobacteria_Corynebacterium NS 0.0006 0.0000 0.0049 3.5149 3.1852 to 3.8787
Actinobacteria_Propionibacterium NS NS 0.0021 0.0216 0.8907 0.819 to 0.9747
Bacteroidetes_Bacteroidales 0.0064 NS 0.0005 <0.0001 1.8294 1.4235 to 2.351
Bacteroidetes_Prevotellaceae 0.0090 0.0233 0.0002 <0.0001 0.7479 0.6048 to 0.9249
Bacteroidetes_Prevotella 0.0010 0.0021 0.0131 0.0001 0.6659 0.6367 to 0.6964
Bacteroidetes_Capnocytophaga NS <0.0001 0.0400 <0.0001 1.9237 1.5432 to 2.3981
Firmicutes_Lactobacillus <0.0001 0.0013 <0.0001 <0.0001 0.7051 0.5665 to 0.8775
Firmicutes_Streptococcus 0.0010 NS NS 0.0020 0.9719 0.9514 to 0.9928
Firmicutes_Streptococcus 0.0449 0.0450 0.0005 <0.0001 0.8919 0.8715 to 0.9128
Firmicutes_Gemella NS NS 0.0090 0.0012 1.6980 1.5916 to 1.8115
Firmicutes_"Lachnospiraceae" 0.0277 0.0000 NS 0.0270 1.3966 1.2579 to 1.5505
Firmicutes_Veillonella 0.0100 0.0240 0.0179 0.0040 0.6808 0.6547 to 0.708
Fusobacteria_Fusobacterium NS 0.0000 0.0456 0.0056 0.7615 0.6252 to 0.9275
Fusobacteria_Leptotrichia 0.0010 0.0006 NS 0.0003 0.7005  0.6457 to 0.7599
Proteobacteria_Burkholderia NS 0.0088 0.0131 <0.0001 2.1818 1.5815 to 3.0099
Proteobacteria_Neisseriaceae 0.0175 0.0119 <0.0001 0.0166 0.8317 0.6088 to 1.1362
Proteobacteria_Pasteurellacea NS 0.0011 NS 0.0002 0.9986 0.9434 to 1.0571
Proteobacteria_Haemophilus 0.0100 0.0300 0.0430 0.0400 2.1295 1.896 to 2.3918
Proteobacteria_Moraxella 0.0010 0.0440 NS 0.0487 3.3673 2.9784 to 3.8069
Total 
OTUs
Table 4.1. Summary of Statistical Analysis at OTU level. Only OTUs with greater 
than 100 sequences are shown. P values obtained on Metastats with 1,000 
iterations were calculated comparing cases versus controls. The comparisons were 
performed per age group and in total. Additionally Odds Ratio and Confidence 
Intervals at 95% were calculated for the total analysis. • indicates the results when 
the OR was less than 1 (protective), and • when the OR is higher than 1 (increased 
risk). 
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but also could act as a commensal bacteria) was more prevalent in cases than 
in controls (P=0.0049, OR 3.514, CI=3.185 to 3.878).  This finding was also 
seen at 12 months (P=0.0006) and at 24 months (P=5.2E-11). 
For the phylum Bacteroidetes, two OTUs were more common in controls 
(Prevotellacea and Prevotella) and two in cases (Bacteroidales and 
Capnocytophaga). On overall, Prevotellacea and Prevotella sp. were more 
commonly found in controls (P=3.02E-05, OR 0.747 CI=0.60 to 0.92 and 
P=0.0001, OR 0.66, CI=0.63 to 0.69 respectively). Considering age, both OTUs 
were also significantly different for controls versus cases at 7 months (P=0.0089 
and P=0.0009), 12 months (P=0.023 and P=0.002), and 24 months (P=0.0002 
and P=0.013). Prevotella has been usually considered a protective commensal 
in the oral and upper airways. Within this phylum, Bacteroidales was more 
prevalent in cases (P=1.66E-05, OR=1.829, CI=1.423 to 2.351), particularly at 7 
months (P=0.0066) and 24 months (P=0.0004). Capnocytophaga sp. was more 
common in cases (P=19.59E-10, OR=1.923, CI=1.543 to 2.398), and at 12 
months (P=2.21E-06) and 24 months (P=0.039). Both Bacteroidales and 
Capnocytophaga are also considered commensals of the mouth but can 
produce in rare cases opportunistic infections. 
For Firmicutes, two OTUs assigned to Streptococcus spp. were more 
common in controls compared to cases (P=0.0020, OR=0.971, CI=0.951 to 
0.992 and P<0.0001), OR=0.891, CI=0.871 to 0.912). The first OTU was only 
statistically different at 7 months (P=0.0009), whilst the other was different for 
all ages: 7 months (P=0.0448), 12 months (P=0.0449) and 24 months 
(P=0.0005). In the same phylum, Lactobacillus sp. was also more common in 
controls (P=1.50E-11, OR=0.705, CI=0.566 to 0.877), similarly at 7 months 
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(P=1.93E-05), 12 months (P=0.0012) and 24 months (P=1.16E-11). Veillonella 
sp. was more prevalent in controls (P=0.004, OR=0.680, CI=0.654 to 0.708), 
and the differences were seen at 7 months (P=0.009), 12 months (P=0.023) 
and 24 months (P=0.017). Gemella sp. (P=0.0012, OR=1.698, CI=1.5916 to 
1.811) and Lachnospiraceae (P=0.027, OR=1.396, CI=1.257 to 1.550) were 
more common in cases, and whilst Lachnospiraceae was significant at 7 
months (P=0.027) and 12 months (P=4.2E-05), Gemella sp. was only 
statistically different at 24 months (P=0.008). All these bacterial generas are 
considered commensals of the upper airways usually associated with protective 
functions with the exception of S.pneumoniae that acts as a virulent pathogen in 
the airways of children. 
For Fusobacteria, both OTUs (Table 4.1) were more prevalent in 
controls. Fusobacterium sp. (P=0.0056, OR=0.761, CI=0.625 to 0.927), and at 
12 (P=1.94E-06) and 24 months (P=0.0456). Leptotrichia sp. (P=0.0003, 
OR=0.7005, CI=0.645 to 0.759) with differences at 7 months (P=0.0009) and 12 
months (P=0.0005).  Both Fusobacterium and Leptotrichia are commensals of 
the oral and airways microbiotas. 
An OTU assigned to Neisseriaceaea, within the phylum Proteobacteria, 
was more common in controls (P=0.016, OR=0.83, CI=0.608 to 1.13). This OTU 
was also significantly different when compared at 7 months (P=0.017), 12 
months (P=0.011) and 24 months (P=2.63E-08). Pasteurellaceae was more 
prevalent in controls (P=0.0002, OR=0.998, CI=0.608 to 1.13), this OTU 
presented differences at 7 months (P=0.017), 12 months (P=0.011) and 24 
months (P=2.63E-08). Within this phylum Burkholderia sp., Haemophilus sp. 
and Moraxella sp. were more abundant in cases (Burkholderia P=1.78E-05, 
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OR=2.18, CI=1.58 to 3.00; Haemophilus P=0.040, OR=2.129, CI=1.896 to 2.39; 
and Moraxella P=0.048, OR=3.367, CI=2.97 to 3.80). For Burkholderia sp. the 
differences were also found at 12 months (P=0.0088) and 24 months (P=0.013), 
in Haemophilus sp. at 7 months (P=0.0099), 12 months (P=0.029) and 24 
months (P=0.042), and Moraxella sp. at 7 months (P=0.0009) and 12 months 
(P=0.043). Haemophiuls, Neisseria and Burkholderia are considered as 
important pathogens of the airways, however in many circumstances are 
encountered being part of the ´commensal´ ecosystem in the upper airways.   
The OTUs distribution of samples grouped by age and also case/control 
status is graphically represented (heatmap) in Figure 4.7.  This highlights as 
previously commented that the most abundant OTUs present are Streptococcus 
spp. followed by Prevotella spp., Veillonella spp., Neisseria spp. and Moraxella 
spp. Although from the figure it is a little difficult to appreciate differences 
between cases and controls for each group (7, 12 and 24 months respectively), 
it is nonetheless possible to see how the diversity (by OTUs abundance) 
increases with age. 
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Figure 4.7. Heatmap that represents the OTUs abundance per sample.   Each box ranges from white being the 
complete absence of sequences in that OTU, to yellow with a few and dark red with a high number of sequences. 
In red font are the most common OTUs found. 
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4.2.2.2 Comparisons of Cases versus Controls 
4.2.2.2.1 Alpha Diversity 
The alpha diversity analysis was performed calculating multiple 
rarefaction curves to determine Richness, Evenness and Diversity (using the 
Shannon index and the Inverse Simpson index) (Chapter 2: Section 2.7.5.2). To 
determine the normal distribution of the results, the Shapiro-Wilkinson normality 
test was performed. It showed that Richness (P<0.0001), Evenness (P=0.0012), 
and Inverse Simpson (P<0.0001) indexes were not normally distributed and 
therefore non-parametric statistics were performed. In contrast the Shannon 
index of diversity showed normal distribution (P=0.5718) and therefore 
parametric statistics were used (Figure 4.8). 
170 
 
There were encountered statistical differences on alpha diversity when 
case/control status was compared. Richness (Kruskal-Wallis P=<0.001), 
Inverse Simpson (Kruskal-Wallis P=0.04), and Shannon diversity index 
(ANOVA P<0.001) all confirmed there were significant differences. On the other 
hand Evenness was not statistically significant (Kruskal-Wallis P=0.11). 
Figure 4.8. Alpha Diversity normality plots using Shapiro-
Wilkinson test. Richness, Evenness, and Diversity with Inverse 
Simpson and Shannon indexes were calculated. Plots show the 
comparison of the theoretical versus sample quantiles to determine 
normality. Only Shannon index showed normal distribution.  
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Comparison of alpha diversity plots using the Shannon diversity index revealed 
significant differences only at 7 months of age when comparisons between 
pairs of age groups were conducted (t-test P<0.001) (Figure 4.9). A trend in the 
same direction -although not significant- was seen for the 12 months age group 
comparison (cases versus controls).  
 
When samples at different ages were pooled into cases versus controls, 
no significant differences for Richness (Kruskal-Wallis P=0.55), Evenness 
(Kruskal-Wallis P=0.3907), diversity in Inverse Simpson (Kruskal-Wallis 
P=0.1148) or diversity using Shannon index (ANOVA P=0.356 [Figure 4.10]) 
were seen.  
Figure 4.9 Per group Shannon Index Plot Analysis. * represents 
significant differences (P<0.001). Standard Deviation bars are 
shown. 
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4.2.2.2.2 Beta Diversity 
Comparing between groups at OTU level, statistical differences were 
found using Canberra (P<0.0001), Bray-Curtis (P<0.0001), UNIFRAC 
(P<0.0001), and Weighted UNIFRAC (P<0.0001). The type of group (cases 
versus controls) however was found to explain a different proportion of the 
variance each time, which means how belonging to a group (cases or controls) 
explains the microbiota differences: Canberra = 17%, Bray-Curtis 7%, 
UNIFRAC = 12%, weighted UNIFRAC = 8%.  It can be concluded that the 
abundance of the different OTUs is not particularly important (UNIFRAC and 
Canberra are presence/absence and show higher values), and that 
phylogenetic information is not relevant to show differences (UNIFRAC versus 
Canberra).  
On the NMDS plots, the stress (disagreement between 2-D configuration 
and predicted values from regression) is 0.17 in Bray-Curtis, 0.22 in Canberra, 
Figure 4.10. Alpha Diversity Shannon Index Comparison per 
Type of Sample: Cases versus controls. NS=non-significant 
differences. Standard Deviation (SD) bars are shown. 
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0.23 in UNIFRAC and 0.10 Weighted-UNIFRAC, which denotes a very good 
representation in condensed dimensions, which means that 2D plots are a good 
representation of what happens during clustering. The NMDS bi-dimensional 
plots on the whole do not show very clear clustering when each group is 
compared separately.  The exception is at 7 months when clustering is clearer 
in Canberra and UNIFRAC (Figure 4.11). 
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  Figure 4.11. Beta Diversity NMDS2 Bi-dimensional Plots. Red dots represent cases and light blue 
dots represent controls. A) Canberra total, B) Canberra split by age C) UNIFRAC total D) UNIFRAC 
split by age. 
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By principal coordinate analysis (PCoA 3D plots), good clustering 
was observed when comparing cases versus controls at 7 months (Figure 
4.12 A). Using Bi-plots at 7 months of age, demonstrated significant 
differences in clustering driven by a higher presence of Streptococcus spp. 
and Prevotella spp. in the controls group and a high prevalence of 
Staphylococcus spp. and Haemophilus spp. in cases were revealed (Figure 
4.12 A). 
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Figure 4.12. Beta Diversity: UNIFRAC PCoA analysis for each Age 
group Cases and Controls. Each dot represents a sample. A) 7 months 
PCoA with additional taxonomic information of the main genus that drives 
clustering B) 12 months PCoA C) 24 months PCoA. 
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Beta diversity analysis, with samples pooled into cases and control 
groups, showed no significant differences using Bray-Curtis (P=0.062) and 
Weighted UNIFRAC (P=0.076), whilst significant results were observed by 
Canberra (P=0.001) and UNIFRAC (P=0.024). The type of overall group 
(cases versus controls) however only explains on the variance in 7% on 
Canberra and 8% on UNIFRAC. The NMDS plots do not show any evidence 
of clustering on the bi-dimensional plots and in the PCoA tri-dimensional 
plots (Figure 4.13). 
 
 
Figure 4.13. Beta Diversity Analysis between Cases and Controls. 
Each dot represents a sample with red being cases and blue controls. 
A) Canberra NMDS bi-dimensional plot, B) UNIFRAC NMDS bi-
dimensional plot, C) PCoA UNIFRAC tri-dimensional plot. 
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4.2.2.3 Age Group Comparisons 
In contrast with the previous analysis in Section 4.2.2.1, the following 
statistical comparisons were not performed using cases or controls grouping 
but only differences per age groups. This analysis was performed to see 
how the upper airways microbiota develops over time. 
4.2.2.3.1 Alpha Diversity 
Alpha diversity analysis for the per age group comparisons used the 
same values of normal distribution, because the richness, evenness and 
diversity indexes Shapiro-Wilkinson tests were calculated before grouping. 
Richness (Kruskal-Wallis P=2.2E-16), diversity using Inverse Simpson 
(Kruskal-Wallis P=0.023), and diversity using the Shannon index (ANOVA 
P<0.0001) were statistically different, whilst Evenness was not (Kruskal-
Wallis P=0.549). Pairwise comparisons using t tests showed that between 
groups of age the Shannon diversity index and the raw observed species 
were statistically different with an increase in the number of species with 
age (Figure 4.14).  
 
 
 
 
 
 
 
179 
 
4.2.2.3.2 Beta Diversity 
Beta diversity analysis for the per age group comparisons revealed 
significant statistical differences using all four methods: Adonis Canberra 
(P<0.0001), Bray-Curtis (P<0.0001), UNIFRAC (P<0.0001), and Weighted 
UNIFRAC (P<0.0001). Still the type of age group (7 months, 12 months and 
24 months) explains a different proportion of the variance each time: 
Canberra = 11%, Bray-Curtis 4%, UNIFRAC = 8%, weighted UNIFRAC = 
5%.  Consequently the variety of OTUs found is more important than 
abundance (UNIFRAC and Canberra are presence/absence and show 
higher values), and the phylogenetic information is not relevant to show 
such differences (UNIFRAC has lower values than Canberra).  
Per age Shannon
7 
m
o
n
th
s
12
 m
o
n
th
s
24
 m
o
n
th
s
0
2
4
6
* P < 0.001Age
S
h
a
n
n
o
n
 i
n
d
e
x
*
* *
A Per age Observed Species
7 
m
o
n
th
s
12
 m
o
n
th
s
24
 m
o
n
th
s
0
50
100
150
200
Age
O
b
s
e
r
v
e
d
 S
p
e
c
ie
s
* P < 0.001
*
* *
B
Figure 4.14. Alpha Diversity Plots for Age Group Comparison.  A) 
Shannon index comparisons, B) Observed species comparisons.  * 
Statistically significant on pairwise analysis. SD bars are shown. 
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On the NMDS plots, the stress found was similar than previously with 
good representation of clustering in them. The NMDS bi-dimensional plots 
show evidence of some clustering related with increase of age.  When case 
control status is considered the clustering is more evident for the control 
group (Figure 4.15). 
 
 
 
 
Figure 4.15. Beta Diversity: NMDS Bi-dimensional Plots comparing 
Groups by Age in months. Each dot represents a sample and are 
coloured on a scale according to age (lighter colour represents oldest) 
A) Canberra analysis on the total NMDS plot, B) Canberra analysis on 
plots separated by case control status, C) UNIFRAC analysis on the 
total NMDS plot, D) UNIFRAC analysis on plots split by case control 
status. 
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Principal coordinate analysis using UNIFRAC did not show a clear 
clustering when samples were grouped per age (Figure 4.16). 
 
 
4.2.2.4 Investigation of Sequencing Batch Effect 
With all next generation sequencing platforms it is only possible to 
sequence a set number of samples per run and this number varies 
depending as well on depth of sequencing required.  For the Roche 454 
Junior platform it is only possible to sequence a maximum of 170,000 
bacteria at the same time, consequently to achieve the desired depth in 
sequencing for around 400 samples six independent sequencing runs had 
to be conducted and the data then merged. For that reason it was important 
Figure 4.16. Beta Diversity PCoA using UNIFRAC.  Each dot 
represents a sample and each colour represents an age group as 
indicated by the key. 
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to verify that the effect of merging multiple runs had not had any impact or 
underpinned the results in relation to OTU differences and diversity.  
Metastats was therefore used to examine whether at OTU level 
significant differences in abundance where seen when sequencing runs 
were compared.  No differences were found. Similarly no differences were 
seen when alpha and beta diversity were examined using Shannon index 
and in NMDS and PCoA plots  (Figure 4.17).  
 
 
 
4.2.2.5 Epidemiological Analysis 
To determine if the epidemiological variables were different between 
wheezing infants and healthy controls, several parameters were compared 
Figure 4.17. Beta Diversity PCoA between runs using UNIFRAC. 
Each dot represents a sample and each colour represents a sequencing 
run – six runs in total. 
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using the questionnaires taken during each sampling occasion. Gender was 
not different between groups with 54% in the wheezing infants and 46% in 
the controls. The crowdedness was measured by the number of individuals 
per room of the house, and was not different between groups with 3.15 
individuals/room in cases and 3.06 in controls. Both groups also presented 
a similar parental income with 222 USD in cases and a slightly higher 229 in 
controls (Table 4.2).  
 Cases Controls P<0.05 
Sex (% male) 54 46  
Number of individuals per rooms of the 
house 
3.15 3.06  
Average parental income (USD per month) 222 229  
Average birth weight (grams) 3390 3341  
Average birth height (cm) 49.6 49.1  
Maternal Education    
Illiterate 2% 2%  
Primary Incomplete 17% 13%  
Primary Complete 23% 22%  
Secondary Incomplete 15% 16%  
Secondary Complete 32% 44% * 
University Incomplete 10% 3% * 
University Complete 1% 0%  
Respiratory Tract Infections (episodes per 
person) 
0.02 0.04  
Antibiotics (numbers of times used per 
person) 
0.06 0.07  
Malnutrition (% reported) 2% 2%  
Anaemia (% reported) 1% 3%  
Table 4.2. Epidemiological Characteristics of Cases and 
Controls. * P<0.05 
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Beta diversity analysis was performed to determine whether gender, 
crowdedness and parental income, however none of these variables 
account for the differences observed in the microbiota between cases and 
controls (Figure 4.18). Canberra statistics (stress 0.10) were the best 
representation of the beta diversity in bi-dimensional plots. 
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Biometrical measures at birth such as weight and height were also 
not different between groups. The average birth weight in grams for the 
Figure 4.18. NMDS Beta Diversity Plots considering Epidemiological 
Variables: parental income, gender, people per room. Canberra 
statistics were used to determine the influence of epidemiological variables 
on the microbiota changes. Each dot represents a sample. A) Gender, B) 
Individuals per room per house, C) parental income in USD. 
186 
cases was 3390 whilst in the controls 3341, and the average height in 
centimetres for the cases was 49.6 whilst for controls it was 49.1. These 
variables also were not able to explain the microbiota patterns present at 7, 
12 and 24 months of age in cases or controls (Figure 4.19). 
 
Maternal education was not different in the illiterate, primary 
incomplete, primary complete and university complete groups between 
cases and controls. However there were more mothers in the controls group 
that have the secondary studies complete compared with cases (44% 
versus 32%), and more mothers with university incomplete in the cases 
group compared with controls. Overall maternal education did not explain 
the microbiota patterns present in the samples (Figure 4.20). 
Figure 4.19. NMDS Beta Diversity Plots considering 
Epidemiological Variables: birth weight and height. Canberra 
statistics was used to determine the influence of epidemiological 
variables on the microbiota changes. Each dot represents a 
sample. A) birth weight B) birth height. 
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The infants included on the study did not have a high number of 
respiratory tract infections (pharyngitis, pneumonia, bronchitis, etc.), or a 
history of high antibiotic usage. The respiratory tract episodes in the 2 years 
follow up per person were only 0.02 for the cases group whilst for the 
controls it was 0.04, the use of antibiotics per any reason in the clinical 
records per infant was 0.06 times use in cases and 0.07 in controls. All the 
infants in the study had no history of oral or inhaled corticosteroid use.  
Malnutrition and anaemia were present in the clinical records of a few 
infants in both groups, but were not present at the time of sampling. 
However these two conditions were not significantly different between cases 
and controls. Malnutrition was found in 2% of infants in both groups and 
anaemia 1% in cases and 2% in controls. Neither variable explained the 
microbiota patterns found on beta diversity analysis using Canberra (Figure 
4.21). 
Figure 4.20. NMDS Beta Diversity Plots considering Epidemiological 
Variable: maternal education. Canberra statistics were used to 
determine the influence of maternal education on the microbiota patterns.  
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4.3 Discussion 
There were encountered several differences in the upper airways 
microbiota of infants with a current wheezing episode (Stage 1a) versus 
infants at the same age with history of wheezing but that at the sampling 
time did not have an episode (Stage 1b). When comparing the overall 
microbiota patterns between current and past wheezers the main features of 
bacterial diversity and abundance were conserved. Firmicutes was the most 
common phylum in both groups and streptococci was the most abundant 
genus as reported in previous chapters and in other studies (Hilty et al., 
2010, Bisgaard et al., 2007). 
The other commonly found bacteria i.e. Prevotella and Veillonella 
were also present in both groups equivalently when compare at genus level, 
however some OTUs of them were more common in the infants with history 
Figure 4.21. NMDS Beta Diversity Plots considering 
Epidemiological Variables (Malnutrition and anaemia). 
Canberra statistics was used to determine the influence of 
epidemiological variables on the microbiota patterns. A) 
malnutrition, B) anaemia.  
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of past wheezing. For instance Prevotella spp. (not possible to assign 
taxonomy at species level) were more common in past wheezers but 
Prevotella melanogenica was more common in current wheezers. 
Interestingly Prevotella spp. (non-melaninogenica) have been encountered 
as possible protective bacteria against the development of asthma in adults 
and children (Hilty et al., 2010), and were consistently more abundant in 
healthy infants as shown in the previous chapter. On the other hand, P. 
melaninogenica, that in this part of the study is present very abundantly in 
current wheezers but very rarely in past wheezers, has been associated 
with the development of otitis media, oral plaque, and tonsillitis (Jensen et 
al., 2013, Saini et al., 2005, Tanaka et al., 2008). Veillonella spp. the other 
reported bacteria present mostly in healthy infants in previous chapters and 
in conventional culture-dependant studies (Bisgaard et al., 2007), is present 
more commonly in past wheezers as well. Its abundance however is not 
comparable with the higher proportions of these bacteria in healthy infants.  
In the Actinobacteria phylum the genera Actinomyces and 
Corynebacterium was more common in current wheezers, and moreover 
these bacteria have been commonly reported as causes of upper 
respiratory tract infections (Celebi et al., 2009, Byard, 2013).  
Other usually reported ‘protective’ bacteria like Lactobacillus 
(Messaoudi et al., 2013), were encountered more in past wheezers 
compared with current wheezers. Its abundance however did not reach the 
higher values found in healthy controls with no history of wheezing.  
Strikingly Staphyloccoccus, that is a well-known pathogen (Vissing et 
al., 2013, Stokken et al., 2014, Wolter et al., 2013), was also more abundant 
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in the current wheezing infants compared with the past wheezers, and 
almost absent in healthy infants. Other Firmicutes present regularly in the 
upper airways and in the oral normal microbiota such as Gemmellacea and 
Leptotrichia (Hilty et al., 2010, Wolff et al., 2013), were more common in 
past wheezers. 
The phylum Proteobacteria has been reported to be usually more 
frequent in asthmatics (Hilty et al., 2010, Bisgaard et al., 2007), and several 
potentially pathogenic bacteria that belong to this phylum were found more 
commonly in current wheezers. Neisseria, Haemophilus and Moraxella were 
significantly more frequent in current wheezers and this higher prevalence 
compared with controls was maintained over time (Chapter 3).  
Beta diversity analysis revealed statistical differences when the 
current and past wheezing infants were compared, with the 
presence/absence of particular OTUs determining the differences. The 
sequences abundance did not explained the main differences. It therefore 
would appear that purely the presence of new bacteria is related with a 
wheezing episode as opposed to the overgrowth of the bacteria already 
present in a healthy individual. For that reason, Canberra statistics were the 
best way to represent the clustering on NMDS plots. 
In terms of alpha diversity no differences were observed between 
current and past wheezers in richness and diversity, however evenness was 
statistically different. This means that the number of taxa was not different 
between the groups but the distribution of taxa encountered was dissimilar. 
These results show that particular OTUs appear temporarily during a 
wheezing episode but the core microbiota remains unaltered. 
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Stages 1b and 2 of the ECUAVIDA were analysed in order to 
determine the mid and long term changes in microbiota after a history of 
wheezing. The current part of the study (Section 4.2.2) has resulted in the 
identification of significant differences in the upper airways microbiota at 
different ages of development between wheezing and healthy infants. 
As in previous studies the upper airways microbiota was found to be 
represented principally by Firmicutes, with the most common genus being 
Streptococcus spp. (Hilty et al., 2010). In addition, common to prior 
publications, Firmicutes was found to be in this study the most diverse 
phylum of the airways with the highest number of OTUs (Hilty et al., 2010, 
Marsland, 2013, Molyneaux et al., 2013, Marsland et al., 2013). 
Proteobacteria, Bacteroidetes and Actinobacteria were also prevalent in the 
oropharynx microbiota in both non-wheezing and wheezing infants again 
agreeing with early observations (Hilty et al., 2010, Zemanick et al., 2011).  
The most common pathogens that have been found in the airways 
are Gram-negatives belonging to the phyla Actinobacteria and 
Proteobacteria (Watt et al., 2009, Sabra and Benger, 2011, Gkentzi et al., 
2012, Celebi et al., 2009).  Interestingly in this current study these 
pathogens were found to be more prevalent in infants with a history of 
wheezing. Additionally, the previously reported protective bacteria 
Firmicutes and Bacteroidetes (Hilty et al., 2010, van der Gast et al., 2014, 
Huang et al., 2010) were found to be more common in the control infants. 
When the samples were separated by case/control status, significant 
differences were seen at the phyla level. At this taxonomic level the most 
remarkable dissimilarities were encountered between Firmicutes for the 7 
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months group of cases compared with the controls for all three age groups 
(7 months group but also 12 and 24 months groups). For instance, cases at 
7 months show an unusual high abundance of Firmicutes with lower 
abundances seen for the other phyla. These differences were not 
attributable to particular Firmicutes genera but as will be discussed further 
are due to a decreased diversity of other phyla in wheezing infants at 7 
months of age. 
Resembling the results seen in Stage 1a (Chapter 3: Section 3.2.2.2), 
when compared at genus level in infants with wheezing history there were 
more potential pathogenic bacteria (e.g. Corynebacterium, Haemophilus, 
Moraxella and Burkholderia) present and this was statistically significant. 
Furthermore, a lack of some of the reported ‘protective’ bacteria species 
(e.g. Veillonella, Prevotella, and Lactobacillus) in wheezing infants 
compared with controls was observed (Chapter 3: Section 3.2.2.2 and 
Section 4.2.2 above). These concordances reveal that changes during an 
episode of wheezing remained stable both medium and long term during 
infancy, and the alterations in the normal microbiota may in turn be of 
importance in relation to host resistance to pathogen colonization in the 
airways (Crowe et al., 1973).  
At the OTU level, Corynebacterium spp. were more common in 
infants with history of wheezing, and this finding was evident at 12 and 24 
months of age. This bacterial genus includes many bacteria that are part of 
the normal oral (Jiang et al., 2014) and nasopharynx microbiota (Biesbroek 
et al., 2014).  The genus also includes some extremely pathogenic bacteria 
that cause high rates of morbidity e.g. C. diphteriae (Byard, 2013). The 
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Actinomyces and Propionibacterium genera showed an increased 
abundance in controls. Although they can cause opportunistic infections 
(Celebi et al., 2009, Kutluhan et al., 2011) they are common constituents of 
the healthy oral and airways microbiota (Francavilla et al., 2014, Hilty et al., 
2010).  
Bacteroidales is a common phylum of the upper airways, oral and 
nasopharyngeal microbiota. Several of their genera have been implicated 
for causing opportunistic infections in immunocompetent and 
immunodepressed patients (Piau et al., 2013, Papadaki et al., 2008, 
Mahenthiralingam, 2014, Sherrard et al., 2014, Rath et al., 2014). One of 
the genera within Bacteroidales is Prevotella which has been considered 
protective against the development of asthma in adults (Hilty et al., 2010). 
Reinforcing this premise, the present study found that Prevotella and other 
Prevotellacea were significantly more prevalent in controls (at all ages and 
in total) compared with infants with a history of wheezing.  
Firmicutes, being the most diverse phylum in the airways microbiota, 
presented several genera that were more abundant in infants with history of 
wheezing. The most common genus found in the infants’ upper airways 
microbiota was Streptococcus, with two OTUs seen more frequently in 
controls than in infants with history of wheezing. One of them presented 
significant differences at all ages whilst the other only at 7 months. 
Streptococcus spp. can be considered as commensal bacteria part of the 
“normal” microbiota (Hilty et al., 2010, Francavilla et al., 2014) but members 
of the genus, e.g. pneumococcus, do cause life-threatening infections in 
childhood (Harmes et al., 2013, Gil et al., 2013). Due to the uniformity of the 
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16S rRNA gene within Streptococcus spp. it was not possible to differentiate 
at the species level.  Consequently although the OTUs found are related 
with protection against wheezing further discrimination at species level is 
clearly desirable (see Chapter 5).  
Strikingly an OTU assigned to the well-recognized “protector” of the 
microbiota Lactobacillus was more prevalent in controls in the total analysis 
as well as at all ages. Lactobacillus spp. are associated with the protection 
of the microbiota against the development of pathogenic bacteria due to 
their fermentation properties which acidify the microbial environment and 
inhibit the growth of non-acidophilic bacteria (Messaoudi et al., 2013, Nardis 
et al., 2013, Walker, 2013). Veillonella spp. are Gram-positive anaerobic 
bacteria with interesting metabolic pathways that can cause them to appear 
to be Gram-negatives (Vesth et al., 2013). They are commonly present in 
saliva of healthy people (Belstrom et al., 2014), although they are usually 
considered opportunistic pathogens in patients with chronic pulmonary 
disease (Rogers et al., 2014, Abel Nour et al., 2013). In this present study 
they were found to be more abundant in controls with differences seen for 
all three time points - 7, 12 and 24 months.  
Gemella and Lachnospiraceae are common bacteria of the oral and 
gut microbiota but have also been associated with opportunistic infections 
(Iwai et al., 2014, Garcia-Lechuz et al., 2002). They have been shown to be 
important in the early colonization in infants’ mucosal barriers depending on 
the delivery method (Hansen et al., 2014). Anaerobic bacteria of the genus 
Clostridium, which are important pathogens in the human (Gabriel and 
Beriot-Mathiot, 2014, Li et al., 2013), are members of the family 
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Lachnospiraceae. The genus Clostridium are potent triggers of the immune 
system notably chemotaxis of macrophages (Nakanishi et al., 2014). In the 
present study Gemella and Lachnospiraceae were found to be at a higher 
abundance in infants with history of wheezing although not at all ages. For 
Gemella differences were seen at 24 months only whilst for 
Lachnospiraceae the differences were at 7 and 12 months. 
Within the phylum Fusobacteria there are bacteria commonly found in 
the oral microbiota which form biofilms like Fusobacterium and Leptotrichia 
(Wolff et al., 2013) and that are only associated with infections in immune-
compromised patients (Eribe and Olsen, 2008). Interestingly Fusobacterium 
has been implicated to have a role in chronic inflammation of the gut and 
inflammatory bowel disease (IBD) and colorectal carcinoma (Allen-Vercoe 
and Jobin, 2014). Stages 1a and 2 of the ECUAVIDA microbiota study 
revealed the phylum to be present more commonly in healthy infants 
compared with infants with a history of wheezing although the significance 
of this was somewhat variable with age (Fusobacterium at 12 and 24 
months, Leptotrichia at 7 and 12 months). 
Members of the phylum Proteobacteria include a large variety of 
Gram-negative bacteria that previously have been shown to be related with 
the development of disease in children.  Members include: Haemophilus 
influenza, Neisseria meningitidis, Moraxella catarrhalis and Burkholderia 
spp.  In this current study Burkholderia, Haemophilus and Moraxella were 
found (Section 4.2.2) to be more abundant in wheezing infants; particularly 
Haemophilus, which at all ages, was related with disease. This finding is in 
agreement with the microbiota studies in adult asthmatics (Hilty et al., 2010) 
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and with culture-dependent studies in children (Bisgaard et al., 2007). 
Pasteurellacea and Neisseriaceae were found to be more common in 
controls (Pasteurellacea at 12 months and Neissereaceae all ages). Even 
though it was not possible to identify them at species level nonetheless from 
the 16S rRNA sequences it was possible to establish that the OTU assigned 
to Neisseriaceae did not belong to the genus Neisseria.  Consequently it 
therefore might be another member of that family Neisseriaceae like 
Eikenella or Kingella (part of the oral normal microbiota) (Belstrom et al., 
2014). 
When comparisons between cases and controls were performed 
using beta diversity inter-groups comparisons, significant differences were 
seen. The differences found were more important when statistics that take 
account the presence/absence of OTUs were implemented whilst the 
abundance levels of OTUs was of less importance. Additionally the 
phylogenetic information was also not relevant, since the UNIFRAC 
statistics were no better at discriminating differences than the conventional 
statistics.  
When comparing between groups statistically significant differences 
were seen overall as well as between infants with history of wheezing and 
controls at 7 months. These differences were also revealed through the 
cluster analysis (NMDS and PCoA plots). Of particular interest was that for 
the 7 months age group the PCoA bi-plot revealed that Streptococcus spp. 
was distributed evenly across groups (Figure 4.12 A), whilst Acetobacter 
and Staphylococcus underpinned the clustering of the cases, with 
Prevotella, Bacteroidales and Neisseria being key in the clustering of the 
197 
controls. When the samples were plotted all together however, or at 12 and 
24 months, clear clusters could not be discriminated (Figure 4.12 B and C).  
The alpha diversity analysis revealed that diversity was different 
when comparisons between all groups were conducted using the raw 
number of observed species. Richness was statistically different but not 
Evenness (Li et al., 2012).  
Considering healthy infants versus infants with a history of wheezing 
at 7 months of age, it is interesting to note that for the healthy infants the 
microbiota is more diverse. This suggests that a lack of diversity results in 
the infant having a higher risk of developing wheezing and asthma later in 
life. 
One of the key aims of this part of the ECUAVIDA microbiota study 
was to establish the composition of the airways microbiota and its 
development during early life. What has been revealed is that a more 
diverse microbial community is acquired with age (7 months up to 24 
months). These differences are evident from the alpha diversity (analysis by 
Shannon and Inverse Simpson diversity indexes)/ between age groups, and 
was mainly caused by an increase in Richness (number of unique taxa on 
the multiple rarefaction curves). In contrast, the distribution of taxa was not 
found to be different between ages (analysis of Evenness). Paired 
comparisons between all ages revealed that the differences are maintained, 
and there was clear evidence of an increase of diversity with age (Figure 4.7 
heat map and Figure 4.9 alpha diversity plots).  
The beta diversity analysis between age groups also revealed 
significant differences specifically presence/absence of new taxa with 
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increasing age but with no abundance or phylogenetic differences (Section 
4.2.2.3.2). The NMDS plots show a clear clustering of samples dependent 
on their age particularly for the control group. 
The epidemiological characteristics of the infants used on the study 
show firstly that there is a very low frequency of antibiotics usage reported 
in the clinical records for cases and controls. Secondly there is no history of 
corticosteroids use for these infants. These results reassure that the 
microbiome patterns encountered were not skewed by the use of antibiotics 
or corticosteroids.  
Several epidemiological parameters were tested in order to 
characterize the population studied in both groups. The gender ratio was 
almost a half-half relation between male and female for each group, and the 
microbiome patterns seen were not attributable to sex. Parental income was 
on average 226 USD with no differences between cases and controls, 
strikingly this value is much lower than the minimum salary necessary 
established by the Ecuadorian government (Diario, 2014), and shows that 
the population living in the tropics of Ecuador have high rates of poverty. 
A number of epidemiological variables were variables were examined 
for cases and controls to determine whether any of them accounted for the 
differences seen in microbiota patterns between the two groups. Between 
the variables studied there were included: relative ratio of crowdedness (the 
number of people that live with each child in the house per the number of 
rooms in the house), biometric measures at birth, maternal education level, 
and comorbidities like respiratory tract infections, anaemia and malnutrition.  
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None of them were able to explain the microbiota differences found between 
these two groups.  
In conclusion the microbiome patterns are different between past and 
current wheezing infants, and unlike healthy controls in whom diversity of 
the airways microbiota increases over time, children with repetitive past 
wheezing episodes during their first year of age maintained mid and long-
term differences. The wheezing episode is characterized by the presence of 
potentially pathogenic bacteria that decrease in abundance afterwards but 
remain present at mid and long-term.  
Additionally, another key finding of this part of the study is that the 
development of the airways microbiota in infants consists principally of the 
acquirement over time of a more complex and diverse flora. The differences 
in bacterial diversity are also important in infants that reported wheezing 
episodes until the 7 months of age, and based on the current results a more 
diverse microbiota at this time is protective against the development of 
wheezing. 
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Chapter 5: Streptococcus Identification at 
Species Level using a New Culture 
Independent Technique based on 
Pyrosequencing 
Analysis of the 16S rRNA gene to characterize bacterial communities is 
a very useful tool to obtain a wide panorama of the whole bacterial taxa 
present. The 16S rRNA gene however has several limitations in the 
taxonomy assignation at species level for a number of genera. 
Consequently pending on initial findings from 16S rRNA gene analysis it can 
be important to perform a further characterization of particular genera of 
interest. 
In the ECUAVIDA microbiota study of oropharynx samples, the 
characterization of possible pathogenic bacteria was of particular 
importance in order to fully understand the relationships between the 
bacteria present and the wheezing syndrome phenotype.  The 16S rRNA 
gene analysis conducted in the prior chapters (Chapters 3 and 4) revealed 
that more than 70% of the airways microbiota belonged to the phylum 
Firmicutes, which was also the most diverse phylum (more than 50% of 
OTUs found).  The most common and diverse genus within Firmicutes was 
consistently Streptococcus. Due to the genetic uniformity of the 16S rRNA 
gene however, it was not possible to differentiate between some members 
of the Streptococcus genus.  
Consequently the pathogen S. pneumoniae (also known as 
Pneumococcus) which is a major cause of morbidity and mortality in infants 
(Galli et al., 2013, Harmes et al., 2013, Nau et al., 2013), ends up 
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categorized as part of the S. mitis ´group´ that encompasses mostly 
commensal, harmless bacteria (Mitchell, 2011, Kilian et al., 2014).  
A good strategy to achieve differentiation between members of a genus 
is to perform further genotyping of other housekeeping genes.  This allows 
the identification of Streptococcus at species level and potentially even 
serotype categorization (El Aila et al., 2010). Methods in order to conduct 
this genotyping still necessitate an element of culture (multi locus sequence 
typing [MLST] and multi locus sequence assignation [MLSA]). To date there 
are no culture-independent methods for this genotyping and cutting edge 
next generation sequencing has not been applied.   
The aim of this part of the study was therefore to develop and optimise a 
culture-independent robust technique to identify streptococci at species 
level using next generation sequencing. The technique was then applied to 
the ECUAVIDIA oropharyngeal swab DNA samples to enable species 
differentiation of the Streptococcus genus, determination of the relative 
abundance of the streptococci identified and examination of their 
relationship with the wheezing syndrome phenotype.  
5.1 Development of Streptococci Species Assay  
To develop a new robust next generation sequencing based technique 
capable of identifying streptococci at species level and that could be used 
starting from mixed microbial DNA samples, a strategic plan was created as 
shown in Figure 5.1. 
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5.1.1 Candidate Genes Selection 
Multi locus sequence typing (MLST) and multi locus sequence 
assignation (MLSA) have been and are currently the gold standard methods 
to identify streptococci taxonomically at species level (Bishop et al., 2009, 
Picard et al., 2004). Such techniques however require the prior culturing and 
isolation of the Streptococcus strain to be identified.  
Based on the housekeeping genes commonly used for MLSA and 
MLST, candidate genes to develop a culture-independent identification 
technique using next generation sequencing (pyrosequencing) were 
identified. The gene selection was additionally informed by the currently 
Figure 5.1 Strategic Plan to Create a new 
Molecular Tool to Identify Streptococci at the 
Species Level. 
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available MLSA and MLST online databanks (www.emlsa.org and 
http://www.mlst.net). For each gene selected, primers were chosen to 
ensure an amplicon length between 200 and 700 bp would be generated, as 
this is optimal for successful pyrosequencing.   
Based on the prior literature nine-primer pairs were identified for 8 
selected genes (Table 5.1). 
Name Gene Product Primers sequences (5’ – 3’) 
Amplicon 
size (bp) 
guaA 
GMP synthase 
guaA_spratt_fwd: 
ATYCARTTYCACCCMGAAGT 
567 
guaA_spratt_rev: 
CWGGNCCWGGRAATGGTTG 
map 
Methionine 
aminopeptidase 
map_spratt_fwd: 
GCWGACTCWTGTTGGGCWTATGC 
348 
map_spratt_rev: 
TTARTAAGTTCYTTCTTCDCCTTG 
pfl 
Pyruvate 
formate lyase 
pfl_spratt_fwd: 
AACGTTGCTTACTCTAAACAAACTGG 
351 
pfl_spratt_rev: 
ACTTCRTGGAAGACACGTTGWGTC 
ppaC 
Inorganic 
pyrophosphatase 
ppaC_spratt_fwd: 
GACCAYAATGAATTYCARCAATC 
552 
ppaC_spratt_rev: 
TGAGGNACMACTTGTTTSTTACG 
pyk 
Pyruvate kinase 
pyk_spratt_fwd: 
GCGGTWGAAWTCCGTGGTG 
492 
pyk_spratt_rev: 
GCAAGWGCTGGGAAAGGAAT 
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rpoB 
RNA 
polymerase beta 
subunit 
rpoB_spratt_fwd: 
AARYTIGGMCCTGAAGAAAT 
516 
rpoB_spratt_rev: 
TGIARTTTRTCATCAACCATGTG 
sodA 
Superoxide 
dismutase 
sodA_spratt_fwd: 
TRCAYCATGAYAARCACCAT 
378 
sodA_spratt_rev: 
ARRTARTAMGCRTGYTCCCARACRTC 
tuf 
Elongation 
factor Tu 
 
 
 
tuf_spratt_fwd: 
GTTGAAATGGAAATCCGTGACC 
426 
tuf_spratt_rev: 
GTTGAAGAATGGAGTGTGACG 
tuf_picard_fwd: 
GTACAGTTGCTTCAGGACGTATC 
865 
tuf_picard_rev: 
ACGTTCGATTTCATCACGTTG 
 
 
As can be seen in Table 5.1, one set of primers (tuf_picard_fwd and 
tuf_picard_rev combination) for the candidate gene tuf unavoidably result in a 
larger than ideal amplicon.  They were nonetheless still considered as the key 
polymorphisms used to determine species identification were located at the 
beginning and middle of the amplicon [Picard et al. (2004)]. For each primer a 
blast search was conducted to ensure primer specificity for streptococci versus 
other bacteria and human DNA. Using the online databases for molecular 
typing based on MLSA (http://www.emlsa.org), MLST (www.mlst.net) and the 
Streptococcus spp. sequences found using Entrez search on the Genebank, 
multiple alignments were performed using the ClustalW algorithm for each of 
Table 5.1. Summary of the Genes and Primers used to 
Develop the Molecular Tool for Streptococci Identification. 
Based on online databases (Bishop et al., 2009, Picard et al., 
2004). 
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the eight candidate genes in order to double check the amplicon sequences 
and the localization of the key polymorphisms within them (Figure 5.2).  
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Figure 5.2. Example (for tuf) of the ClustalW Multiple Alignments performed 
on Geneious version 7.1.6. Sequences were obtained from www.emlsa.org and 
Pubmed nucleotide for the tuf gene downloaded and aligned to determine the 
principal polymorphisms hotspots and how each set of primers captures them. 
On light blue are shown the tuf primers based on Piccard et al. 2004, and in 
purple the primers pair based on Bishop et al. 2009. There are included in the 
alignment the forward (FWD) and complementary (REV) chains obtained in the 
databases. 
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Additionally, phylogenetic trees of all the 9 primer set candidates were 
created on MEGA 6 based on the emlsa database sequences to determine 
the molecular distances of each gene. This was performed to validate their 
importance on taxonomic identification. Examples are shown for map and 
tuf (Figure 5.3). 
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Figure 5.3. Neighbour Joining Non-rooted Phylogenetic trees of map and 
tuf to Determine the Taxonomy Usefulness for Streptococci. Map shows a 
good taxonomy differentiation between S. mitis and S. pneumoniae, whilst tuf 
is better to discriminate S. pyogenes from the others. Images based from the 
emlsa.org database and the study of Bishop et al. (2009) under permission 
(see appendix). 
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5.1.2 Construction of a Bacterial Library  
In order to test primer specificity, a bacterial library was constructed 
using conventional culturing. A total of 22 strains of bacteria (obtained from 
Professor Simon Kroll strains library, St. Mary´s Campus, Imperial College 
London), previously cultured from the human microbiome in health and 
disease, as well as reference strains of commonly found bacteria, were 
selected including different species in order to determine specificity in 
taxonomy assignation. Each strain was cultured using different types of 
media (solids or broths) according to individual bacterial requirements 
(Table 5.2).  
 
Strain Media 
Escherichia coli DH5α 
BHI 
Agar 
Haemophilus ducrey 
Haemophilus haemolyticus ATCC 33390 
Haemophilus parasuis 
Micrococcus luteus ATCC 9341 
Moraxella catarrhalis MIDG 635 B59455 
Moraxella haemolytica 
Neisseria flava 
Neisseria flavescens 
Neisseria lactamica 
Neisseria meningitidis 
Pasteurella sp. 
Pseudomonas multocida 
Streptococcus pyogenes ATCC 19615 
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Sallmonella dublin 
Shigella flexneri 
Staphylococcus aureus ATCC 
Bifidobacterium dentium 
Chocola
te Agar 
Streptococcus agalactiae ATCC 13813 
Streptococcus mitis ATCC 49456 
Streptococcus pneumoniae ATCC 27336 
Haemophilus influenzae Rd 
BHI 
broth + 
Factors 
X and V 
 
 
After culturing for 24 hours at 37oC a single colony was isolated from 
each plate. Each colony was then re-cultured in BHI broth and then cultured 
to exponential growth phase confirmed by spectrophotometry (Chapter 2: 
Section 2.8). DNA was extracted using the MPBio kit for soil and quantified 
using the Nanodrop (DM-1000 Thermo Scientific, USA) (Chapter 2: Section 
2.8). 
Each bacterial DNA obtained was verified in terms of taxonomy 
assignation using conventional Sanger sequencing of the entire 16S rRNA 
gene. For verification the universally used 16S rRNA gene primers at 
positions 27F, 341F and 1942R (according to E. coli genome) (Frank et al., 
2008, Marchesi et al., 1998, Lane, 1991) were utilised. Sanger sequencing 
was performed and the sequences results were aligned with the Ribosomal 
Table 5.2. List of Bacterial strains. Strains used to create 
the bacterial library and the media used for their culture.  
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Database Project (Cole et al., 2003) sequences bank. Each strain obtained 
by culture was confirmed 100% by DNA alignment. 
5.1.3 PCR Validation 
5.1.3.1 PCR Conditions Optimization 
PCRs were optimized by testing a number of cycling conditions including 
different annealing temperatures, primers, BSA and Betaine concentrations. 
The final optimized PCR reaction set up is detailed in Table 5.3.  
 
µl 1X 
DNA (10 ng) 1 
Fwd primer 1µM 1 
Rev primer 1µM 1 
dNTP mx (10nM each) 0.2 
Buffer 2 10X 1 
BSA (20mg/ml) 0.4 
Betaine (1.3M final) 2.6 
Taq 2.5 U/µl 0.1 
H2O 2.7 
TOTAL 9 µl 
 
 
The PCR temperature and cycling conditions were also optimized in 
order to produce successful amplification (Table 5.4). 
Step temp time cycles gua, map, 
pfl, tuf 
ppaC, pyk, 
rpoB, 
sodA 
hot start 94°C 2 min    
denaturation 94°C 30 s 
30 
 
55°C 
 
 
50°C 
 
annealing  30S 
extension 72°C 30s 
Table 5.3. Optimized PCR reaction. 
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final extension 72°C 5 min    
 
 
5.1.3.2 PCR Specificity Verification 
Using DNA extracted from the 22 bacterial strains, the nine sets of 
primers were tested. This test was performed to determine which primers 
resulted in specific amplification of the streptococci species only.  If false 
bands or amplification of non-streptococcal strains were observed this 
would highlight further optimisation was required and/or potential primer 
redesign (Table 5.5).  
Strain 
g
u
a
A
 
m
a
p
 
p
fl
 
p
p
a
C
 
p
y
k
 
rp
o
B
 
s
o
d
A
 
tu
f_
S
 
tu
f_
P
 
Bifidobacterium dentium - - - - - - - - - 
E. coli DH5α - - - - - - - - - 
Haemophilus ducrey - - - - - - - - - 
Haemophilus haemolyticus ATCC 
33390 
- - - - - - - - - 
Haemophilus influenzae Rd - - - - - - - - - 
Haemophilus parasuis - - - - - - - - - 
Micrococcus luteus ATCC 9341 - - - - - - - - - 
Moraxella catarrhalis MIDG 635 
B59455 
- - - - - - - - - 
Moraxella haemolytica - - - - - - - - - 
Neisseria flava - - - - - - - - + 
Table 5.4. PCR Temperature and Cycling 
Conditions. 
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All the primer sets were designed to specifically target Streptococcus 
and 8 of the nine primer sets did only give products when the Streptococcus 
strains were used as PCR templates. The exception was the PCR using one 
of the primer sets targeting the tuf gene – primers by Picard et al. These 
were found to amplify the Neisseria spp. strains but as seen later (Section 
5.1.2.5) nonetheless the sequencing still enabled to differentiate between 
Streptococcus spp. and Neisseria spp. 
Neisseria flavescens - - - - - - - - + 
Neisseria lactamica - - - - - - - - - 
Neisseria meningitidis - - - - - - - - + 
Pasteurella sp. - - - - - - - - - 
Pseudomonas multocida - - - - - - - - - 
S. agalactiae ATCC 13813 + + + + + + + + + 
S. mitis ATCC 49456 + + + + + + + + + 
S. pneumoniae ATCC 27336 + + + + + + + + + 
S. pyogenes ATCC 19615 + + + + + + + + + 
Sallmonella dublin - - - - - - - - - 
Shigella flexneri - - - - - - - - - 
Staphylococcus aureus ATCC 25923 - - - - - - - - - 
Table 5.5. Specific PCR Tests in the Nine Primer Sets. 
There were used the 22 bacterial strains and positive signs 
show when there was produced amplification. 
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5.1.3.3 PCR Sensitivity Verification 
Since the amount of template of DNA of each bacterium in a mixed 
microbial sample, like that of the oropharyngeal swab, is likely to be variable 
it was necessary to determine the range of concentrations required to obtain 
amplification. For that reason, a DNA concentration series test was 
performed using Streptococcus pyogenes DNA (used as a standard 
Streptococcus strain) at decreasing concentrations 100, 10, 1, 0.1, 0.01, 
0.001 ng/µl (Table 5.6).  
PRIMERS 
S. pyogenes (ng/µl) 
100 10 1 0.1 0.01 0.001 0 
guaA + + + - - - - 
map + + + + + + - 
pfl + + + + + + - 
ppaC + + + + - - - 
pyk + + + + + - - 
rpoB + + + + + - - 
sodA + + + + + - - 
tuf_P + + + + + + - 
tuf_S + + + + + + - 
 
Table 5.6. Sensitivity PCR tests using the Nine Primer 
Sets and Streptococcus pyogenes DNA. Decreasing 
concentrations ranging from 100 ng/µl to 0.001 ng/µl of DNA 
were used.  + indicates successful amplification, and - 
indicates no amplification. 
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No PCR amplification was seen at with a concentration of 0.1 ng/µl 
template for the guaA set of primers, at 0.01 ng/µl for ppaC, and at 0.001 
ng/µl for pyk, rpoB and sodA. Map, pfl, tuf (P and S) were found to be the 
most sensitive sets of primers resulting in amplicons for all concentrations of 
template DNA.  
5.1.3.4 PCR Sensitivity using a Mixed Microbial DNA 
Template 
To determine the sensitivity in primers detection when dealing with a 
mixed microbial DNA sample/template, decreasing concentrations of 
Streptococcus. pyogenes DNA and increasing concentrations of Escherichia 
coli were used (S.pyogenes/E.coli in ng/µl: 10/0, 10/10, 1/10, 0.1/10, 
0.01/10 and 0/10) (Figure 5.4). 
 216 
 
The mixed combination of S. pyogenes and E. coli highlighted that for 
two of the candidate genes: map and pfl no amplification inhibition by the 
presence of non-streptococcal DNA was observed for one set of primers for 
each gene. No amplification inhibition was seen for either of the primer sets 
for the candidate gene tuf.   These set of primers were therefore focussed 
upon for the next optimization experiment. 
5.1.3.5 PCR Validation using Oropharyngeal DNA 
Samples 
Four DNA samples (extracted from throat swabs) which had undergone 
previous 16S rRNA gene sequencing were selected. Two of the samples had 
Figure 5.4. PCR Amplification Tests using a Mixed 
DNA Template. There were used varying 
concentrations of Streptococcus pyogenes and 
Escherichia coli DNA. 
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shown the presence of Streptococcus, the other two samples being 
Streptococcus negative.  PCR was performed using the two sets of primers for 
tuf and the single set of primers for map and pfl  (Figure 5.5).   
Amplification products using the four sets of primers was only seen for 
those samples that had through 16S rRNA gene sequencing been shown to 
be positive for the Streptococcus genus (Samples 3 and 4 labelled Strep 
Pos figure 5.5). 
5.1.3.6 Pyrosequencing: Primer Design 
In light of the results of the PCR primer tests with the bacterial DNAs 
library and real sample templates (Sections 5.1.1.2 to 5.1.1.5), modifications 
Figure 5.5. PCR Validation Tests using DNA 
Extracted from Real Orophayngeal Swabs. 
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in the design of the primers for map, pfl and tuf_S were made to allow 
inclusion of barcoded sequences and adaptors both being required for 
pyrosequencing. 
For each forward primer a sequence adaptor was added: 5’ 
CCATCTCATCCCTGCGTGTCTCCGACTCAG 3’. The sequence adaptor 
enables bead ligation (Chapter 2: Section 2.7.1). On each reverse primer 
the same adaptor sequence was added but in addition a barcode sequence 
was included (between 15 and 20 nucleotides).  In total 30 different barcode 
sequences were utilized to allow amplicons from up to 30 different samples 
to be multiplexed and combined into one pyrosequencing run. The barcodes 
were selected from the list of barcodes previously tested and released to the 
scientific community by the Human Microbiome Project Consortium 
(Jumpstart Consortium Human Microbiome Project Data Generation 
Working, 2012).  
As for the standard primers, the modified primers were tested for 
sensitivity, specificity and inhibition of PCRs using the same approach and 
set of experiments as outline previously (Sections 5.1.1.2 to 5.1.1.5). The 
results of these experiments for three sets of primers were identical to those 
obtained with the standard primers confirming that the addition of adaptor 
and barcode sequences did not have any undesirable impact on 
amplification of the target genes map and pfl, or tuf using the _Bishop 
primers. The primers corresponding to tuf based on Picard et al. (2004) 
encountered several errors during PCR that included the barcoded 
sequences and these primers were not pursued any further. Consequently 
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10 primer sets for each of the three genes were finally designed and used in 
the downstream sequencing.  
5.1.4 Sequencing: Test Experiment 
5.1.4.1 Test Set Construction 
A sequencing test set of three samples was created using DNA 
extracted from four different streptococci strains: S. pneumoniae, S. mitis, S. 
pyogenes and S.agalactiae. The three samples were created with varying 
concentrations of each strain in order to determine the sensitivity of the 
pyrosequencing assay in detecting the varying abundances of the 
streptococci (Figure 5.6). The first constructed sample contained the same 
quantity of each streptococcal DNA strain (25% S. pneumoniae, 25% S. 
mitis, 25% S. pyogenes and 25% S.agalactiae) whilst the second sample 
was constructed with 50% S. pyogenes with the other three strains (S. 
pneumoniae, S. mitis and S.agalactiae) each at 17%. The third sample was 
constructed with S. pyogenes DNA almost completely dominant (90%) and 
the other remaining strains at variable percentages - 7% S. mitis, 2% 
S.agalactiae and 1% S. pneumoniae. The design of the third sample, with 
only 1% of S.pneumoniae, was specifically to determine the sensitivity of the 
assay in detecting such an important pathogen when present at very low 
levels.  
Additionally included in the test set of samples were two of the 
ECUAVIDA DNA oropharyngeal samples identified by 16S rRNA 
sequencing to have different streptococcal patterns. All five of the test set 
samples were sequenced twice to determine reproducibility of the assay.  
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5.1.4.2 Sequencing Results for Test Set Samples  
The 10 samples (Figure 5.5) underwent PCR and were multiplexed into 
a single sequencing run on the Roche 454 Junior titanium machine. The run 
resulted in a total of 148,000 sequences and after denoising 75,238 valid 
sequences remained.  
Figure 5.6. Samples used for the Pyrosequencing Test of 
the Four Candidate Primer Sets. Sample 1a and 1b: 
duplicates containing 25% S. pneumoniae, 25% S. mitis, 
25% S. pyogenes and 25% S.agalactiae. Samples 2a and 2b: 
duplicates containing 50% S. pyogenes, 17% S. 
pneumoniae, 17% S. mitis and 17% S.agalactiae. Samples 
3a and 3b: duplicates containing 90% S. pyogenes, 7% S. 
mitis, 2% S.agalactiae and 1% S. pneumoniae. Samples 4a 
and 4b: duplicates of oropharyngeal human sample one, with 
5a and 5b: duplicates for oropharyngeal human sample two.  
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5.1.4.2.1 map  gene Sequencing Results 
A range (70% to 99%) of percentage similarity between sequences was 
tested for OTUs assignation. The most accurate results, when compared 
with the OTU assignment by 16S rRNA sequencing, were obtained at the 
level of 80% similarity. At this level in the streptococci constructed test 
samples map sequencing resulted in eight different OTUs although four 4 
OTUs accounted for more than 95% of the sequences.  
For OTUs taxonomic assignation a manual alignment using the 
streptococci MLSA database found in www.emlsa.org was performed.  
Taxonomic assignment with the RDP databases part of QIIME was not 
feasible because it was analysed a gene different from the 16SrRNA. A total 
of 421 different Streptococcus sequences were included in the phylogenetic 
alignments. The phylogenetic tree was constructed on Mega 6 (Tamura et 
al., 2013b) using the neighbour-joining algorithm and bootstrap with 1000 
iterations included to measure phylogenetic distances. 
The taxonomy assignations on map were accurate identifying the four 
strains used for the three constructed samples S. pneumoniae, S. mitis, S. 
pyogenes and S.agalactiae (Figure 5.7). For the two oropharyngeal DNA 
samples, sample 4 despite good PCR amplification failed to produce any 
sequences.  This will have been due to interference of the nucleotide 
barcode in the sequencing process. Errors caused by barcodes (including 
barcodes that the HMP Consortium has released) are common and non-
predictable until sequencing is performed.  For the other oropharyngeal 
DNA sample, sample 5, most of the OTUs were assigned to S. salivarius, S. 
termophilus and S.parasanguis. 
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Looking at the relative abundance (Figure 5.8), the results revealed that 
map did reasonably well in determining the percentages and ratios to one 
another for three of the four streptococci (main OTUs) present in the 
constructed test samples (P>0.05). The abundance of S. mitis was however 
Figure 5.7. Neighbour-joining Phylogenetic Tree Showing the Taxonomic 
Assignations of the OTUs Identified in the Constructed Samples and in 
the Oropharyngeal Swab DNAs. The arrows show how the main four OTUs 
encountered in the constructed samples are accurately aligned with S. 
pneumoniae, S. mitis, S. pyogenes and S.agalactiae respectively. Scale bar is 
shown and the branches with more than 70% of bootstrap level are labelled. 
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somewhat underestimated (P<0.001). Comparing the relative abundance 
proportions seen for the duplicate samples revealed that the assay was 
robust. The presence of S.pneumoniae was accurately identified even at the 
minimal percentage of 1% (Samples 3a and 3b).  
 
 
Figure 5.8. Relative Abundance Results for the Constructed Test 
Samples. Each sample duplicate is shown as A and B, with the average 
abundance obtained from the 2 duplicates labelled as TOTAL SAMPLE. In all 
samples there is an underestimation of S.mitis abundance but the relative 
proportions of the other three streptococci are maintained. 
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The oropharyngeal sample (Sample 5) produced interesting results in 
terms of relative abundance. It distinguished four different OTUs of S. 
salivarius and one of S. parasanguis. The proportions identified were 
comparable with the proportions of OTUs assigned to Streptococcus spp. 
using 16S rRNA sequencing although the latter data could not identify the 
actual species (i.e. OTUs 1328 and 1057 were assigned as S. salivarius 
using map but 16SrRNA could not differentiate them from other ‘mitis’ 
streptococci) (Figure 5.9). Again agreement between the duplicates 
(Samples 5a and 5b) was high. 
 
In conclusion map is a very good and reliable candidate gene in this 
pyrosequencing assay as it has enabled streptococci taxonomic assignation 
and has provided an accurate insight of the relative abundance of streptococci 
within each sample. 
5.1.4.2.2 pfl gene Sequencing Results 
As for map, a range (70% to 99%) of percentage similarity between 
sequences was tested for OTUs assignation and 80% was again found to be 
Figure 5.9. Relative Abundance of Streptococcal OTUs using 
map Gene Sequencing. S.salivaius OTU1 was the most common 
OTU and then in decreasing abundance S. parasanguis and S. 
salivarius OTUs 2, 3, and 4. 
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the most accurate value. The taxonomy assignation was also performed 
manually by the construction of a phylogenetic tree on Mega 6 (Tamura et al., 
2013b) using the neighbour-joining algorithm and bootstrap with 1000 iterations 
that included the OTUs representative sequences obtained and the pfl 
streptococci database found in www.emlsa.org. A total of 421 different 
Streptococcus sequences were included in the phylogenetic alignments. 
Disappointingly the barcodes for samples 1A and 2B failed to produce 
any sequences despite good amplification (Section 5.1.2.3) so could not be 
analysed any further. The taxonomic assignation for the other samples showed 
an accurate assignation on S. pyogenes, S. agalactiae and S. pneumoniae 
(Figure 5.10). S. mitis, correctly identified by map, was however identified as S. 
infantis.  Interestingly S. infantis belongs to the same group (‘mitis’) as S. mitis.   
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The relative abundance results showed a comparable proportionality of 
OTUs between the sequencing results and the expected concentrations on 
the constructed samples. In the results it is shown a high variability of 
S.infantis (wrongly assigned to S. infantis as it should be S. mitis) 
Figure 5.10. Neighbour-joining Phylogenetic Tree Showing the 
Taxonomic Assignations of the OTUs found by pfl in the 
Constructed Samples and in the Oropharyngeal Swab DNAs. 
The arrows show how the three OTUs encountered in the 
constructed samples are accurately aligned with S. pneumoniae, S. 
pyogenes and S.agalactiae respectively. Disappointedly S. mitis 
was assigned to S. infantis. Scale bar is shown and the branches 
with more than 70% of bootstrap level are labelled. 
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abundance compared with the expected, there is an underestimation on 
samples 1 and 3 but an overestimation on sample 2 (P<0.001). The rest of 
strains were fairly precise with the expected abundance, and in all samples 
it was possible to identify S. pneumoniae (Figure 5.11).  
 
  
For the oropharyngeal samples DNA, pfl was able to identify several 
streptococcal OTUs but in contrast to map and reflecting the results obtained 
for the constructed test samples, there were issues in relation to S. mitis 
assignation. For Sample 4, OTUs were predominantly belonged to the ‘mitis’ 
group, being to species of this group including S. vestibularis, S. infantis and S. 
constellatus. Sample 5 also had several OTUs assigned to the ‘mitis’ group but 
again assigned to species like S. salivarius, S. infantis, S. parasanguis and S. 
Figure 5.11. Relative Abundance Results for pfl the Constructed 
Samples and the Comparison with the Expected Results (PLAN). 
Sample 3 has duplicates A and B which abundances were averaged on 
TOTAL SAMPLE 3.  
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australis (Figure 5.12). For both the samples the taxonomy assignation 
diverged with the approximation of species identification by 16S rRNA 
sequencing.  The latter and the results of the constructed test samples highlight 
that pfl performs poorly for streptococci identification in this assay. 
 
5.1.4.2.3 tuf gene Sequencing Results 
For the tuf sequencing results, as for the prior two candidate genes, a 
range (70% to 99%) of percentage similarity between sequences was tested for 
OTUs assignation and 80% was again found to be the most accurate value. In 
terms of taxonomic identification accuracy when phylogenetic trees were 
performed using Mega 6 (Tamura et al., 2013b), tuf was able to identify all four 
species in the constructed test samples: S. pneumoniae, S. mitis, S. pyogenes 
and S. agalactiae (Figure 5.13). 
Figure 5.12. Relative Abundance for Two Oropharyngeal 
Samples previously Analysed using 16SrRNA Pyrosequencing. 
A) sample 4 and B) sample 5. 
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With regard to the relative abundance of OTUs, tuf encountered 2 OTUs 
of S. pneumoniae and 3 OTUs of S.agalactiae that were pooled to compare 
with the expected proportions of streptocci strains. This gene compared with 
the prior map and pfl could not assign accurately single OTUs from a strain but 
encountered inexistent differences and therefore more OTUs than the existent. 
Figure 5.13. Neighbour-joining Phylogenetic Tree Showing the 
Taxonomic Assignations of the OTUs found by tuf in the 
Constructed Test samples and in the Oropharyngeal Swab 
DNAs. The arrows show how the main four OTUs encountered in 
the constructed samples are accurately aligned with S. 
pneumoniae, S. mitis, S. pyogenes and S.agalactiae respectively. 
Scale bar is shown and the branches with more than 70% of 
bootstrap level are labelled. 
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Also tuf overrepresented the abundance of S. mitis and underestimated the 
abundance of the rest of species (P<0.001), particularly S.pyogenes that to be 
identified by tuf had to be present in at least 90% of the sample (sample 3) 
(Figure 5.14).  
 
The sequencing analysis of the oropharyngeal DNA samples (Samples 
4 and 5) identified streptococci species similar to what was anticipated 
(although not possible to definitely determine) by 16S rRNA sequencing for 
example S. vestibularis, S. infantis, S.peroris and S. salivarius. For both 
samples however, the relative abundance of sequences could not be 
Figure 5.14. Relative Abundance Results of tuf in the constructed 
samples and the Comparison with the Expected Results (PLAN). 
Samples 1, 2 and 3 have duplicates A and B, which abundances were 
averaged on TOTAL SAMPLE.  
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contrasted with the obtained by16S rRNA sequencing because OTUs 
abundances could not be extrapolated (Figure 5.15). 
 
 
 
5.1.5 Selection of a Primer Set 
Due to the high accuracy and reliability of the map gene for both the 
taxonomic identification of the streptococci as well as the relative abundance 
measurements, the gene was selected to take forward to perform the 
streptococci species identification for the oropharyngeal samples of the 
ECUAVIDA infants’ cohort. The other genes pfl and tuf were not pursued 
further in light of neither being as robust as the map gene particularly when it 
came to taxonomic identification and to some extent relative abundance.  
Figure 5.15. Relative Abundance Determined using the 
tuf Gene for the Two Oropharyngeal DNA samples 
Previously Analysed using 16S rRNA Pyrosequencing. 
A) Sample 4 and B) Sample 5. 
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5.2 ECUAVIDA Microbiota Study: Streptococcus species 
Analysis using map Pyrosequencing  
5.2.1 Materials and Methods  
From the cases/controls study of wheezing in infants from the rural 
tropics of Ecuador, a total of 76 samples were selected from Stage 1b (from 
172 samples) for the streptococcal species characterization by map (following 
the protocols optimized in Section 5.1). The rest of samples from the study 
(Stages 1a and 2) did not have enough DNA to perform the streptococcus 
analysis (122 samples) or did not produce amplification (136 samples) (mainly 
because some samples were frozen at least 4 years prior the experiments). In 
the streptococci species typing using map infants included had a history of 
wheezing that had been sampled between 7 and 12 months of age.  A total of 
37 cases and 39 controls were studied.  Amplification and sequencing was 
performed as previously described using the Roche 454 Junior Platform, and a 
total of 2 runs were performed (Section 5.1.2 and Chapter 2: Sections 2.7.1 
and 2.7.4). 
The sequences were filtered with ampliconnoise and analysed with 
QIIME 1.7 (Caporaso et al., 2010b) (Chapter 2: Sections 2.7.5). The OTUs 
were picked at 80% similarity range and OTU taxonomic assignation was 
performed manually using the map streptococci database from www.emlsa.org 
(Bishop et al., 2009) as well as the map sequences uploaded on the NCBI 
Genebank. The alignments were performed on Mega 6 using the ClustalW 
algorithm (Tamura et al., 2013b).  The alpha and beta diversity calculations 
were performed on the R package phyloseq (Dixon, 2003, Pages et al., 
McMurdie and Holmes, 2013). Statistical analysis of beta diversity was 
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performed using UNIFRAC statistics (Lozupone and Knight, 2005a) and OTUs 
comparisons on Metastats (White et al., 2009). 
5.2.1 Results 
From a total of 138,000 sequences after annoising and singletons 
removal 136,000 sequences remained. Although a total of 51 OTUs were five 
OTUs accounted for 95% of the 136,000 sequences with the remaining 46 
OTUs being less common. The taxonomy assignation using the Neighbour-
joining phylogeny determined that the most common OTU corresponded to S. 
mitis (OTU 5), the second most abundant (OTU 32) was assigned to 
S.salivarius, with the third and fourth (OTUs 45 and 18) assigned as 
S.parasanguinis and the fifth more abundant (OTU 22) was S. peroris (Figure 
5.16). For the less common OTUs S.pneumoniae was assigned once but only 
seen in 2 samples and with less than 5 sequences each. For all the rest of less 
common OTUs, the taxonomy assignation as species level was equally 
straightforward. Since the rarity of these OTUs, they were dropped from 
subsequent analysis, which only was focused on the five main OTUs IDs: 5, 18, 
22, 32 and 45. 
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Figure 5.16. Neighbour-joining Phylogenetic Tree Showing the Taxonomic assignations by 
the map Gene for the Stage 1b Oropharyngeal DNA Samples. The arrows show how the main 
five OTUs encountered in the sample set are aligned allowing taxonomic identification  to be 
determined. Scale bar is shown and the branches with more than 70% of bootstrap level are 
labelled. 
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5.2.1.1 OTUs Analysis 
Previously the 16S rRNA sequencing had found that one OTU 
(OTU1328) assigned to Streptococcus spp. (with similar distribution of 
sequences per sample) was consistently more common in controls (P<0.0001) 
(Chapter 3: Section 4.2.2).  Thanks to this new technique it was possible to 
identify at species level the OTUs assigned to streptococci, as consequence 
OTU1328 in 16SrRNA could be inferred as OTU5 in map analysis and 
therefore assigned to S.mitis.   When comparing at OTUs level between cases 
and controls, there were encountered statistical differences in this particular 
OTU (P=0.045), which was more commonly found in controls (Figure 5.17).  
  
 236 
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S.mitis 5 97 17 14 0 1 178 33 132 0 15 0 0 11 236 25 23 46 254 62 96 80 66 296 55 76 348 2 150 15 109 365 122 126 219 ### 191 129 33 86 183 106 37 3 14 54 211 18 12 106 19 52 11 15 8 51 80 35 26 51 62 20 72 41 261 58 213 57 98 61 21 23 71 109 93 19 38
S.salivairous 32 0 9 0 0 0 0 0 0 0 0 8 2 0 0 5 0 0 0 0 0 28 0 0 0 0 0 18 0 0 0 1 12 0 0 0 0 2 25 0 127 1 0 217 0 0 0 29 212 334 345 0 483 220 382 24 0 0 55 58 788 242 2 118 26 534 3 190 51 42 413 72 0 0 128 0 0
S.parasanguinis 45 13 192 7 412 339 80 126 170 201 77 173 177 49 31 155 62 73 77 9 1 3 99 27 35 0 68 1 21 161 84 1 36 116 5 0 102 0 0 2 7 0 15 0 22 2 0 7 0 0 0 3 0 0 0 6 10 2 3 0 0 0 0 0 0 0 0 0 0 0 24 0 0 1 0 0 4
S.parasanguinis 18 0 1 411 0 0 0 0 0 0 0 0 0 0 0 2 78 0 80 0 1 54 0 0 0 75 6 95 0 0 0 0 0 0 0 6 0 0 2 0 25 0 0 42 0 0 0 8 97 36 47 0 16 31 48 79 0 0 93 4 62 12 2 6 5 77 2 62 2 12 101 10 0 0 24 0 0
S.peroris 22 2 0 0 2 12 2 0 57 190 44 4 9 34 0 0 4 79 31 61 0 12 1 0 89 9 3 8 10 93 39 6 11 2 7 2 93 3 0 0 5 80 7 1 203 19 0 1 7 7 31 0 2 2 0 22 38 0 23 0 2 0 2 11 1 4 0 0 0 4 0 0 0 0 0 21 0
Cases Controls
12_months
Taxonomy #OTU?ID Controls
7_months
Cases
Figure 5.17. Heatmap Showing OTU Abundance per Sample for the Five Main OTUs Identified by map Gene 
Pyrosequencing.  Each box ranges from white complete absence of sequences in that OTU, to yellow with few and dark red 
with high number of sequences.  
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Using metastats doing comparisons between age groups, at 7 months 
S. parasinguinis OTU 45 was more common (P<0.0001) as was S. peroris OTU 
22 (P<0.001), whilst at 12 months there was a higher abundance of S.mitis 
OTU 5 (P=0.042), S. salivarius OTU 32 (P<0.0001), and S. parasanguinis OTU 
18 (P=0.0006).  
5.2.1.2 Alpha Diversity 
Alpha diversity analysis was performed calculating richness, evenness 
and diversity (using the Shannon Index and the Inverse Simpson Index). To 
determine the normal distribution of the results, the Shapiro-Wilkinson normality 
test was performed. It showed that richness (P=0.002) and inverse Simpson 
(P=0.0006) indexes were not normally distributed and therefore non-parametric 
statistics were performed. On contrary Shannon index of diversity (P=0.154) 
and evenness (P=0.054) showed normal distribution and therefore parametric 
statistics were used. 
Statistical analysis of the streptococci data revealed no differences in 
alpha diversity indexes between cases and controls, irrespective of whether 
age, 7 and 12 months, was taken into consideration. 
5.2.1.3 Beta Diversity 
When compare between cases versus controls at OTUs level, there 
were not found statistical differences using Canberra, Bray-Curtis, UNIFRAC or 
Weighted UNIFRAC. NMDS plots do not show a clear clustering when 
comparing cases versus controls. However when compare between ages (7 
versus 12 months), there were statistical differences in Canberra (P<0.0001), 
Bray-Curtis (P<0.0001), UNIFRAC (P<0.0001), and Weighted UNIFRAC 
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(P<0.0001). However the age explains a different proportion of the variance 
each time: Canberra = 8%, Bray-Curtis 16%, UNIFRAC = 13%, weighted 
UNIFRAC = 18%.  It can be inferred that the abundance of the different OTUs 
is important in determining differences as weighted UNIFRAC and Bray-Curtis 
show higher values), and that the phylogenetic information is also relevant to 
show differences (weighted UNIFRAC versus Bray-Curtis). Though Bray-Curtis 
has a reasonable level of stress and is a good representation of clustering in 2 
dimensions. NMDS plots show a clear clustering of samples when grouped by 
age (Figure 5.18). 
 
Figure 5.18. Beta Diversity NMDS Plots: Clustering 
between Samples. Bray-Curtis analysis between 
ages at 7 months versus 12 months.  
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5.3 Discussion 
In order to complement the ECUAVIDA analysis of the human microbiota using 
16S rRNA pyrosequencing, a new tool was designed for characterization of sub-
populations of bacteria (streptococci) at species level. The tool designed was also 
capable of calculating relative abundance measures comparable to that obtained 
with the 16S rRNA sequencing. It was necessary to investigate several candidate 
genes commonly utilized by MLSA and MLST methodologies (Bishop et al., 2009, 
Picard et al., 2004) in order to find a reliable candidate gene for the pyrosequencing 
assay. After PCR standardization, validation and sequencing tests, the methionine 
aminopeptidase gene (map) was the best candidate differentiating streptococci 
species and providing a good insight of the sequences abundance. 
The candidate genes selection and the primers design were based on the 
availability of broad databases www.emlsa.org, www.mlst.net and the NCBI 
Genebank that included all known Streptococcus species including S.mitis, 
S.pyogenes, S.pneumoniae, S.agalactiae, etc. (Section 5.1.1.1). Each set of primers 
was aligned with the streptococci sequences present within the databases and 
phylogenetically tested to determine how accurate they were for taxonomy 
assignation. PCR optimization of parameters and the validation process 
implemented (Section 5.1.1.2 to 5.1.1.5) determined three candidate genes to be 
suitable for further investigation map, pfl and tuf. The sequencing pilot study using 
constructed samples (with known concentrations of streptococci strains) and with 
real oropharyngeal bacterial DNA determined that map was the best candidate to 
study the streptococcal microbiota on the airways.  Map provides accurate 
taxonomic assignation and relative abundance results comparable with that 
observed for 16S rRNA sequencing. 
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The analysis of the Streptococcus microbiota of the ECUAVIDA Stage 1b 
samples determined that infants have many different streptococcal species.  Fifty-one 
OTUs in total were observed with 95% of sequences being assigned to 5 OTUs. The 
most common species were S. mitis (subtype mitis), S.salivarious, S.parasanguinis and 
S. peroris, which are members of the Streptococcus ‘mitis’ group. The ECUAVIDA 
infants had surprisingly a very low prevalence of S.pneumoniae, an important pathogen, 
which was seen only in 2 samples.   
Comparing cases and controls at 7 and at 12 months, a higher abundance of S. 
mitis at both ages was seen for controls in controls.   These bacteria have been 
related with protection against the development of pathogens due to their ability to 
secrete hydrogen peroxide which inhibits the growth of Gram negative bacteria 
(Tano et al., 2000). No differences were seen for alpha and beta diversity measures 
when wheezing infants were compared to healthy controls irrespective of age. 
When comparisons between age groups, 7 and 12 months, were done marked 
differences were observed. Some species like S.peroris were more common at 7 months 
whilst at 12 months addidtional species were acquired including S.mitis, salivarious and 
S.parasanguinis.  
In conclusion a new culture-independent pyrosequencing based tool that is robust 
in assessing the streptococcal communities of the upper airways has been successfully 
designed and optimised. This is an important advancement as it now allows 
characterization of streptococci at species level which is not feasible and a limitation of 
current 16S rRNA sequencing.  The application of this new tool to the ECUAVIDA 
microbiota study has revealed that S. mitis is potentially an important protective factor 
against the development of airways chronic inflammation and that the microbiota of the 
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upper airways becomes more complex with age involving a higher abundance of 
streptococci species.  
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Chapter 6: General Discussion 
Asthma is a chronic disease of the airways characterized by a dysfunctional 
mucosa, intermittent airway inflammation and symptoms of wheezing, dyspnoea and 
cough. The syndrome results from a complex interplay between genetic and 
environmental factors (Cookson, 2004, Cookson, 2002, Cookson et al., 2011) 
(Chapter 1). Several microbiological studies have determined the important effects of 
bacteria in asthma recurrences (Kraft, 2000) as well as in the development of 
asthma. A rich microbial environment in early life has been shown to be protective 
against the development of asthma (Eder et al., 2006, Ege et al., 2011). The airways 
of the lung have been shown to contain a characteristic flora that in asthma is 
disturbed by the presence of pathogens (Hilty et al., 2010) whilst birth cohort studies, 
using standard culture methods and throat swabs, have found the presence of some 
pathogens to be predictive of the subsequent development of asthma (Bisgaard et 
al., 2007).  
Laboratory microbiological culture techniques do not however always result in 
successful bacterial identification and around 90% of bacteria cannot be grown by 
standard routine culture (Turnbaugh et al., 2007). Consequently, the most powerful 
approach to study the microbial diversity in a community is to implement molecular 
culture-independent techniques (Turnbaugh et al., 2007, Cox et al., 2013a) 
employing key bacterial genes to enable bacterial identification (Chapter 1: Section 
12). In the work presented in this thesis, this approach was used focusing on the 16S 
rRNA gene in the first instance and subsequently performing subtyping of the 
Streptococci seen using the map gene (Chapter 5). The use of state of the art 
bioinformatic tools in the data analysis was also essential in determining microbiota 
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patterns and to look for statistical differences between groups (Morgan and 
Huttenhower, 2012). 
The focus of this thesis has been the examination of the respiratory 
microbiome in a set of infants selected from the ECUAVIDA case/control 
retrospective study of infants from the rural tropics of Ecuador.  In this region of 
Ecuador general asthma prevalence is low (Mallol et al., 2010) but the wheezing 
syndrome occurrence is comparable with that seen in the urban populations (Cooper 
et al., 2014) (Chapter 1: Section 1.4). The ECUAVIDA population characteristically 
has very low history of antibiotic use (a key inclusion criterion of the study) and the 
selected infants had never taken inhaled corticosteroids. Both antibiotics and 
corticosteroids could be important biases in determining if the microbiota acts as an 
aetiological factor of airways inflammation or is a consequence of the medication 
use.  
Furthermore, there have been to date no studies that have characterized the 
development of the airways core microbiome in early infancy. Additionally no studies 
of the airway microbiome using culture independent techniques have been done in 
Latin American countries where environmental exposures and disease incidence is 
very different to that seen in Europe and North America. According to the hygiene 
hypothesis, factors in the rural tropics of Ecuador including the rural environment, 
low antibiotic usage and the high rate of parasitic infections, would be protective 
against the development of asthma and atopic disease (Strachan, 1989, Cooper et 
al., 2014).  
The study conducted in this thesis was divided into several stages according 
to age (7, 12 and 24 months) and wheezing status (current wheezing, history of 
 244 
wheezing, or healthy controls with no wheezing history). During sampling strict 
inclusion criteria were implemented in order to avoid skewed results in the microbiota 
patterns caused by for example current infectious processes, recent use of 
antibiotics or incorrect oropharyngeal swabbing techniques.  
Considering all infants, irrespective of case/control status, overall the most 
common bacteria seen in the upper airways was Streptococcus spp. and their 
phylum Firmicutes was the most diverse accounting for 70% of sequences obtained 
when compared with the other phyla (Chapters 3 and 4). These results were 
expected based on findings reported by previous microbiome culture-independent 
studies (Hilty et al., 2010).  
 When the bacterial microbiota was compared between infants with current 
wheezing and healthy controls (Stage 1a - ages between 7 and 12 months of age) a 
higher prevalence of potential pathogenic bacteria, principally Neisseria spp. and 
Haemophilus influenzae, was found in cases (Chapter 4: Section 4.2.1). Both 
Neisseria spp. and Haemophilus influenzae have been associated with serious 
infections in childhood (Gkentzi et al., 2012, Watt et al., 2009, Sabra and Benger, 
2011).  They have also been found to be related with asthmatics airways in adults 
(Hilty et al., 2010) and in children, the latter using conventional culturing techniques 
(Bisgaard et al., 2007). Neisseria meningitidis, also known as Meningococcus, is a 
main cause of morbidity and mortality during infancy in developed and developing 
countries (Khatami and Pollard, 2010). It is present in the airways in adult healthy 
carriers in a prevalence of 10 to 35% (Caugant and Maiden, 2009), and causes 
meningitis, otitis, pneumonia, bacteraemia, cerebral abscesses. Its mortality rate can 
reach up to 10%, and the reason why sometimes it acts as a harmless commensal 
and at other times as a highly virulent bacterium is not as yet understood (Khatami 
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and Pollard, 2010). Haemophilus parainfluenzae is a Gram negative rod shaped 
bacteria found in the oral cavity and the pharynx of humans. Usually it has a 
saprophytic behaviour but occasionally can cause disease especially bacteraemia 
and endocarditis, and less commonly meningitis, otitis, pneumonia (Nwaohiri et al., 
2009). Interestingly other potentially pathogenic bacteria have also been found in 
current wheezers like Clostrodiales, Burkholderiales, Pasteurellacea, which are 
enviromental bacteria that act as oportunistic pathogens (Murphy et al., 2009, Corti 
et al., 2009).  
In this present study, when compared with controls current wheezers from 
Stage 1a had a lower abundance of the so-called ‘protective’ bacteria, that have 
previously been reported, including Veillonella, Prevotella and Gemella. These 
genera have been observed to be more common in healthy subjects (Hilty et al., 
2010), and interestingly it has been shown that Prevotella has the ability to inhibit the 
growth of other bacteria in the oropharynx (Murray and Rosenblatt, 1976). 
To determine the mid and long term changes in the airways microbiome as a 
consequence of recurrent wheezing, infants with a history of wheezing were 
compared with healthy controls at 7, 12 and 24 months.  This paired analysis 
identified distinct different microbial patterns with notable increases in potential 
pathogenic bacteria,  Haemophilus, Moraxella, Corynebacterium and Burkholderia, 
in infants with a history of wheezing (Chapter 4: Section 4.2.2). As for current 
wheezers, past wheezers were also found to have a lower abundance of ‘protective’ 
bacteria including Prevotella, Veillonella and Lactobacillus. Additionally an OTU 
assigned to Streptococcus was consistently more common in controls however due 
to16S rRNA uniformity in this genus it was not possible to identify the species from 
this experiment. The differences found between the cases and controls were 
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maintained with increase in age and still present at 24 months (2 years) of age. 
Infants with a history of early wheezing (commencing at less than 7 months of age) 
have very apparent differences in both diversity and abundance differences 
compared with corresponding controls, as result a more diverse microbiome at this 
time appears to be protective against the development of wheezing.   
Due to the structure of the ECUAVIDA study, it was possible to examine for 
the first time how the upper airways microbiota changes during infancy.  The key 
observation was that over time a more complex and diverse flora is acquired 
(Chapter 4: Section 4.2.2.3). The main OTUs remain constant from 7 months up to 
and including 24 months (2 years), however other minor OTUs begin to appear 
through the time period. Consequently the number of species and the other alpha 
diversity parameters were found to increase with age (Chapter 4: Section 4.2.2.3.1).  
 Differences at the OTU level were also seen when comparing current versus 
past wheezers (Stage 1a versus Stage 1b). The wheezing episode (current) was 
characterized by a higher presence of potentially pathogenic bacteria compared with 
controls the differences remain present at mid and long-term (Chapter 4: Section 
4.2.1). The same potentially pathogenic bacteria present in current wheezers i.e. 
Haemophilus, Neisseria, Moraxella, Corynebacterium and Burkholderia, remained 
present in past wheezers. Correspondingly the lack of protective bacteria was 
maintained over time. There was a higher abundance of pathogens and a lower 
abundance of protective bacteria in current wheezers compared with infants with a 
history of wheezing (Chapter 4: Section 4.2.1). Additionally, analysis and comparison 
of the epidemiological data for cases and controls at all stages was conducted and 
was found not to underpin the microbiota patterns observed. 
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As discussed earlier (Chapter 1) 16S rRNA gene sequencing is unable to 
discriminate at species level within the streptococci genus.  Consequently it is 
incapable of distinguishing S. pneumoniae from the Streptococcus mitis ´group´ 
bacteria. S. mitis ´group´ are commensal bacteria of the airways and the upper 
intestinal tract. The S. mitis ´group´ encompasses different species of the 
Streptococcus viridians group such as: S. mitis (subtype mitis), S. gordonii, S. 
pneumoniae, S. oralis, S. sanguis and S. parasanguis (Kawamura et al., 1995). 
Since the results from Chapters 3 and 4 had highlighted the high levels of 
streptococci present in the upper airways of the ECUAVIDA infants, to complement 
the 16S rRNA analysis a new tool to allow subtyping the streptococcal populations at 
species level was designed and established (Chapter 5).  
Using pyrosequencing and variability in the bacterial map gene, the tool 
enables one to classify taxonomically, as well as distinguish, several species of 
streptococci present in a mixed microbial sample. Additionally relative abundance 
results obtained for each streptococci present can be correlated with 16S rRNA 
pyrosequencing results. The latter is particularly important as it allows one to 
establish how important each Streptococcus species is in the overall microbial 
community.  
The results of the map sequencing for the seventy-six ECUAVIDA infant 
oropharyngeal samples revealed that Streptococcus mitis was consistently more 
commonly found in healthy subjects compared with current wheezers or infants with 
history of wheezing (Chapter 5: Section 5.2). S. mitis are alpha hemolytic Gram-
positive cocci, facultative anaerobes and do not form spores. The S. mitis ´group´ 
bacteria are not pathogenic in normal circumstances (Coykendall, 1989) although 
they are an important cause of bacterial endocarditis and bacteraemia especially 
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after orthodontic treatments (Matsui and Jin, 2014). There are several in vivo and in 
vitro studies where Streptococcus spp. has been catalogued as: “inhabitants of the 
oropharynx that suppress the growth of Gram-positive and Gram-negative 
microorganisms” (Sachs et al., 1993). Studies have hypothesised that in the upper 
airways, S. viridans could act as protective bacteria replacing possible pathogenic 
bacteria (Tano et al., 2000). There are several mechanisms postulated as the 
molecular reason behind this inhibition, the most important of which is the production 
of hydrogen peroxide by S. viridians, which would restrict the growth of pathogenic 
bacteria (Tano et al., 2003).  
In the ECUAVIDA infants, both cases and controls, the prevalence of 
Streptococcus pneumoniae was found to be notably low (Chapter 5: Section 5.2). 
This is of particular interest because S. pneumoniae (also known as Pneumococcus) 
is categorized as part of the ‘mitis’ group using the 16S rRNA gene sequencing 
approach (Johnson and Tunkel, 2000). Pneumococcus is also part of the human 
normal upper respiratory tract microbiome but compared with S. viridans is more 
prevalent in causing disease. S. pneumoniae commonly causes pneumonia, 
sinusitis, otitis media and meningitis (secondary to one of the previous infections). 
Less common pathologies, secondary to S. pneumoniae infection, are cellulitis, 
peritonitis, osteomyelitis, septic arthritis and endocarditis especially in 
immunocompromised patients (Krzysciak et al., 2013).  
In the national regulations of the Ecuadorian Health System, pneumococcus 
vaccination is not considered compulsory and therefore is only provided to selected 
populations at risk. In this current study none of the infants had received the 
pneumococcus vaccination. The new streptococci typing tool also confirmed the prior 
16S rRNA results (Chapter 4: Section 4.2.2) that the abundance and diversity of the 
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streptococci group of bacteria increases over time and they contribute to the 
formation of a more complex respiratory microbiome.  
In conclusion the upper airways bacterial microbiota is different between 
infants with wheezing versus healthy age matched controls. There is a marked 
increase of potentially pathogenic bacteria in the wheezing infants and a lower 
abundance of the previously reported ‘protective’ bacteria. Such differences are of 
relevance to the pathophysiology of asthma and its development later in life, and 
also because could potentially provide a new therapeutic angle based in the bacterial 
microbiota modification. It is important to mention that the statistical software used 
has been refined over time to reflect the data structure, however the p values quoted 
in this thesis will need correction before publication in final form. 
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3.1. Future Work 
The current study identifies the microbiota patterns related with the 
development of early onset wheezing on infants from the rural Tropics of Ecuador. In 
light of the findings it would be interesting to investigate further the microbiome 
structure in an extended part of the ECUAVIDA cohort (that in total has more than 
2,500 children). As oropharyngeal samples have been continued to be collected 
since initiation of this thesis project as infants have been recruited into the birth- 
cohort, the project could retrospectively analyse such samples (collected during 
current wheezing and in past wheezers). Additionally as the project plans to continue 
prospectively until children will reach the 8 years old, there is an opportunity to 
continue to study the development  of the upper airways microbiota over time and as 
children develop asthma (not only wheezing).  
Another complementary study to be performed would be the relationships of 
the gut microbiota and the airways microbiota at different time points in development. 
As the mouth is the entrance for both the digestive and respiratory systems it is likely 
that a close relationship exists, and that dysbiotic changes in one body-system 
microbiome may influence the other. In the ECUAVIDA cohort where antibiotic intake 
is low overall hence limited skewing of results, the relationship between both 
systems in health and disease could be analysed as well as their influence in the 
development of asthma and allergies.  
Another goal of the ECUAVIDA cohort is to determine the environmental 
influences in the development of asthma and allergies, and an important part of the 
study is the ‘protective’ effect conferred by geohelminth infection. The effect of these 
infections in the gut microbiome has been reported in a pilot study (Cooper et al., 
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2013) with a reduced number of samples, however it would be interesting to analyse 
the gut and airways microbiome patterns related with wheezing and asthma in an 
extended study and the effect of anti-parasitic therapies on this. 
Technologically the study could be further continued using the new generation 
sequencing technologies like the Illumina HiSeq and MiSeq (released in the last 
months of 2013), which would allow a deeper analysis of the microbiota with 
increased number of sequences per sample, and the possibility of longer amplicon 
sequencing (which could provide a better taxonomical identification of bacterial 
OTUs). The development of metagenomics experiments for a better microbiota 
analysis would also be important allowing not only more even more accurate 
characterization of the bacteria present but also their activity and the activity of the 
host. Consequently consideration of the use of metabolomics and proteomic 
platforms could also be key in enabling the molecular relationship between 
microbiome and the epithelial and immune cells in the airways to be determined. 
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Abstract
Background: Observations that the airway microbiome is disturbed in asthma may be confounded by the widespread use
of antibiotics and inhaled steroids. We have therefore examined the oropharyngeal microbiome in early onset wheezing
infants from a rural area of tropical Ecuador where antibiotic usage is minimal and glucocorticoid usage is absent.
Materials and Methods: We performed pyrosequencing of amplicons of the polymorphic bacterial 16S rRNA gene from
oropharyngeal samples from 24 infants with non-infectious early onset wheezing and 24 healthy controls (average age 10.2
months). We analyzed microbial community structure and differences between cases and controls by QIIME software.
Results: We obtained 76,627 high quality sequences classified into 182 operational taxonomic units (OTUs). Firmicutes was
the most common and diverse phylum (71.22% of sequences) with Streptococcus being the most common genus (49.72%).
Known pathogens were found significantly more often in cases of infantile wheeze compared to controls, exemplified by
Haemophilus spp. (OR = 2.12, 95% Confidence Interval (CI) 1.82–2.47; P= 5.46610223) and Staphylococcus spp. (OR = 124.1,
95%CI 59.0–261.2; P= 1.876102241). Other OTUs were less common in cases than controls, notably Veillonella spp.
(OR = 0.59, 95%CI = 0.56–0.62; P= 8.06610286).
Discussion: The airway microbiota appeared to contain many more Streptococci than found in Western Europe and the
USA. Comparisons between healthy and wheezing infants revealed a significant difference in several bacterial phylotypes
that were not confounded by antibiotics or use of inhaled steroids. The increased prevalence of pathogens such as
Haemophilus and Staphylococcus spp. in cases may contribute to wheezing illnesses in this age group.
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Introduction
Asthma is a chronic disease of the airways that is characterized
by an abnormal mucosa, intermittent airway inflammation and
symptoms of wheezing, dyspnea and cough. The syndrome results
from a complex interplay between genetic and environmental
factors [1].
A worthwhile understanding of the causes of asthma needs to
reconcile consistent epidemiological indications of the impor-
tance of the microbiome (also known as microbiota) to the
disease [1]. These include the protection afforded by a rich
microbial environment in early life [2,3], observations that the
bronchial tree contains a characteristic flora that is disturbed by
the presence of pathogens such as Haemophilus infuenzae in
asthma [4,5], birth cohort studies showing that the presence of
the same pathogens in throat swabs predicts the later
development of asthma [6] and recognition that these bacteria
have consistently been associated with exacerbations of asthma
[7].
Of potential importance is the finding that organisms commonly
found in healthy airways and mucosal surfaces are significantly
reduced in asthmatic airways [4]. Investigations of inflammatory
bowel disease have shown that a normal bacterial flora is essential
in maintaining a healthy mucosa [8] and similar mechanisms are
likely to be important in the airways [9–11]. Murine studies have
shown that sterility of the airways and intestinal tract results in
enhanced inflammatory responses to a variety of stimuli [10,12].
Ninety percent of the cells in the human body are microorgan-
isms including bacteria, parasites and archaea [13]. These
microorganisms are commensal on body surfaces exposed to the
external environment including the gut, respiratory tract and skin.
Allergy, and other immune diseases are associated with differences
in microbial communities, but it is unclear if these differences are
causes or consequences of disease [4,5,12]. Although most bacteria
PLOS ONE | www.plosone.org 1 October 2012 | Volume 7 | Issue 10 | e46803
are not cultivable with standard methods [14], the membership of
complex microbial communities can be quantified and classified
by DNA sequencing of the conserved bacterial 16S rRNA gene
[15,16]. Bacteria are classified by these sequences into Operational
Taxonomic Units (OTUs). OTUs approximate closely but not
completely to taxonomy derived from classical techniques, and
sequences of other regions may be necessary for precise
discrimination at the species level.
Previous studies of the airway microbiome in healthy and in
diseased subjects have been carried out in Westernized societies
[4–6] where antibiotic use and the prescription of inhaled
corticosteroids is almost ubiquitous and confounds understanding
of the microbiome. We have therefore carried out a sequence-
based study of the upper airway microbiome in children from the
Esmeraldas province in rural Ecuador who have had minimal
exposure to antibiotic medications and no exposure to inhaled
steroids.
Ecuador has strong regional differences in the prevalence of
wheeze in rural compared to urban areas. The prevalence of
wheezing in children has been estimated to be 16.6% in urban
areas [17] while in rural areas of the Pichincha province the rate of
current wheezing has been estimated between 0.8% and 2.2%
[18,19]. Factors that may be protective against asthma in this
region include exposures associated with living in a rural
environment, low antibiotic usage and a high rate of geohelminth
parasitic infections. We therefore sought to compare and contrast
the airway microbiome in infants with non-infective wheeze and
healthy controls, and to relate our findings to surveys of the airway
microbiome in European children.
Materials and Methods
Subjects
A case-control study was designed to investigate the upper
airway microbiota profiles of early onset non-infectious wheezing
infants (cases) and healthy infants (controls). The project used
DNA extracted from oropharyngeal swabs samples collected from
the hypopharynx of 48 infants (average age 10.2 months) that were
recruited as part of a birth cohort (the ECUAVIDA cohort) in the
Esmeraldas Province in Ecuador. The aim of the ECUAVIDA
cohort study is to investigate the effects of early infant infections on
the development of immunity, allergic sensitization and allergic
disease and the methodology has been previously described in
detail [18,19]. The study is an unselected population-based birth
cohort that has recruited 2,403 newborns in the rural District of
Quininde in the Esmeraldas Province, Ecuador. Detailed data has
been collected from the mothers at the time of the first antenatal
visit using questionnaires and environmental sampling. The
protocol for the ECUAVIDA cohort was approved by the Ethical
Committees of the Hospital Pedro Vicente Maldonado and
Universidad San Francisco de Quito, Quito, Ecuador.
Twenty-four infants were selected with early onset multiple-
trigger non-infectious wheezing according to the GINA guidelines
(http://www.ginasthma.org/). Wheezing illness was diagnosed by
a physician. Twenty-four healthy controls (no history of wheezing,
current respiratory disease, chronic disease or current infections)
were selected and paired by age range to cases. The samples were
collected when the cases and controls did not have any evidence of
a current airway infection (cold symptoms and fever). The infants
in both groups had a minimal history of antibiotic use, with 87%
never being exposed to antibiotics, and the whole group receiving
Table 1. Epidemiologic characteristics of the children investigated in the study.
Cases Controls
Mean age (months) 9.9 10.5
Sex (% male) 50% 42%
Number of Individuals per room of the house 3.57 3.11
Average parental income (USD per month) 186 238
Average Birth weight (grams) 3306 3154
Maternal Education Level (percentage)
Illiterate 0% 4%
Primary School Incomplete 21% 8%
Primary School Complete 17% 33%
High school Incomplete 42% 46%
High school Complete 21% 4%
University Incomplete 0% 4%
University Complete 0% 0%
Respiratory Tract Infections (average occurrences per month of age) 0.21 0.15
Average Number of Antibiotic Courses 0.166 0.083
Antibiotics (number of times used )
Trimethoprim/sulfamethoxazole 1
Cephalexine 1
Amoxicilin 3 1
Antibiotic Use for Respiratory Tract Infection
Upper RTIs 1 1
Lower RTIs 1 1
doi:10.1371/journal.pone.0046803.t001
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on average 0.12 courses of antibiotics per child (Table 1). None of
the infants had received antibiotics for any reason for at least two
weeks prior to sampling. None of the subjects had ever received
corticosteroids. All subjects were of the same mixed ethnic
background, lived in the same town and had access to the same
basic electricity, water, and sanitation services. All subjects had
received vaccines recommended by the Ecuadorian Ministry of
Public Health. None had received anti-Streptococcal vaccination.
Sample Collection and Storage
Throat swabs were collected by a physician using sterile cotton
swabs and were placed in collection tubes (Qiagen, UK). Sampling
was performed carefully without touching any surface other than
the oropharynx and using a tongue depressor. Each swab was
rubbed approximately five times around the oropharynx. An even
pressure was applied and the swab was rotated without
interruption. Post sampling, the swab was immediately placed
back into the collection tube and stored at 220uC and
subsequently within the next 24 hours at 280uC. Samples were
shipped to Imperial College, London on dry ice.
Bacterial DNA Extraction from Throat Swabs
Bacterial DNA was extracted from the throat swabs using a
modified protocol of the commercial QIAmp DNA Mini Kit
(Qiagen). Additional steps at the beginning of the protocol were
included to improve the lysis of Gram positive bacteria [4].
Each swab head was transferred into a 2 ml microcentrifuge
tube, and 432 ml TE (Tris EDTA pH 8.0)+18 ml 4X lysozyme
solution was added (4X lysozyme in a concentration of 1000 U/ml
was prepared from lysozyme stock at 30,000 U/ml Ready-LyseTM
Lysozyme Solution of EPICENTRE, UK).
Samples were incubated for 1 hour at 37uC; to allow improved
lysis of Gram +ve bacterial walls. During this hour, samples were
vortexed for 20 seconds at intervals of 15 minutes. Next 30 ml of
Proteinase K and 450 ml of Buffer AL were added to the tube and
samples were incubated at 56uC for 30 minutes. To terminate the
Proteinase K step, samples were then incubated for 5 min at
95uC.450 ml of Ethanol (96–100%) was added to the sample. In
order to obtain a homogenous solution this was mixed by
vortexing. This solution was then applied to the QIAamp Spin
Column as per the manufacturer’s protocol. In the final step 40 ml
of nuclease free water was added instead of the elution buffer
supplied by the kit. If the DNA was not being used immediately
after extraction samples were stored at 220uC until required.
Amplification of 16S rRNA Gene
Polymerase chain reaction (PCR) was used to amplify the
variable regions 3 to 5 (V3–V5, Primers 454B_357F and
454A_926R [20]) of the gene that encodes for 16S rRNA in
bacteria. Samples were multiplexed using sample specific barcodes
[20] and Roche 454 adaptor sequences (Roche Diagnostics,
Oakland). To minimize PCR nucleotide insertion mistakes, a high
fidelity Taq polymerase was used, and samples were amplified in
quadruplicate reactions with 20 cycles each and then pooled.
Pyrosequencing and Data Analysis
The DNA amplicons were pyrosequenced using a GS Junior
Titanium 454 (Roche Diagnostics, Oakland) following manufac-
turer’s protocols (http://www.gsjunior.com/454-gs-junior.php).
Data analysis was performed using the software ‘‘Quantitative
Insights into Microbial Ecology’’ (QIIME) [21]. Reads were
removed if they were ,200 and .800 nucleotides (nt) in length, if
there were mismatches in the barcodes or primers, if ambiguous
nucleotides were present or if the read quality score was ,25. The
denoiser algorithm version 1.2.1 [22] was used to avoid
overestimation of diversity and chimeras were removed using
ChimeraSlayer [23]. Phylogenetic classification was assigned using
the Ribosomal Database Project database (RDP). [24] Sequences
were clustered in Operational Taxonomic Units (OTUs) using
UCLUST version 2.1 at 97% sequence identity [25]. Any
sequences present once (singletons) or in only one sample were
filtered out.
Remaining sequences were aligned using PyNast [26]. Se-
quences were rarefied (to remove the heterogeneity of the number
of sequences per sample) prior to calculation of alpha and beta
diversity statistics. Alpha diversity indexes were calculated in
QIIME from rarefied samples using for diversity the Shannon
index [27], for richness the Chao1 index [28], and evenness by the
equitability index [29]. Beta diversity was calculated using
weighted and unweighted UniFrac [30] and principal coordinate
analysis (PCoA) performed. Neighbour joining with nearest
neighbour interchange phylogenetic trees were created using the
representative sequences of each OTU and FastTree version 2.1.3
[31]. The heatmap to represent the abundance of sequences was
constructed in iTOL [32]. Microbial community comparisons
were performed using parametric statistics in METASTATS, with
the P values corrected by multiple hypothesis testing using the false
discovery rate (FDR) [20]. Sequences are available in EBI
(European Bioinformatics Institute) with the accession number
ERP001558.
Representative sequences from significantly different OTUs of
further interest were investigated using more intensive phyloge-
netic approaches in order to maximize the quality of the
identification. These test sequences were aligned using the online
SINA aligner (http://www.arb-silva.de/aligner/version 1.29 [33])
and this was imported into the ARB phylogenetic software (version
5.1, http://www.arb-home.de/[34]) running on Biolinux 6.0
(http://nebc.nerc.ac.uk/tools/bio-linux/bio-linux-6.0, ref 3 [35]).
The aligned SILVA reference database SSU_REF108 of 618,442
high quality 16S rRNA gene sequences was downloaded and
merged with the aligned test sequences. All Haemophilus spp. (or
Streptococcus spp.) sequences within the database were selected and
the SINA alignment individually checked for each test sequence in
the ARB alignment editor. The length of the alignments used
depended on the length of the available reference reads for each
OTU. Thus, for the Haemophilus spp. alignment, the 522 bp region
corresponding to the region between positions 384 and 908 of the
Escherichia coli reference were selected, and for Streptococcus spp.
470 bp between positions 470 and 908. Columns of the alignment
containing uninformative positions (gaps) were masked from the
phylogenetic analysis. Three trees were constructed for each of the
genera, an ARB neighbor joining (NJ) tree with 1000 bootstraps, a
Maximum Parsimony (MP) tree with 500 bootstraps and a
RAxML Maximum Likelihood (ML) tree (version 7.0.3, [36]) with
GTR substitution model in rapid hill-climbing mode. Trees were
rooted with sequences from near neighbours outside the genus of
interest. Tree topology was compared between the three methods
and bootstrap values for the NJ and MP trees were used to
determine stability of the phylogeny. Accession numbers for the
reference sequences used are recorded in the tree labels and those
for the outgroup were DQ358146, AJ301681, AF008582,
AJ301682, AF008581, AM040491, and AM040495.
Results
Examination of the clinical data showed no significant
differences between the 24 cases of non-infectious wheezing and
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the 24 controls in age, sex and antibiotic use (Table 1). The
controls appeared to have higher parental income ($238 per
month compared to $186) and slightly fewer individuals per room
in their houses (3.1 compared to 3.6), although only 4% of their
mothers had finished high school compared to 21% of cases.
An initial 108,042 raw sequences were obtained from all
subjects. After denoising, singleton exclusion, chimera checking
and removal of OTUs present in only one sample a total of 76,627
sequences remained (37,235 in cases and 39,392 in controls).
Between 969 and 6269 sequences were obtained per sample. In
order to control sample heterogeneity, sequences were rarified to
the same minimum of 969 for all subjects. Consequently, we
identified 182 operational taxonomic units (OTUs) at 97%
Figure 1. Phylogenetic tree and Heatmap of bacterial 16S rRNA sequences derived from throat swabs. Total sequence counts for
individual operational taxonomic units (OTUs) are shown in the right column. Taxonomy assignments at the phylum level are shown in the inner
column and colour coded. Intrusions of different colours within particular phyla indicate discrepancies between the phylogenetic and database
classifications.
doi:10.1371/journal.pone.0046803.g001
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sequence identity level that were assembled into a phylogenetic
tree using FastTree and iTOL (Figure 1).
By extrapolation of collectors’ curves we estimated that the
samples contained an average of 289.8 OTUs (95% CI 218.39–
361.30). Multiple rarefaction curves using the Shannon index
(Figure 2) showed that a plateau of diversity was achieved in
around 360 sequences per sample. This value would be considered
as the minimum sampling depth to capture diversity. Our
rarefaction was performed at a minimum of 969 sequences per
sample, which therefore is a realistic panorama of each sample’s
diversity. Phylogenetic classification of the ungrouped sequences
showed a high prevalence of the phylum Firmicutes (72% of the
total number of sequences obtained) followed by Proteobacteria
(12%), Actinobacteria (8%), Bacteroidetes (7%) and Fusobacteria
(1%) (Figure 1). Firmicutes was the most diverse phylum
containing 93 distinct OTUs (51% of the total OTUs), followed
by Actinobacteria with 30 OTUs (16%), Proteobacteria with 20
OTUs (11%), then Fusobacteria and Bacteroidetes with 18 and 19
OTUs respectively (10%). Streptococcus was the most common genus
(49.72% of the total) followed by Veillonella (14.5%), Atopobium
(5.37%) and Prevotella (4.72%).
We performed analysis of OTU taxonomy assignments
summarized at genus level (when it was not possible to define at
genus level, the next best determined taxonomy assignment was
used), and the number of samples from where differences were
detected at greater than 1% was included (Table 2). We found that
members of the groups Actinomyces (P=1.89610202, OR 1.10),
Atopobium (P=8.99610220, OR 2.27), Corynebacterium
(P= 1.376102129, OR 24.99), Flavobacteriaceae (P=4.02610231,
OR 12.07), Prevotella (P=3.24610213, OR 1.38), Staphylococcus
(P=1.876102241, OR 124.11), Neisseriaceae (P=5.84610205, OR
1.19), and Haemophilus (P=5.46610223, OR 2.12) occurred highly
significantly more often in the cases of infantile wheeze compared
to non-wheezing controls.
By contrast in controls there was a significantly higher
prevalence of Bacteroidales (P=9.57610208, OR 0.55), Porphyromo-
nas (P=2.81610232, OR 0.20), Gemella (P=4.29610221, OR
0.40), Lachnospiraceae (P=7.79610214, OR 0.39), Veillonella
(P= 8.06610286, OR 0.59), Leptotrichia (P= 9.37610214, OR
0.42), Pasteurellaceae (P= 1.13610220, OR 0.20) and Moraxella
(P= 4.54610206, OR 0.79) (Table 2). We repeated the statistical
analysis excluding the 6 children that had a minimal use of
antibiotics and obtained similar results to the full sample set.
Inspection of the data for individual subjects (Figure 1) showed
that the high abundance of Moraxella sp. in a single sample resulted
in the whole genus being significantly more prevalent in controls.
If this particular sample was excluded from the analysis, Moraxella
became more prevalent in cases.
The biological interpretation of the differences in the frequen-
cies of individual OTUs is limited by the imprecision of OTU
assignments in identifying individual species. In particular, this
problem was obvious in our data with OTUs assigned to
Streptococcus and Haemophilus spp., which were likely to contain a
mixture of pathogenic and non-pathogenic strains. We therefore
attempted to improve the classification of these OTUs by
including them in phylogenetic tress constructed from reference
sequences.
Using three independent phylogenetic treeing methods it was
not possible to increase the specificity of the identification of the
Streptococcus spp. OTUs beyond that of the basic Ribosomal
Database Project (RDP) classifier. Tree topology between the
Figure 2. Shannon diversity collector curves. Multiple rarefaction curves were collated from each sample’s Shannon diversity index. The graphic
shows the estimated diversity plotted against the number of sequences per sample. Each line represents one sample. The plateau in each estimated
diversity curve indicates the minimum number of sequences to capture diversity. For all samples the plateau was achieved at approximately 320
sequences (red vertical line), well below our chosen rarefaction threshold of 969 sequences (blue line).
doi:10.1371/journal.pone.0046803.g002
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three methods of treeing was not conserved and significance of
assignment to major nodes was low.
By contrast, the tree topology for Haemophilus spp. was
conserved in all three methods of phylogenetic inference
(Figure 3), with robust significance for assignment for each
Haemophilus spp. OTU. This enabled confident assignment of
OTU 162 to Haemophilus influenzae, OTU 32 and 38 to Haemophilus
haemolyticus, and OTU 190 to Haemophilus parainfluenzae. OTU 162
which was assigned to the known pathogen Haemophilus influenzae
was significantly more common in cases (P=1.66610249, OR
3.45) compared with controls, whilst OTU 190 (assigned to
Haemophilus parainfluenzae) was significantly more prevalent in
controls (P=2.74610248, OR 0.05).
We next tested if changes in the abundance of individual OTUs
were associated with alterations in the overall structure of the
microbial populations between cases and controls. We did not
detect any differences between cases and controls in species
richness, taxa abundances, or evenness (Figure 4 A, B and C). We
found no large-scale differences in microbial community cluster
patterns between cases and controls (beta diversity) using the
principal coordinate analysis (PCoA) of the UniFrac distance
matrix (weighted and un-weighted) (Figure 4, D and E).
Discussion
This study has shown significant perturbations of the airways
microbiota in infants with early onset non-infectious wheeze from
a rural district in the tropics of Ecuador. Previous studies
conducted in a geographically adjacent area with similar climatic,
population, and geographic characteristics estimated the preva-
lence of asthma in school age children to be just 2.2% [18] and our
subjects were characterized by minimal use of antibiotics and a
complete absence of use of corticosteroids and anti-Streptococcal
vaccination. Our samples may therefore exemplify a naturally
developing microbial community in the early months of life.
Bacterial diversity in these infants (estimated mean 290 OTUs)
Figure 3. Phylogenetic identification of Haemophilus OTUs. Phylogenetic analysis of the 16S rRNA sequences of the OTUs assigned
taxonomically to Haemophilus genus (OTUs 32, 108, 162 and 190, shown in Red) together with reference Haemophilus sequences from the SILVA
database, using the ARB alignment editor. The scale bar indicates 10% sequence divergence, and NCBI accession numbers are included. The tree was
rooted with a near neighbour outgroup constructed with sequences from Morganella morganii, Proteus mirabilis and Providencia stuartii.
doi:10.1371/journal.pone.0046803.g003
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may be higher than that in seen previously in European children
(mean 85 OTUs) [4], although differences in methodology mean
that this inference should be treated with caution.
It is of interest that Firmicutes was the most common and most
diverse phylum with Streptococcus the most prevalent genus,
consistent with observations of the airways microbiota in
European children [4]. We were not able to differentiate well
between members of the important Streptococcus group on the basis
of the 16S sequences, and the typing of alternative chronometers
(such as pheS, rpoA, and gyrB ) and the incorporation of mutilocus
sequence analysis (MLS) [37] will be important in future studies of
the airway microbiome.
Figure 4. Alpha and Beta diversity comparisons between Cases and Controls. A) Scatter dot plot comparing cases versus controls values of
chao1 richness index. B) Scatter dot plot comparing values of Shannon diversity index. C) Scatter dot plot comparing equitability evenness index. D)
Unweighted UNIFRAC Principal Coordinate Analysis (PCoA) plot comparing presence/absence metrics. E) Weighted UNIFRAC Principal Coordinate
Analysis (PCoA) plot comparing presence/absence metrics and abundance.
doi:10.1371/journal.pone.0046803.g004
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We defined our phenotype in infants by non-febrile episodic
wheezing, according to the GINA guidelines (http://www.
ginasthma.org/). These guidelines recognize that asthma diagnosis
before the age of 6 years is complicated by the difficulty in
performing accurate lung function tests. The recognition of
recurrent wheezing not related to infections is as a consequence
the most important diagnostic indicator of asthma in this age
group [38]. Because not all children who experience wheezing
events will develop asthma and not all children with asthma
wheeze [39], we have followed the recommendation that the
phenotype of recurrent non-infectious wheezing syndrome be
applied to children less than 24 months old [38,39].
We used culture-independent molecular techniques to charac-
terize microbial communities and to quantitatively investigate
dissimilarities. We, and others have shown previously that the
microbiome of the oropharnyx correlates with that of the
bronchial tree assessed by brushings or by lavage [4,40], and
therefore oropharyngeal swabs were used for this epidemiological
survey. Pyrosequencing robustly determines the diversity and
abundance of microbial communities in a quantitative and
qualitative form. The assignment of approximately 1,600 individ-
ual sequences for each subject has conferred substantial statistical
power to our study. We have reduced the possibility of bias by
stringent removal of chimeric sequences, sequences present only
once in the dataset and OTUs that were present in only one
sample.
We were aware that a high abundance of sequences in few
samples could drive the overall prevalence of bacteria in cases or
controls, as occurred with Moraxella spp. in this study. We have
therefore confined our tests for significant differences to OTUs
present in three or more subjects with a total of more than 100
sequences per sample.
Our study identified a higher frequency of potential pathogens
(Neisseriaceae, Prevotella, Corynebacterium, Staphylococcus, Actinomyces and
Haemophilus) in wheezy infants compared to healthy controls. This
finding is consistent with substantial epidemiological studies of
European neonates that used standard bacterial cultures to show
carriage of pathogens in neonates predicted later asthma risk [6].
The finding is also consistent with earlier studies in older children
and adults with asthma that used 16S rRNA gene sequencing for
bacterial characterisation [4].
The incorporation of reference strain sequences into our
phylogenetic trees allowed us to discriminate between Haemophilus
spp. OTUs at species level, and to show that the pathogen
H. influenzae was more prevalent in wheezing infants, in concor-
dance with previous studies [6]. H. parainfluenzae was more
abundant in healthy children which might be associated with
wheezing protection. The 16S rRNA gene has previously been
suggested for use as a marker in MLST of H. influenzae [41] and
our results confirm that its phylogeny is well matched to species
and strain identification in airway samples.
In this study we found a lack of potentially ‘protective’ bacterial
genera in non-infectious wheezing infants compared with controls,
particularly Veillonella, Pasteurellaceae and Gemella. Alterations in the
normal microbiota may alter the host resistance to pathogen
colonization in the gut [42] and in the airways [43]. Possible
mechanisms for this include direct inhibition of pathogen growth
by commensal secreted factors [44]. Commensal bacteria may also
elicit tonic signals in the gut epithelium that prevent activation of
innate and adaptive immune responses [45,46]. It may be relevant
that manipulating the airway microbiome in gnotobiotic mice may
produce major changes in airway responsiveness and immunity
[10,11].
Our results suggest that the upper airways microbiota of early
onset wheezing infants from the tropics exhibit an increase in the
frequency of pathogenic bacterial OTUs that is not confounded by
antibiotic or steroid medications. These specific differences do not
appear to have been accompanied by detectable community
changes in the numbers of species and their overall relative
distribution in our samples. Larger studies and direct measure-
ments of the communities in the lower airways may change this
perception. The results provide further support for a hypothesis
that pathogenic bacteria may contribute to a wheezy diathesis in
infants [6].
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